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Abstract 
Mycolic acids are high molecular weight α-alkyl-branched β -hydroxy long chain fatty acids 
(60-90 carbon atoms). Different species of Mycobacteria may produce different classes of 
mycolic acids including α-, methoxy and keto mycolic acids, each present as mixtures of 
homologues. These may also contain different functional groups such as ester, keto, methoxy, 
hydroxyl, and alkene groups. Mycolic acids and their trehalose esters are very important 
components of the mycobacterial cell wall. They show very interesting toxic and 
immunological properties; these offer considerable potential for application in the detection, 
control, and treatment of mycobacterial infection, and also in developing new methods for the 
detection of disease. 
 
The first part of this project involved the development of a new method for the synthesis of the α-
alkyl-β-hydroxy fragment of mycolic acids, which required fewer steps compared to 
previous syntheses and used L-malic acid as starting material. 
 
The second part was to synthesise cis-alkene-α-methyl-trans-alkene mycolic acid (A), 
which contains a double bond at the distal and proximal positions. This type of mycolic 
acid has been isolated from Mycobacterium brumae. 
 
 
The third part of the project included the preparation of a number of sugar and glycerol 
esters of mycolic acid (A). These included the GroMM (B), GMM (C), the arabino-MA 
fragment from AG (D) and the trehalose esters TDM (E) and TMM (F). 
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The final part of the project involved the synthesis of a different kind of fatty acid: the 
methyl esters of cyclopropene fatty acids, such as α-methoxy cyclopropane fatty acid (G).  
 
These compounds have been tested and were shown to inhibit Toxoplasma gondii growth in 
vitro, with compound (G) being the most effective. 
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Chapter 1 
1. Introduction 
1.1 Tuberculosis (TB) 
Tuberculosis is an infectious disease, which has an ancient history,1,2 and is caused by 
Mycobacterium tuberculosis (M.tb). Although the lungs are the main place of infection in 
the body, other parts can be infected, such as the kidneys, lymph nodes and central nervous 
system.3,4 The transmission of this disease usually occurs when a person breathes in air that 
contains species of M. tuberculosis from infected people, via coughing, sneezing, talking or 
spitting.1 Nowadays it is believed that one third of the world’s population is infected with 
TB, however only in 10% of the cases does TB become active and cause illness.5 TB is 
known by many names, such as: ‘The king of diseases’ in India; ‘The captain of all these 
men of death’;5 and ‘phthisis’ by the Greek physician, Hippocrates.6 TB has been suggested 
to have originated in Africa as far back as 35,000 years ago.2,7,8 Investigations have shown 
signs of death as a result of TB in Egyptian mummies, which are over 5,000 years old,9 as 
well as in a 9000 year old human skeleton in the Eastern Mediterranean.7 There is also 
evidence showing the presence of TB in China 2300 years ago and in India 3300 years 
ago.10,11 It is believed that TB in the Americas was present before the arrival of European 
explorers, with a similarity to that found in Egypt.12,13 Throughout the middle ages there is 
widespread archaeological evidence of TB.13 TB was responsible for many deaths and it 
was not until 1819 when a group of French physicians, the most notable being Rene 
Theophile Hyacinthe Laennec who wrote D’Ausculation Mediate, outlined the physical 
signs of TB and its pathology.13 During Laennec’s era death rates in many major European 
and American cities had reached 800-1000 per 100,000 deaths per year.13,14,15,16 
There were no significant advances in the knowledge of TB until 1882 when Robert Koch 
gave their famous presentation on the tubercle bacillus and on their work to postulate the 
link between a microbe and disease. More commonly known as the Koch postulates, they 
are still the standard explanation for how an infectious disease arises.17,18 In 1905 Robert 
Koch, who was the winner of the Nobel Prize in Medicine and Physiology, first discovered 
a stain which enabled the visualisation of the M. tuberculosis bacilli and identified the 
causative agent of TB.19,20 Koch isolated a substance from tubercle bacilli which rendered 
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the bacterium harmless. He named it tuberculin and in a demonstration, he injected himself 
with it.21 Since Koch’s work a reliable vaccine has never been developed because TB 
immunity differs from immunity to many other common microbial diseases.18 Albert 
Calmette and Camille Guérin developed a vaccine from Mycobacterium bovis (M. bovis) 
called Bacille Calmette-Guérin (BCG).22 Acceptance of the vaccine was slow as many 
people did not believe it to be safe, as it was based on live TB bacteria. The BCG vaccine 
was first used on humans in 1921 in France,23 having agreed to share the responsibility for 
this first human experiment, Weill-Hallé and Calmette administered three oral doses of 2 
milligrams of BCG to a new born baby, but it was not until after World War II that BCG 
received widespread acceptance in the United States, Great Britain and Germany.24 The 
protection against disease by the vaccine does vary and overall is approximately 50%, for 
example, that against disseminated and meningeal disease in children is higher than that 
against pulmonary disease in adults.25,26 In addition, it is not known how long and to what 
extent the protective effect lasts, although giving the vaccine to new-borns (who are 
mycobacterially naïve) increases its efficiency.27 Although the reactivation of pulmonary 
TB cannot be protected against by routine vaccination, it does, however, reduce mortality 
and infection from TB in infants.28,29 Thus the development of a more effective vaccine 
would help enormously in the fight against TB. A new vaccine would also assist against the 
scepticism surrounding the BCG vaccine, which has led to some countries not routinely 
vaccinating infants. Currently only 5% of deaths are prevented by the BCG vaccine,30 a 
percentage which needs to be increased. One advantage of the BCG vaccine is that it also 
protects against Buruli ulcer, leprosy and helminth infection.31 In addition, it reduces the 
risk of superficial bladder cancer progression, and it may help against atopic diseases such 
as asthma.32 Recent studies show a 37% reduction in asthma in those who received a 
neonatal BCG vaccination.33 
TB has surged in great epidemics and then receded, and epidemics have been recorded 
during the 18th and 19th centuries in Europe and North America.15 During the early to mid-
19th century there was a noticeable decline in TB cases in Europe and North America and 
the World Health Organization (WHO) has reported that TB infects one person every 
second, of whom 5-10% die as a direct result.20 In 1993, the WHO announced TB as a 
major health problem and declared a global health emergency.34 In 2007, there were an 
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estimated 9.27 million cases of TB,35 as a comparison there were 9.24 million cases in 
2006, 8.3 million cases in 2000 and 6.6 million cases in 1990. In 2009, 9.4 million new 
cases of TB were recorded, more than at any time in history.36 A recent WHO report on 
Global TB Control, reports that from 2013-2015, new incidents of TB increased, with 
around 10.4 million new cases of TB being recorded worldwide in 2015 leading to 1.8 
million deaths, with most being concentrated in six countries: South Africa, China, India, 
Nigeria, Indonesia and Pakistan.37,38  Figure (1) shows the estimated number of new cases 
of TB per 100,000 population in 2016.38 
 
 
Figure (1): Map showing estimated TB incidence in 2016, for countries with at least 100 000 incident cases.38 
Today TB is a major cause of preventable deaths by infection and is the leading cause of death 
in people who are infected with HIV/AIDS. People with HIV who are TB positive are more 
likely to move to active disease and are approximately 30 times as likely to die from TB 
compared to a person infected with TB alone,39 because the HIV virus weakens the immune 
system, causing the TB bacteria to be more harmful. TB and HIV work in conjunction with 
each other and form a fatal combination, each increasing the progression rate of the other 
disease, with HIV infection being one of the major conditions that make people more 
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vulnerable to developing active TB. Moreover, if the patient stays untreated, active TB could 
cause a rapid death, therefore early diagnosis of TB is important, as recent studies showed that 
the late diagnosis of TB patients co-infected with HIV result in the death of 48-85% of these 
cases, i.e one in three patients.40 It is estimated that in 2010 alone there were 8.8 million new 
cases of TB, with an estimated 1.45 million deaths.41 An estimated 1.1 million (13%) of the 8.6 
million people who developed TB in 2012 were HIV-positive; about 75% of these cases were 
in the African Region and this is thought to be related to poor health services in these countries. 
About 82% of TB deaths among HIV-negative people occurred in the WHO African Region 
and the WHO South-East Asia Region in 2016; these regions accounted for 85% of the 
combined total of TB deaths in HIV-negative and HIV-positive people. India accounted for 
33% of global TB deaths among HIV-negative people, and for 26% of the combined total TB 
deaths in HIV-negative and HIV-positive people (estimates of TB mortality rates per 100,000 
population). Figure (2) shows the estimated worldwide distribution of TB patients co-infected 
with HIV. Statistics have shown a high incidence of HIV/AIDS-TB in Sub-Saharan Africa and 
other developing countries, where early and accurate diagnosis with effective therapy is still not 
easily accessible.42,43,44,45 Invariably, the pathogenesis of the HIV/AIDS-TB pandemic presents 
an urgent challenge to global science. 
 
 
Figure (2): Map showing estimated HIV prevalence in new and relapse TB cases, 2016.38 
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Prevention and treatment are two aspects that must be harmonized in the battle against TB. 
The treatment of TB is hard and includes long courses of multiple antibiotics.43,46 
Antibiotics are usually part of the therapy in people who have no symptoms and whose 
germs are in an inactive state, and in this case are helpful in preventing the activation of 
infection. In the 1940s the first drug proven to be effective against TB was streptomycin (1) 
which was first isolated from Streptomyces griseus.47 Another antibiotic, isoniazid (2) was 
introduced in the 1950s; subsequently, both drugs were used together in a multi-drug 
therapy.48,49 The rifamycins (3) are a family of antibiotics obtained by fermentation and 
chemical modification. They were isolated in 1957 from a fermentation culture of 
Streptomyces mediterranei.50 para-Aminosalicylic-acid (4),51 is used to treat tuberculosis 
and is able to kill bacterial cells hiding in the intracellular compartment of macrophages. 
Ethambutol (5) is also used to kill the bacteria that cause tuberculosis by interfering with 
cell wall synthesis (Figure 3).52 These drugs are the recommended first-line treatments and 
are also used together to provide a multi-pronged sustained assault on the bacteria. The aim 
is to kill all the bacteria infecting the host, as a single cell may give rise to drug-resistant 
strains. 
 
Figure (3): The structures of first-line anti-TB drugs. 
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The second-line drugs are for drug-resistant TB (see below) and for patients who cannot tolerate 
the first-line drugs; they are less effective, more toxic and require longer use than the first-line 
drugs.53 Today, there are more than thirty different types of anti TB drugs being used, however 
most of them are analogues of the above products. According to the WHO, in 2007 the overall 
success rate for TB treatment was 70%.35 
TB germs were found to be still growing in the sputum of a patient who had completed a course 
of streptomycin treatment, and a new deadly form of TB appeared in patients who had seemingly 
been treated with success.54 This resistance has become more and more frequent and is most 
alarming as it is becoming apparent in the case of both first-line and second-line drugs.55 This 
growing problem of antibiotic resistance, is coupled with the emergence of Multi–Drug Resistant 
Tuberculosis (MDR-TB) and Extensively-Drug Resistant Tuberculosis (XDR-TB). 
MDR-TB caused by M. tuberculosis shows high-level resistance to both isoniazid and rifampicin 
with or without resistance to other drugs.55,56 The probability of resistance is much higher for less 
effective antitubercular drugs.57 MDR-TB can occur during the treatment for fully sensitive 
tuberculosis if a patient misses a dose, a patient doses not complete the course, or if the doctor 
administers the wrong treatment.58 
XDR-TB is a form of TB caused by bacteria that are resistant to the most effective anti-TB drugs. 
XDR-TB is defined as TB that has developed resistance to the first line anti-TB drugs that define 
MDR-TB.59  XDR-TB is associated with a much higher mortality rate than MDR-TB.60 
1.2 Mycobacteria 
Mycobacterium is a genus of actinobacteria, given its own family, which can cause fatal 
diseases in both humans and animals. Over 150 species are recognized in this genus and 
they can be divided into two classes: Tuberculous Mycobacteria such as Mycobacterium 
tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium microti, 
Mycobacterium caprae and M. canettii;61 and Non-tuberculous mycobacteria (NTM) which 
comprise over 90 species,62 the most common ones associated with disease being 
Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium 
brumae, Mycobacterium chelonae, Mycobacterium gordonae, Mycobacterium fortuitum 
and Mycobacterium smegmatis.  
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1.3 Tuberculosis mycobacteria 
The tuberculosis mycobacteria constitute a collection of M. tuberculosis, M. bovis, M. 
microti and M. africanum, collectively known as M. tuberculosis complex, which can all 
cause tuberculosis disease in both humans and animals.63 
1.3.1 Mycobacterium tuberculosis 
As indicated, TB is mainly caused in humans by certain members of the Mycobacterium 
genus. The most important of these, in terms of number of infections, is M. tuberculosis 
which can be seen in Figure (4) below.1,64 
 
Figure (4): Scanning electron micrograph of M. tb.65 
It is classified as an acid fast gram-positive bacterium; it is gram positive and is acid fast because 
it does not retain methyl violet stain well.66 It is a small rod-shaped bacillus, approximately (1-4.4, 
0.3-0.6 µm) in size and divides every 16 to 20 hours. This rate of division is slower than that of 
most other bacteria.67,68  
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1.3.2 Other relevant mycobacteria 
M. tb is linked to other pathogenic mycobacteria, with some responsible for causing 
tuberculosis in other animal species.69 Of the tuberculosis causing mycobacteria in mammals 
one of the more well-known is M. bovis, which is responsible for tuberculosis in cattle, which is 
of concern as there is evidence that M. bovis is transferable to humans via an infected cow’s 
milk or via an aerosol.70 Mycobacterium africanum, a heterogenous group of strains found in 
West Africa with similar symptoms to M. tb, has also been observed.71,72 Other mycobacterial 
species causing disease in humans are Mycobacterium leprae which causes leprosy, 
Mycobacterium ulcerans which is responsible for the dangerous and potentially fatal Buruli 
ulcer, a skin and sometimes bone infection.73,74 Mycobacterium microti is the causative agent 
behind tuberculosis in small mice and voles, but occurrence in humans is very limited.75 Other 
pathogens include Mycobacterium kansasii which causes disease in HIV infected 
individuals, Mycobacterium marinum which causes disease in fish and skin infections in 
humans. Aronson first isolated this Mycobacterium in 1926 from a salt water fish. Tuberculosis 
is rarely caused by M. marinum in humans, however some skin infections can occur after 
contact with contaminated water sources.76 
1.4 Non-tuberculous mycobacteria (NTM) 
Non-tuberculosis mycobacteria, are small, rod shaped bacilli, also known as environmental 
mycobacteria, which enter the human body through environmental sources such as natural 
water, soils, foods, and water pipes of the distribution system. These kinds of bacteria are 
resistant to chlorine in water therefore they survive in the water pipes.77 The species of NTM do 
not cause tuberculosis, but have the ability to cause other diseases in both humans and animals 
such as skin disease, disseminated disease, and pulmonary disease in HIV negative patients.61 
Unlike tuberculosis mycobacteria NTM are not transmitted directly from one person to another, 
with the organism being acquired exclusively from environmental sources.78 It has been found 
that the rate of worldwide NTM infection is increasing significantly. In the UK, the rate of all 
NTM reported cases increased from 0.9/100,000 to 2.9/100,000 persons between the years 
1996-2006.79 Another report from Canada found an increase of pulmonary NTM cases from 
9.1/100,000 in 1997 to 14.1/100,000 by 2003.80 Similar reports also showed the prevalence of 
pulmonary NTM infection in other countries.81,82 
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1.4.1 Mycobacterium brumae 
Mycobacterium brumae (M. brumae) as seen in Figure (5) is a strain of non-tuberculosis 
mycobacteria (NTM). It is a new species of rapidly growing, environmental and non-
photochromogenic mycobacteria. It is also gram-positive, nonmotile, strongly acid-fast and 
rod shaped (2.0-2.5 µm long and 0.3 to 0.5 µm wide). It was first identified having been 
isolated from water, soil, and human sputum samples in 1993 in Barcelona, Spain.83 
  
Figure (5): (A) Mature M. brumae colonies on micrograph (magnification x120). 
(B) No magnification.83 
 
The inclusion of this organism in the genus Mycobacterium is based on its acid-alcohol fastness, 
DNA relatedness studies showed that the M. brumae strains studied form a single DNA 
hybridization group which is less than 30% related to 15 other species of the genus 
Mycobacterium. Thin-layer chromatographic analysis showed that only alpha-mycolates (see 
page 28 for mycolic acids) are present. Unlike Mycobacterium fallax and Mycobacterium triviale 
-mycolates, M. brumae -mycolates release only 22-carbon atom esters after pyrolysis.83 One of 
the factors that has been related to the virulence of mycobacteria is their ability to form cords, 
with studies in this area suggesting that cords only occurred in virulent strains. A recent study 
suggested that this cording could be due to the fine structure of the α-mycolic acids, in particular 
the presence of a cyclopropane at the proximal position, in mycolic acids isolated from 
Mycobacterium tuberculosis and M. bovis BCG.84 Luquin et al.83, however, described the 
presence of cords in M. brumae, despite there being no cyclopropane α-mycolic acids present. 
They therefore investigated whether M. brumae formed true cords and by using SEM images 
showed this to be the case. This therefore suggests that the relationship between the presence of a 
cyclopropane in the α-mycolic acids and cording cannot be extended to all mycobacteria.85  
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The use of M. brumae as an efficient candidate for the treatment of bladder cancer (BC) has 
been investigated.86,87 Although BCG has been shown to be an effective therapy, side effects, 
such as BCG infection, can occur, thus limiting its use. Much research has therefore been 
carried out in order to find alternative therapeutic agents. Yuksel et al.86 found that 
Mycobacterium phlei showed antitumoral activity, and that fractions rich in cell wall proteins 
caused the activation of TNF-α and IL-12. They studied a further 88 mycobacterial strains 
and found that 12 additional strains, including M. brumae were candidates for superficial BC 
treatment. More recently Julián et al.87 also investigated the use of M. brumae in inhibiting 
BC cell growth. They showed that M. brumae had improved effects, compared to BCG, in 
inhibiting low grade bladder cancer (BC) cell growth while similar effects against high grade 
cells were observed. In tumor-bearing mice, M. brumae treatment prolonged their survival, 
while posing a lower risk of infection, thus suggesting that M. brumae could be a potential 
candidate as a therapeutic agent for non-muscle-invasive BC. Julián et al.88 also suggested 
that the antitumor effect could be improved by obtaining homogenous mycobacteria 
suspensions. Due to the high lipid content of the mycobacterial cell wall, they are likely to 
aggregate and form clumps when re-suspended in aqueous solutions, which could interfere 
with their activity. Different emulsions containing M. brumae were prepared and their 
efficacy studied, with that prepared using olive oil giving the best results. The olive oil-M. 
brumae emulsion triggered the highest cytokine production in infected tumour cell cultures 
and induced a robust immune response in tumour bearing mice. In a different study Valero-
Guillén et al.89 showed that trehalose dimycolates (TDM) known as ‘cord factors’ from M. 
brumae stimulate the secretion of some pro-inflammatory cytokines that are relevant in 
tuberculosis; they studied these cord factors and compared them to those from M. 
tuberculosis. The cord factors were strong inducers of TNF-α and IL-1β, with comparable or 
higher levels than the cord factor from     M. tuberculosis, however the opposite was true for 
cytokines IL-6, IL-12p40 and IL-23. These results could are of interest when considering the 
adjuvanticity of these cord factors, however further investigation is required to determine 
whether mycobacteria such as M. brumae and its mycolic acids and cord factors could have a 
role as adjuvants (substances which enhance the body's immune response to an antigen). 
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1.4.2 Mycobacterium smegmatis 
M. smegmatis is a fast-growing Mycobacterium which is typically 3.0 to 5.0 µm long with a 
bacillus shape belonging to the family of environmental NTM.90 M. smegmatis is non-
pathogenic to humans, but there are a few cases of skin infection attributed to M. smegmatis 
which are treated with anti-mycobacterial drugs such as doxycycline, trimethoprim-
sulfamethoxazole, and ethambutol.91 Lustgarten first discovered and isolated M. smegmatis 
in 1884, and found that it lives in aggregate layers of cells attached to each other in a 
community called a biofilm. It is found in water, soil and plants.92 The study of biofilms in M. 
smegmatis as seen in Figure (6) can aid in understanding biofilm formation in other pathogenic 
mycobacteria like M. tb.93 M. smegmatis is found to belong to the same genus as 
M.tuberculosis, but it is not pathogenic, therefore it has been used for many research 
experiments as a model instead of M. tuberculosis and M. bovis.94, 95 
 
Figure (6): M. smegmatis.96 
1.4.3 Mycobacterium gordonae 
M. gordonae is another type of NTM which is classed as a slow growing NTM. M. gordonae 
is an acid and alcohol-fast bacillus belonging to group II of scotochromogenous 
mycobacteria.97 It can be found and isolated from environmental sources such as soil, natural 
water, tap water, or even unpasteurized milk.97 It was thought to be non-pathogenic and rarely 
cause disease to humans, but recent reports showed cases of significant disease caused by M. 
gordonae infection such as pulmonary disease, disseminated infection, and genitourinary 
disease.98,99,100 M. gordonae infections, those which entail co-infection with HIV-negative 
patients is rarely a pathogen, but in HIV-positive patients with a low CD4 cell count,101 it can 
cause significant disease and treatment is beneficial. Reports indicate that M. gordonae was 
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isolated from the blood of HIV infected patients and caused serious health 
complications.102,103 Nevertheless, it is important to establish a timely diagnosis so that 
optimal treatment can be administered.104 M. gordonae (Figure 7) is classed as the second 
most common non-tuberculosis Mycobacterium in the UK, with the rate of reported 
infections increasing from 1 report in 1995 to 153 reports in 2006, with these cases being 
found to occur mainly in patients over 60 years of age.79 Studies using molecular-based 
identification methods, such as PCR-restriction length polymorphism analysis (PRA), have 
concluded that M. gordonae is the most heterogenous member of the Mycobacterium genus 
studied to date.105 
 
Figure (7): M. gordonae (coloration de Ziehl).106 
1.4.4 Mycobacterium avium complex (MAC) 
Mycobacterium avium complex (MAC), as seen in Figure (8) is the most frequently 
encountered NTM associated with both human and animal disease, classified as an acid-
fast, slowly growing bacillus that may produce a yellow pigment in the absence of light 
(exposure to light often intensifies pigment production).107 
 
Figure (8): Mycobacterium avium complex (MAC).108 
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There are three subspecies of M. avium including M. avium, M. avium subsp paratuberculosis 
and Mycobacterium intracellulare collectively known as M. avium complex (MAC).78,109,110 
MAC is a serological (the scientific study or diagnostic examination of blood serum, especially 
with regard to the response of the immune system to pathogens or introduced substances) 
complex of 28 serovars  (a subdivision of a species or subspecies distinguishable from other 
strains on the basis of antigenicity) of two species, M. avium and M. intracellulare, which 
sometimes has been extended to include three additional serovars of a third species, 
Mycobacterium scrofulaceum.111 The distinction between M. avium and M. intracellulare is now 
well established, and Thorel et al.112 have proposed three subspecies of M. avium on the basis of 
phenotypic properties and nucleic acid studies: M. avium subsp. avium, M. avium subsp. 
paratuberculosis, and M. avium subsp. silvaticum.112 M. avium species are considered to be 
pathogenic especially for immunocompromised patients, such as HIV positive patients. They are 
distributed widely in the environment; the main sources are natural water, tap water, food, and 
soil.113,114 M. avium paratuberculosis (MAP) can cause Johne’s disease in cattle and may have 
implications for human health.115 Johne’s disease is one of the most widespread and economically 
important disease of ruminants. Recently, MAP has been associated with different autoimmune 
diseases such as Crohn’s disease,116 type 1 diabetes (T1D) and multiple sclerosis in humans.116 
Bovine paratuberculosis and bovine TB are still a major concern in many countries and are 
responsible for heavy economic losses as a result of decreases in weight, milk production and 
fertility of the infected animals. Additional costs include increased culling rates, diagnostic 
testing, and control measures.117 
1.4.5 Mycobacterium kansasii 
M. kansasii is probably the easiest NTM pathogen to treat successfully, and it is the second 
most common NTM after MAC to cause disease in HIV infected individuals.118 It causes 
both pulmonary and extra-pulmonary infections. Indeed, more information exists showing 
how effective antituberculosis drugs are for treating M. kansasii than all the other NTM 
infections. Also, because it is similar to tb. M., mycobacterial isolates may be linked to lung 
disease which can be both aggressive and destructive (Figure 9).119 
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Figure (9): Mycobacterium kansasii (coloration de Ziehl).119 
Infection by M. kansasii probably takes place via aerosols, although research has yet to 
confirm tap water as a major reservoir for M. kansasii causing human infection.120 In fact, it  
can be found virtually anywhere in the environment; these bacteria live in water, soil, foods 
and a variety of animals. The organism has been isolated from tap water in some 
communities as cases of identified M. kansasii disease.120,121,122 
1.5 The cell wall of M. tuberculosis 
Significant to the pathogenesis of M. tb is the organisation and structure of the cell 
envelope. As a result it is important to have an understanding of these factors in the fight 
against TB and other related diseases.123 The cell envelope in M. tuberculosis has an 
unusual structure, comprising a thick, multi-layered and extremely hydrophobic cell 
envelope, and this is important for the organism because it prevents the passage of 
antibiotics into the cell and protects it from the immune system of the host by allowing it to 
survive in macrophages, acting as a permeability barrier. The general structure of the 
mycobacterial cell envelope is now well understood (Figure 10) and it was proposed by 
Minnikin with its complex architecture of lipids, glycolipids, polysaccharides and 
proteins.124,125 The cell wall of mycobacteria consists of three main organelles: the plasma 
membrane, the cell wall (inner layer) and the outer layer (capsule). 
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Figure (10): The cell wall of M. tuberculosis.128 
The capsule-like layer consists of polysaccharides, proteins and also contains small amounts 
of lipids.126 The composition of the plasma membrane remains similar to the lipid bilayer of 
other organisms. It is composed of phospholipid derivatives from phosphatidic acid (PIMs). 
The cell wall (inner layer) consists of peptidoglycan (PG), consisting of long polysaccharide 
chains that give shape and rigidity to bacteria. N-Glycolylmuramic acid is linked in β-(1,4) to 
N-acetyl glucosamine in alternating position and cross linked to a four chain amino acid L-
alanine, disoglutamine, meso- diamino-pimmelic acid and D-alanine. The PG is linked to 
arabinogalactan (AG) by a phosphodiester bridge. The AG layer is composed of arabinose 
and galactose.127 Mycolic acids, high molecular weight long chain fatty acids alkylated at the 
α-position and hydroxylated at the β-position,128,129 are the main constituent of the cell wall; 
they occur along with a large number of different lipids, for example several different lipids 
with multi-methyl branched fatty acids.128 The mycobacterial lipids, constituting up to 40% of 
the dry weight of the cell envelope, have been the subject of numerous studies in order to 
determine their structure, biosynthesis and role in the virulence of the mycobacteria.130,131 
MAs bound to trehalose are extractable lipids also found in the cell wall. These are known as 
‘cord factor’ and are bio-medically important glycolipids. They are made up of a trehalose 
which is esterified at either one or both primary alcohol groups to form either a trehalose 
6,6’–monomycolate (TMM) or trehalose 6,6’–dimycolate (TDM).132,133 In biosynthesis, 
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TMM transfers newly synthesised mycolic acids to the cell wall. It remains unproven that this 
is the case for TDM.132,134,135 Among the most interesting and potentially useful lipids found 
in M. tuberculosis are the mycolic acids, cord factors trehalose mono- and dimycolate (TMM, 
TDM), glucose monomycolates (GMM) and glycerol monomycolates (GroMM). 
1.6 Mycolic acids 
Mycolic acids are characteristic of mycobacteria and give unique properties to the cell wall 
structure, making it resistant to all of the host’s defences and other chemotherapeutic agents 
which would otherwise damage or render unviable normal bacterial cells.128,133,136 Anderson 
et al. characterised the first “hydroxyl acids of very high molecular weight” which 
contained complex mixtures with different compositions. They proposed the name 
ꞌꞌmycolicꞌꞌ acid and reported the presence of one carboxylic group, one hydroxyl group and 
possibly a methoxy group. It was also reported that pyrolysis of the mycolic acid at 300 °C 
under vacuum gave hexacosanoic acid.137,138,139 However, pyrolysis at 300 °C also released 
a series of aldehydes (7) alongside the hexacosanoic acid (8). This helped to determine the 
basic structure of mycolic acids as β–hydroxy fatty acids with a long alkyl chain at the α-
position-[RCH(OH)CH(CO2H)R
’]140 (Scheme 1). 
 
Scheme (1): Pyrolysis of a mycolic acid. 
 
The first M. tb mycolic acid structures were published by Minnikin et al. in 1967141,142,143,144 
who used different analytical methods such as  I.R. spectroscopy, proton NMR 
spectroscopy and mass spectrometry to show that mycolic acids have a cyclopropane ring 
in different sterochemistry, and also suggested the main structure of mycolic acids.145,146  
The chemical complexity of the mycobacterial cell wall is not only the consequence of the 
presence of different mycolic acids, but also the presence of a mixture of different 
homologues of those mycolic acids presenting different carbon chain lengths. 
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It has been noted that there maybe over 500 types of mycolic acids in M. tuberculosis, with 
closely related chemical structures.147 They have been studied since their discovery and 
research continues because they are unique to mycobacteria and because they are important 
to their virulence. In the early years, the isolation of mycolic acids and separation from the 
mixture of various structures in the cell wall was the main problem in identifying their 
structures. Not only is isolation of individual mycolic acids difficult, but also the isolation 
and determination of a single compound from a mixture of similar mycolic acids with 
different carbon chain lengths is challenging. For this reason, highly developed analytical 
techniques were required in order to determine the correct structures of these series of 
mycolic acids. Recently a lot of research has been done on MAs using electron impact (EI) 
mass spectrometry, to determine chain lengths of the mycolates groups.145,148,149,150 
Mycolic acids have two key moieties, the meromycolate chain, which is the main part of 
mycolic acids, and generally has two intra-chain functional groups at the distal and 
proximal positions labelled as [X] and [Y] (Figure 11). The other part is the mycolic motif, 
which contains the hydroxyl group the and α-alkyl branched fatty acid, and is essentially 
similar all in mycolic acids, except for a slight difference in the chain length at the -
position.151,152 
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Figure (11): Generalized structures of major mycobacterial mycolic acids.151,152 
The meromycolate part is different from one mycolic acid to another, and it can contain 
different groups at both the distal and proximal positions. As the functionality of these 
positions appears to play an important role in the mycobacterial cell envelope, the resultant 
mycolic acids have been classified by their functionality. These groups may be a 
cyclopropane ring, a methoxy group, a carbonyl group, a methyl group, oxirane ring or a 
double bond. The classification of mycolic acids depends on the groups present. Watanabe 
et al. suggested a comprehensive classification method.152 There are three main types of 
MA which are present in M. tuberculosis the first one (9) where the proximal position, can 
be either a cis or trans-cyclopropane ring; the second (10) where the proximal position is a 
trans double bond; and finally (11) where the proximal position is a cis double bond. 
Figure 12 shows these three different types.151 It has been reported that when the double 
bond or the cyclopropane are in the trans configuration there is a methyl group on the 
adjacent distal carbon while in the cis configuration this is not present.147,153 
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Figure (12): Types of MA structures according to Watanabe et al. classification.151 
In addition, based on the nature of the functional groups present in the meromycolate 
chains, there are three main types of mycolic acid which are present in M. tuberculosis:     
-mycolic acid (12) containing two cyclopropane rings usually in a cis-configuration 
(Figure 13); methoxy-mycolic acid (13) in which the distal group contains a methoxy 
group (Figure 14) and keto-mycolic acid containing a carbonyl group with a trans 
cyclopropane (14) or a cis cyclopropane (15) (Figure 15). Methoxy-mycolic acids and 
keto-mycolic acids have methyl branches next to the oxygenated functional group and 
natural mixtures have both cis-cyclopropane and -methyl trans-cyclopropane rings. 
 
Figure (13): Structure of an α-MA. 
 
 
Figure (14): Methoxy-MA with a cyclopropane ring in the cis-configuration. 
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Figure (15): Keto-MAs with a cyclopropane ring in the trans-configuration (up) (14); cis-configuration (down) (15). 
In addition, other mycobacteria contain completely different sets of mycolic acids with the 
other various functianal groups in the meromycolate chain as illustrated in Figure (16). For 
example, M. smegmatis contains ’and -mycolic acids (16) and (17) with either one or two 
double bonds, either in the cis or the trans configuration. The ’-mycolic acids are shorter than 
α-mycolic acids, containing 60 carbons instead of 80, and are widely distributed within 
mycobacteria although absent from M. tuberculosis. The MA of Mycobacterim fortuitum 
include an epoxide ring (18).154,155 Recently, other different oxygenated mycolic acids have 
been isolated from various mycobacteria; these include a ω-carboxy-MA (19)156 from 
Mycobacterim phlei while  a ω-methoxy-MA was found in Mycobacterim alvei (20).157 Wax 
ester (21) is another variant of MA, found in M. aurum.158 Wax esters are the result of a Baeyer-
Villiger type reaction on the keto group of the keto-mycolic acid.159 MA (both major and 
minor) present in other mycobacteria, have different variations at the proximal and distal 
positions. Following a careful examination of all their mycolic-like fatty acids, small amounts 
of hydroxy MA (22) have been found in M. bovis (BCG) and also M. tb. It was found that a 
gene cluster isolated from M. bovis (BCG) conferred upon M. smegmatis the ability to 
synthesise hydroxy MA with cyclopropanated keto MAs.148,160 
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Figure (16): Some of the mycolic acids present in different mycobacteria. 
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1.7 The chain length of mycolic acids 
The chain length represented in the different homologus of mycolic acids in all types of 
mycobacteria has been recognised.147 In M. tuberculosis alone, a family of over 500 
individual mycolic acids with closely related chemical structures have been documented,147 
while for M. smegmatis about 100 structural isomers are found in the mixture of α-
mycolates.161 In 2001, Watanabe et al.151 was the first to analyse mycolic acids using MALDI-
TOF mass spectrometry to provide a rapid and highly sensitive technique for the analysis of 
mycolic acids and other lipids. They studied the length of all the carbon chains of the various 
mycolates correlated with the growth rate of the mycobacterial strains of the main types of MA. 
It was found that pathogenic strains of mycobacteria such as M. tuberculosis and M. ulcerans, 
synthesised chains containing even numbers of carbons (C74-C82) of α-mycolic acids. Non-
pathogenic strains produced chains with both odd and even numbers of carbons.151 In fact, the 
main chains of oxygenated (methoxy and keto) mycolic acids were between four and six 
carbons longer than the corresponding α-MA in the slow-growing pathogenic species162,163 
whereas rapid growers provided oxygenated homologues possessing the same chain lengths as 
their α-mycolic acids.67 
Watanabe et al. used MALDI mass spectrometry to study mycolic acids (both major and 
minor components) present in 19 strains of the M. tuberculosis complex.151 Combining this 
new methodology with collision-induced dissociation (CID) mass spectrometry they 
succeeded in locating, precisely, the functional groups in the meromycolate moiety of 
different types of mycolic acids.152 To determine the chain lengths (a, b and c) of 
meroaldehyde (24) and the saturated α-chain (25), pyrolysis of MA (23) at 300 ˚C was 
carried out, followed by mass spectrometry. This gives information on the internal chain 
lengths as illustrated in Scheme (2).152 It was revealed that the mycolate chains vary 
between 60 and 90 carbon units and that the α-chain varies between 22 and 26 carbons in 
length.147,164 
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Scheme (2): Pyrolytic cleavage of a mycolic acid, followed by oxidation with Ag2O to prepare meromycolic 
acids for analysis.152,165 
The a-b-c values for the MAs were elucidated as shown in Figures (17-19).  Moreover, it 
was found that the methyl branch next to the trans-double bond was located nearest to the 
carboxylic end of the mycolic acids.  In addition, they discovered a close structural 
relationship between the keto and the methoxy MAs, with their a-b-c values generally 
matching.107 
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Figure (17): Structures and distribution of major and minor α-mycolic acids.107 
 
 
Figure (18): Structures and distribution of major and minor methoxy-mycolic acids.152 
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Figure (19): Structures and distribution of keto-mycolic acids.152 
As previously mentioned, different species of mycobacteria may produce different classes of 
mycolic acids; thus M. smegmatis possesses different sets of ’- and -mycolic acids with one 
or two double bonds, either in the cis or the trans-configuration. The ’-mycolic acids (39) 
contain one double bond in the cis-configuration The -mycolic acids contains two double 
bonds either both in the cis- configuration (40), or the one at the distal position in a cis-
configuration and the one at the proximal position in a trans-configuration (41).161,166,167 Diene 
mycolic acids have also been found in M. brumae which contain two double bonds both in the 
trans- configuration (42).89 In addition diene methoxy mycolic acids have been isolated 
from Mycobacterium alvei; these include -1-methoxy-mycolic acids in two different 
configurations (43, 44).156 The presence of epoxy mycolic acids was reported in M. 
fortuitum (45-48) (Figure 20).166,167 
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Figure (20): Mycolic acids from other mycobacteria. 
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1.8 Mycolic acid stereochemistry 
Much work has been carried out in order to determine the absolute stereochemistries of 
various mycolic acids and to identify whether the specific structure has any effect on their 
biological properties. 
The α- and β- fragment has been found to be in the R,R-configuration for all the mycolic 
acids examined, regardless of the groups in the meromycolate chain.146,168 This was 
confirmed first for the corynomycolic acids (Figure 21).169,170 
 
Figure (21): The (R,R)- configuration for all mycolic acids. 
The relative configuration between the α-alkyl chain and the β-hydroxyl group has been 
proved to affect the film molecular packing in the cell wall of mycobacteria, as a result of 
hydrogen bond formation between the hydroxyl group and the carboxylic group; this is 
believed to have a stabilizing effect on the alignment between two long mycolic acid 
chains.171,172,173,174 The configuration at these two chiral centres is thought to play a vital 
role in T cell recognition,175 and the generation of an immune response by the host 
organism against pathogenic mycobacteria.175,176 
The stereochemistry of the chiral centres in the meromycolate part is difficult to determine 
because it often contains several sets of chiral centres. Recent studies on different 
mycobacteria suggest that the methyl branch adjacent to the hydroxy (49), methoxy (50) 
and keto (51) groups at the distal position are in the S-configuration. The hydroxyl (49) and 
the methoxy (50) groups are also thought to be in the S-configuration (Figure 22).146,149,177 
The wax ester fragment S-(52) derived from keto-mycolic acids, is believed to be via an 
enzymatic oxidation via a Baeyer-villiger  type reaction.178,179 
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Figure (22): The strereochemistry of chiral centres of the mycolic acids. 
Other reports identify R-stereochemistry for the three stereocentres of the α-methyl-trans-epoxy 
unit in related mycolic acids (53a, 53b), and the methyl branch next to the trans-alkene unit 
(54) was found to be in R-configuration.180 However the stereochemistry of the epoxide ring 
(53a) was recently reported to be in a S,S-configuration.181 
1.9 Biosynthesis of mycolic acids 
Mycolic acids play an essential role in the survival of TB bacteria, and it is important to 
find a new anti-mycobacterial drug because most of the drugs relate to the inhibition of 
mycolic acid biosynthesis.182 The biosynthesis of mycolic acids has been investigated in 
great detail,167,183 and although it is not fully understood, research has provided a number 
of different hypotheses.  
There are three major steps in the biosynthesis of mycolic acids. Firstly, the mycobacterial 
FAS-I system (fatty acid synthase I) extends the acetyl group by two carbon units from 
acetyl-CoA (55) and also produces up to C16-C26 chain length fatty acids (56) by 
elongating the short alkyl chain of mycolic acids (Scheme 3). 
 
Scheme (3): FAS I system. 
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Secondly, the mycobacterial FAS II system is used for further chain extension, up to 50 
carbon units in the synthesis of meroacids (57), and modifications to form different 
functional groups (58) (Scheme 4).184,185 The available anti-tuberculosis drugs such as 
thiolactomycin, isoniazed, ethionamide and prothionamide are inhibitors of the enzymes 
involved in the FAS II system.186,187 
 
Scheme (4): FAS II system. 
Thirdly, there is a condensation step in the biosynthetic pathway, to give the mycolic acid. 
The long chain fatty acid obtained from the FAS I, FAS II system undergoes condensation. 
It is believed to be a Claisen condensation between meromycolate (58) and alkyl 
dicarboxylic acid (59), with the occurrence of some more modifications like desaturation, 
cyclopropanation, methylation, elongation and formation of the other functional groups to 
give the mycolic acid (60) (Scheme 5).130 
 
Scheme (5): Condensation step. 
There are numerous modifications carried out in the final step of the biosynthesis, but 
cyclopropanation and methylation have always been more important than the introduction 
of other functional groups. The mechanism of the biosynthesis of methoxy and 
cyclopropane mycolic acids in M. tuberculosis was established by Yuan and Barry.188 
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It has been suggested that most major functionalities in the meromycolate are derived from a 
common intermediate. This intermediate is generated using S-adenosyl-L-methionine (SAM) 
(61). Methylation of a cis-alkene (62), using SAM, gives the carbocation intermediate (63) 
Figure (23). Labelled SAM has been used so that the methylation and any subsequent 
reaction can be monitored. This showed that the methyl group introduced occurs as a bridging 
methylene in cis- cyclopropanes, as methyl branches of trans-olefin and cyclopropanes, and 
the α-methyl branches of hydroxy, keto and methoxy mycolates. 161,177,189  
 
Figure (23): Formation of carbocation intermediate (63).  
The deprotonation of carbocation intermediate (63) could occur by two different processes. 
If the removal of Ha occurs this leads to a cis-cyclopropane ring (64); conversely if 
deprotonation of Hb occurs then the trans-olefin (65) is formed. Additionally, methylation 
of the trans-double bond, involving SAM, gives the trans-cyclopropane mycolic acid (66). 
If the carbocation intermediate (63) undergoes a hydration reaction, the hydroxymycolate 
(67) is formed, which is a precursor for the biosynthesis of the corresponding keto (68) and 
methoxy-mycolates (69) (Figure 24). 
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Figure (24): The insertion of the non-oxygenated functional groups in mycolic acids. 
The gene in M. tuberculosis which is required for the biosynthesis of trans-cyclopropylmycolates,190 
confirms the hypothesized biosynthetic link between the different functionalities. The biosynthesis of 
mycolic acids is of great importance to understanding the impact of individual functionality on 
virulence, cell wall fluidity and permeability, and how the different mycolates are naturally produced 
enables one to determine how to manipulate the cell wall of the pathogen, and thus provides a tool 
with which to combat disease.191 
1.10 Synthesis of mycolic acids 
The synthesis of mycolic acids has been of interest to a variety of research groups, and the 
synthesis of single enantiomers is of the utmost importance in understanding the role they 
play in the mycobacterial cell wall, the identification of natural mycolic acids and to study 
the stereochemistry of the chiral centres present in the mycolic acids. Moreover, one 
application of synthetic mycolic acids is in the detection of TB causing mycobacteria. The 
pattern of individual mycolic acids is exclusive to one Mycobacterium, therefore if the 
structure of these mycolic acids were to be known, an enantiomerically pure synthetic 
compound may be produced and compared to the natural mixture of mycolic acids obtained 
from the particular Mycobacterium infecting a patient.192 In addition, most MAs include at 
least two chiral centres in the α- and β- positions relative to the carboxylic acid. The 
synthesis of a full MA usually involves the meromycolate moiety and mycolic motif being 
synthesized separately, prior to being coupled to each other to produce the complete 
mycolic acid. 
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1.10.1 Synthesis of the α-alkyl-β-hydroxy ester unit (mycolic motif) 
The α-alkyl β-hydroxy fatty acid is present in the R, R-configuration and the mycolic motif 
unit is similar in all mycolic acids except for a slight variation in the length of the -alkyl 
chain R’. There are many methods reported for the preparation of (2R,3R)-α-alkyl-β-
hydroxy esters with different starting materials and catalysts (Figure 25).146,168 
 
Figure (25): Structure of (2R,3R)-α-alkyl-β-hydroxy esters. 
In 1952, Lederer et al.193 first reported the synthesis of the mycolic motif via condensation 
between two fatty acid molecules. Further studies by the same group used a Claisen 
condensation to prepare corynomycolate analogues, but all the attempts produced a mixture 
of diasteromers194,195 Kitano et al.196,197 synthesised the first enantiomerically pure α-alkyl-
β-hydroxy unit.  
In 1987, Utaka et al.198,199 used a stereo-selective chiral reduction of β-keto ester (70) to 
introduce the hydroxy group at the β-position (71) by a Baker’s yeast type reduction. An 
alkyl chain was then directly introduced at the α-position by a Fräter reaction200 to produce 
the α-alkyl-β-hydroxy carboxylate (72) with two chiral centres in the correct configuration 
and with an α-chain of the correct length (Scheme 6). 
 
Scheme (6): Method of Utaka et al.198 
Subsequently, Al Dulayymi et al.201 reported an improved approach to synthesize the α-
alkyl-β-hydroxyl unit, originating from R-aspartic acid (73). This was converted into 
epoxide (74) in 3 steps and was then ring opened with a Grignard reagent to give a single 
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enantiomer of the mono protected diol (75). This was transformed in four steps (protection, 
debenzylation, oxidation and esterfication) into the diol (76) (Scheme 7). 
 
Scheme (7): Ring opening of epoxide (74) (i) BrMg(CH2)9OTHP, CuI, 2h (ii) imidazole, DMF, TBDMSCl; 
(iii) H2, Pd/C, MeOH; (iv) NaIO4, RuCl3.H2O, CCl4; (v) MeOH, H2SO4. 
Protecting the diol (76) at the primary alcohol group as a silyl ether, followed by a Fräter 
alkylation with 1-iodotetracosane gave the α-alkyl-β-hydroxy ester (77). Protection of the 
secondary alcohol of (77) as the acetate, deprotection of the primary alcohol and oxidation 
led to the mycolic motif aldehyde (78) (Scheme 8). 
 
Scheme (8): Reagents and conditions: (i) TBDPSCl, DMAP, Et3N; (ii) LDA, CH3(CH2)23I, HMPA; (iii) 
Ac2O, pyridine; (iv) TBAF, (v) PCC. 
Baird et al.202 also reported the preparation of the mycolic motif unit by an improved 
method using a simple diol as the starting material. 1,10-Decandiol (79) was first 
transformed in to the E-α, β-unsaturated ester (80) in four steps. After that a Sharpless 
asymmetric dihydroxylation was carried out to get the diol (81), which was then 
transformed into a cyclic sulfate (82). The sulfate was further reduced and hydrolysed to 
produce protected β-hydroxy ester (83) followed by a Fräter allylation at the α-position of 
the ester (83). The β-hydroxy position was then protected with a TBDMS group to give the 
alkene (84) which was then oxidized with OsO4 to give aldehyde (85). A coupling reaction 
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was used to chain extend aldehyde (85), with sulfone (86) via a Julia olefination followed 
by hydrogenation to give (87). Finally, deprotection of compound (87) and subsequent 
oxidation gave the desired mycolic motif aldehyde (88) (Scheme 9). 
 
Scheme (9): Toschi et. al. synthesis of the mycolic motif.202 
In a further development work described by Koza et al. to prepare the mycolic motif unit,203 L-
aspartic acid (89) was used as starting material instead of R-aspartic acid, for the preparation of 
the mycolic motif units (102 and 103) This was advantageous as L-aspartic acid is much 
cheaper than the R-aspartic acid (Scheme 10). 
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Scheme (10): The preparation of mycolic motif unit (102 and 103).203 
α-Bromosuccinic acid (90) was firstly synthesized from L-aspartic acid (α-amino acid) with 
retention of configuration by the use of NaNO2 and potassium bromide in the presence of 
sulfuric acid. The concentration of sulfuric acid was critical in this reaction; if it was too high, 
the salt precipitated making the reaction impossible to complete. The subsequent step was 
conversion of the acid to the diol (91) using borane tetrahydrofuran complex solution in 
1.0 M THF  (Scheme 11).204 The borane was able to reduce the two carboxylic acids 
into diols, while leaving the bromine group unchanged because it is a mild reducing 
agent. 
 
Scheme (11): Preparation of diol (91). 
The next step was cyclization to form the epoxide intermediate (92) with simultaneous 
protection of the other hydroxyl with a benzyl protecting group. The intermediate (92) was 
ring opened with a Grignard reagent to extend the chain by two carbon atoms (93). After 
that the protection of the secondary alcohol with an acetyl group was carried out using 
acetic anhydride and pyridine as catalyst in dry toluene to form compound (94). Oxidative 
cleavage of the alkene (94) with OsO4 and oxone in DMF gave the carboxylic acid (95) 
(Scheme 12).203 
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Scheme (12): Preparation of carboxylic acid (95).203 
In the next step both esterification of the carboxylic acid group and the deprotection of the 
secondary alcohol was achieved by refluxing the acid (95) in methanol/H2SO4 to form the 
desired ester (96) (methanol was used as reagent and solvent). After this, the insertion of 
the alkyl chain, using an allyl group at the α-position, with respect to the carboxylic acid 
group was achieved by a Fräter reaction to give alkene (97). The secondary alcohol was 
then protected as a tert-butyldimethylsilyl ether (98). Subsequently, oxidative cleavage of 
olefin (98) with OsO4–NaIO4 and 2,6-lutidine in dioxane-water gave the aldehyde (99) 
(Scheme 13).203,205 
 
Scheme (13): Insertion of allyl group at the α-position. 
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The coupling reaction of the aldehyde compound (99) with a C-20 or C-22 sulfone via the 
modified Julia reaction, followed by hydrogenation of the resulting alkenes and 
debenzylation led to the formation of alcohols (100) and (101) respectively. The final step 
formed the mycolic motif unit (aldehyde compound) by oxidation of the alcohols (100 and 
101) using pyridinium chlorochromate (PCC) in dichloromethane (Scheme 14). 
 
Scheme (14): Preparation of the mycolic motif with two different chain lengths. 
Another route to prepare the β-hydroxy ester unit, starting from L-malic acid (104) was 
described by Khan et al.206  
 
Scheme (15): The malic acid route for synthesis of the α-alkyl β-hydroxy unit. 
Diethyl (S)-malate (105) was alkylated with allylic halides and their saturated counterparts in THF, 
using various conditions: A: LDA (2.5 equiv.), (105) (1 equiv.), R–X (1.5 equiv.); or B: addition of 
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HMPA (HMPA/THF 1:1), (105) (1 equiv.), R–X (1.5 equiv.) (Table 1). Selective reduction of 
diester (106) by treatment with BH3·DMS then gave diol (108).
207 
Table (1): The Fráter–Seebach alkylation using a variety of highly reactive long-chain alkyl halides.206 
Entry R-X n Conditions Yield % Anti/syn 
1 
 
- A 57 14:1 
2 
 
- A 52 9:1 
3 
 
3 A 37 7:1 
4 
 
3 A 55 9:1 
5 
 
10 A 15 9:1 
6 
 
10 A 7 7:1 
7 
 
10 B 35 7:1 
8 
 
10 A 51 10:1 
9 
 
10 B 45 9:1 
10 
 
16 A 5 6:1 
11 
 
16 A 49 9:1 
12 
 
18 A 8 6:1 
13 
 
18 A 42 9:1 
14 
 
20 A 41 9:1 
1.10.2 Synthesis of the meromycolate unit 
The second part of the mycolic acid, i.e. the meromycolate moiety was first synthesised in 
1977 by Gensler et al.208 who described the synthesis of a mixture of four stereoisomers of 
a meromycolic acid containing two cis-cyclopropanes. This method involved using 1,4-
cyclohexadiene (109) as starting material to prepare norcarene (110). Ozonolysis of (110) 
followed by a reduction gave cis-1,2-cyclopropanediol (111).209 After numerous stages, the 
cyclopropane-containing bromide (112) was obtained. Cyclopropane (115) was then 
prepared by alkylation of pentadecyl bromide (113) with the cyclopropane-containing 
bromide (112), followed by desulfurisation of compound (114) with Raney nickel.210 Using 
the bisdithiane (116), chain extension yielded (117), one of two major components which 
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make up the meromycolate acid product. In a separate synthesis the second major component 
of the meromycolate was prepared. To begin with, ozonoylsis of 10-undecenol (118) was 
undertaken, followed by conversion of the resulting aldehyde into the acetal and bromination 
to yield (119). Chain extension, by six carbons with the bis-dithiane (120), gave (121), which 
was coupled to bromide (112). Desulfurisation and deprotection of the tetrahydropyranyl 
group and bromination gave (122), which was the second key intermediate. Coupling of the 
lithio derivative of the bis-dithiane intermediate (117) with intermediate (122) followed by 
desulfurization, gave the desired product (123). Ozonolysis of this gave methyl meromycolate 
(124) which contained two cis-cyclopropane rings, Scheme (16). 
Scheme (16): The first synthetic meromycolic acid. 
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Subsequently, Gensler et al.208 proposed another method involving the conversion of 
compound (125) to the alkyl bromide (126) and alkyl iodide (127) over several steps. The 
methyl meromycolate (128) was then prepared by combining the different portions using 
the Grignard reagent obtained from the alkyl bromide (126), which formed a complex with 
the methyl copper, and the alkyl iodide (127). The methyl meromycolate (128) was 
obtained as a mixture of four stereoisomeric di-cis-cyclopropanes. This mixture was then 
hydrolyzed to give meromycolic acid (129) (Scheme 17). 
 
Scheme (17): Second Gensler et.al. approach. 
This method is shorter and could be more easily scaled up, but suffers from low yield and 
does not control the stereochemistry. 
The first enantiomerically pure meromycolic acid was prepared by Baird et al. in 2000, where single 
enantiomers of cyclopropane intermediates were coupled with no loss of stereochemistry.211 The 
aldehyde (131) was prepared from the anhydride of cyclopropane-cis-1,2-dicarboxylic acid. A Wittig 
reaction of this with nonadecyltriphenylphosphonium bromide and n-butyl lithium, and reduction with 
lithium aluminium hydride, led to the alcohol as a mixture of Z- and E-isomers. Saturation of the 
alkene was achieved with di-imide, prepared in situ by reaction between hydrazine, sodium periodate 
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and acetic acid, this was followed by oxidation of the alcohol, which led to aldehyde (131). Chain 
extension with a second Wittig reaction followed by saturation and oxidation to give the 
aldehyde (133). An important feature of this approach is the coupling reaction, which was used 
to link the different units in several stages, securing the final desired stereochemistry. A Julia 
reaction of sulfone (134) with 13-tetrahydro-pyranyloxytridecanal yielded the protected alcohol 
(135). This was converted into sulfone (136). The Julia reaction between aldehyde (133) and 
sulfone (136) gave (137) as a mixture of E- and Z-alkenes. The enantiomerically pure alcohol 
(139) was obtained by deprotection of the alcohol group and saturation of the derived alkenes 
(138) with di-imide (Scheme 18).  
 
Scheme (18): The first synthesis of a single enantiomer of meromycolate. 
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A better overall yield (50%) and control of the stereochemistry are two important 
advantages of this method. This method can be applied to the synthesis of other 
meromycolates having varied functional groups and chain lengths and permits the 
preparation of different stereoisomers by modifying the sequence of reactions on the 
cyclopropyl groups, providing all the diastereoisomers of meromycolaldehydes. 
1.11 Synthesis of complete mycolic acids 
The full mycolic acid was prepared by linking the mycolic motif to the meromycolic acid. 
The single enantiomer of mero-mycolic acid (140) was converted into the sulfone (141). 
Coupling of this to the mycolic motif aldehyde (78) via a Julia olefination, followed by 
hydrogenation of the resulting alkenes gave the full mycolic acid (142) (Scheme 19). 
 
Scheme (19): Reagents and conditions: (i) benzothiazole, DEAD, PPh3, (ii) MCPBA, (iii) LiHMDS, THF, (iv) 
dipotassium azodicarboxylate, CH3COOH, MeOH, THF. 
 
Methoxy mycolic acids (143145) of M. tb acids have also been synthesized using similar 
procedures. Also, the isolation of this type of molecule from M. tb has been achieved.144,152 
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Figure (26): Synthetic methoxy-mycolic acids. 
A set of hydroxy and keto-mycolic acids has also been prepared by the same group. The 
synthesis of ketomycolates which contain α-methyl-trans and cis-cyclopropane fragments 
(146 and 147) in order to produce a range of absolute stereochemistries and chain lengths 
was also undertaken (Figure (27).212,213  
 
Figure (27): Synthetic keto-mycolic acids of M. tb.212,213 
Baird et al. have not only prepared single enantiomers of the cyclopropanated mycolic 
acids, but also mycolic acids bearing other functionalities such as the epoxy mycolic acids 
(148) and (149) containing an (R)-α-methyl-trans-alkene at the proximal position and the 
cis-alkene mycolic acid (150) (Figure (28).181,214 These have been found in M. fortuitum 
and M. smegmatis.  
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Figure (28): Synthesized epoxy and cis alkene mycolic acids.
181,214 
 
1.12 Derivatives of mycolic acids 
Mycolic acids are found bound to the cell wall, as in penta-arabinose tetramycolate or as 
non-bound species such as sugar esters, usually trehalose di- or mono-mycolates (TDM and 
TMM), glucose monomycolate (GMM) or glycerol monomycolate (GroMM). These 
species are known to show interesting toxicological and immunological properties.215,216 
1.12.1 Cord Factor 
Cord factor is a complex glycolipid, trehalose dimycolate (TDM); trehalose is esterified at 
both primary alcohol positions with mycolic acids giving the 6,6’–dimycolate.217,218,219 It is 
one of the most interesting and potentially valuable glycolipids found in the cell wall of M. 
tuberculosis. However, trehalose is also present in a wide variety of organisms including 
fungi, insects, invertebrates, and in plants.220,221 Most bacteria use trehalose only as a 
general osmoprotectant or thermoprotectant.222 There are two classes of cord factors, 
(Figure 29); each of these derivatives consists of a non-reducing, disaccharide core, i.e. 
trehalose, esterified with one mycolic acid at the 6-position corresponding to trehalose 
monomycolate (TMM) (151) or esterified with two mycolic acids at the 6,6ꞌ-positions 
corresponding to TDM (152). 
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Figure (29): Structures of TMM and TDM. 
Robert Koch, in 1884 was the first to discover that growing tubercle bacilli formed long 
strands or ‘cords’,223  
The term ‘cord factor’ has been used since 1947; Middlebrook et al.224 discovered that the 
formation of ‘serpentine cords’ was typical of contagious strains of tubercle bacilli. In 1950 
Bloch for the first time isolated the glycolipid from the tubercle bacilli cells and he referred 
to it as a ‘cord factor’. Bloch also reported the toxic behaviour of these cords when he 
extracted four different strains with petrol and they tested them on mice.225 
Noll et al.131 in 1956 proposed the structure of cord factor isolated from M. tb and subjected 
it to alkaline hydrolysis. This produced, a free mycolic acid and a non-reducing 
carbohydrate moiety, α,α-trehalose. This was confirmed in two ways: firstly the acid 
hydrolysis of the carbohydrate moiety produced D-glucose; and secondly acetylation to 
give crystalline α,α-trehalose octa-acetate. The position of the MA attached to the trehalose 
was clarified firstly by methylation and then by saponification of the TDM (153); the result 
was hexa-methyltrehalose. Acid hydrolysis gave trimethylglucose (154). This showed that 
the MA is attached to the trehalose sugar at the 6,6’ positions respectively (Figure 30).131 
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Figure (30): Proposed structure of trehalose 6,6-dimycolate by Noll et al.131 
Ioneda et al. revealed the isolation of a glycolipid from Corynebacterium diphtheria and 
showed that it was a trehalose di-ester containing corynomycolic acid (C32H64O3) and 
corynomycolenic acid (C32H62O3) in equal proportions.
226,227 In a later study, glycolipids were 
isolated from M. fortuitum and analysed by mass spectrometry and were found to comprise an 
asymmetric trehalose di-ester.228 Using a strain of M. tuberculosis brevanne, Toubiana et al. in 
1979 extracted and purified dimycolates of trehalose by C wax hydrolysis of the tubercle 
bacilli. They also isolated and characterised all types of mycolic acid (type α, β, γ) in a single 
strain and found molecular peak ions by mass spectrometry.217  
Promé et al. isolated and identified mixtures of α-D-trehalose dimycolate and monomycolate 
from M. phlei. Two types of trehalose monomycolate (TMM) were found; the first one 
comprises an α-mycolic acid and the second one was the trehalose mono wax ester. Another 
three types of trehalose dimycolate (TDM) were also found, one containing two α-mycolic 
acids, one containing two wax esters, and one having one residue of each type.229 In 1977, 
Takayama and Armstrong studied the H37Ra strain and identified a new disymmetrically 
substituted ester which was involved in mycolic acid transfer into the cell wall.230 Fujita et al. 
used MALDI-TOF mass spectrometry in order to analyse the cell wall components of several 
types of mycobacteria. The structure of TMM and TDM were thus confirmed.231 The 
advantage of MALDI-TOF analysis is its ability to determine the molecular weight of the 
molecules in excess of 3000, while no molecular ion peak could be detected for such species 
using other mass spectrometric techniques. This led to a much clearer understanding of cord 
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factor composition.231 Baird et al.232 published the first synthesis of cord factors employing 
single synthetic enantiomers of mycolic acids in 2009 with the method used being easily 
modified to produce cord TDM or TMM from any synthetic mycolic acid. As with MAs, the 
synthesis of single enantiomers of TDM and TMM compounds allows the antigenic 
properties of each of these, and any combination thereof, to be investigated. 
1.12.2 Glycerol monomycolate (GroMM) 
GroMM is a mycolic acid esterified with glycerol at one of the primary hydroxyl groups 
Figure (31). Glycerol mycolate-containing lipid species produced by mycobacteria, can 
stimulate innate immune cells and produce inflammatory cytokines.216 It is found among 
different bacteria of the Corynebacterium, Mycobacterium, and Nocardia (CMN) group.233 
Andersen et al. specified GroMM in vitro as the most immunopotentiating compound 
among a number of different lipids isolated from the mycobacterial cell wall.234 
 
Figure (31): Example of GroMM. 
Hattori et al. immunized guinea pigs with bacillus Calmette–Guérin (BCG) expressing high 
levels of GroMM and then monitored skin reactions at the site of inoculation with GroMM-
containing liposomes. The host responses to GroMM produced by dormant mycobacteria 
contributed to their long-term survival in the host.235 Similar to TDM and 
lipoarabinomannam (LAM), GroMM appears to directly stimulate innate immune cells to 
produce inflammatory cytokines.233 Recent research pointed to a direct degradation 
pathway for TDM by means of enzymatic hydrolysis,236 resulting in the accumulation of 
free mycolates that was associated with the increased influx of nutrients including 
glycerol.237 The synthesis of GroMM using single synthetic mycolic acids will result in a 
rich knowledge of the nature of the cell wall of M. tuberculosis, and hence give a better 
understanding of their effects in the immune system.234 
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1.12.3 Glucose monomycolate (GMM) 
GMM sugar ester mycolate, is a glycolipid consisting of a mycolic acid attached to the 6- 
position of glucose present in numerous bacterial species including Mycobacterium, 
Rhodococcus and Nocardia.238,239 The structure of GMM from M. tuberculosis is shown in 
Figure 32. GMM is a mycobacterial antigen isolated from various species of mycobacteria, 
including M. tuberculosis.238,239 
 
Figure (32): Example of GMM. 
It has been proposed that TDM can be converted into GMM inside the host.240 Environmental 
mycobacteria express TDM on the surface of their cell wall but fail to biosynthesize GMM 
because of the very limited availability of glucose.241 Mycobacteria are unable to synthesise 
GMM outside of the host cell since a non-mycobacterial source of glucose is needed. Therefore, 
GMM is only produced by a pathogenic mycobacteria after infection of the host cell.175 GMM 
can induce a memory T cell response.239 GMM and other antigenic mycobacterial glycolipids are 
presented to T cells by the CD1 family of proteins and the antigen–protein complexes mediate the 
T cells response in the human host.242 However, depending on the species, the meromycolic chain 
carries variable functionalities in the proximal and distal positions, which are characteristic of the 
species.243 GMMs have the capacity to produce T cell proliferative responses in a number of 
species including humans, mice, guinea pigs, and cattle.244 Nguyen et al. have described cell-
mediated and humoral immune responses in cattle upon vaccination with GMM as the only 
antigen; as a result a T cell response was produced but no antibody responses, while the vaccine 
comprising a pure protein as the only antigen generated both T cell and antibody responses. 
However, in humans and cattle,245 Nguyen et al. assumed that a conjugate of GMM with a protein 
may provide T cell help for B cells to produce antibodies against surface exposed glycolipids in 
mycobacteria.244 
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1.12.4 Synthesis of a fragment from arabinogalactan 
The mycolyl-arabinogalactan complex (mAG) is the largest component structure in the cell 
wall of mycobacteria and is located outside the PG. mAG is essential for cell wall integrity and 
mycobacterial survival.246 The arabinans and galactans of mycobacterial cell walls consist of D-
arabinofuranose (D-Araf) and D-galactofuranose (D-Galf).247 Synthetic arabino-mycolates 
induce the production of TNF-α in murine macrophage cell lines at an intensity similar to BCG-
cell wall skeletons. However, the immunological activity of natural arabino-mycolates isolated 
from BCG has not been investigated; this is probably due to the complexity of the molecule.248 
 
Figure (33): Example of fragment from arabinogalactan. 
Isolated natural arabino-mycolates significantly induced TNF-α production and enhanced delayed 
type hypersensitivity (DTH) reactions against inactivated tumour cells and possess potent 
adjuvant immunostimulatory activity.248,249 Intratumour injections of extracts of Re Mutant 
Salmonella typhimurium in combination with TDM or arabinose mycolate were highly effective 
in producing regression of tumours in guinea pigs. 
1.12.5 Synthesis of TDM and TMM 
Baird et al. reported the first unique synthesis of mycobacterial cord factors.232 They were able to 
convert a methoxy mycolic acid and an α-mycolic acid into their corresponding TDM and TMM. 
According to the reported procedure,250 both mycolic acids were protected at the β-hydroxy acid 
position with TBDMS, prior to the coupling with the trehalose, to avoid reactions of the alcohol group. 
The protected mycolic acid was coupled with protected trehalose to obtain a protected TDM and a 
protected TMM. The coupling was carried out by esterification, using EDCI and DMAP. 
Subsequently, deprotection was carried out in two stages. The first deprotection was done with TBAF, 
removing all the trimethylsilyl groups from the trehalose unit. Further deprotection using HF pyridine 
removed TBDMS protection from the β-hydroxy position of the acid to yield the desired cord factors 
(see page 45).232, 250 
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Chapter 2 
2. Results and Discussion 
2.1 Project aims 
This project consists of three main parts. The first objective was to reduce the number of 
steps currently involved in the synthesis of the mycolic motif, by developing an improved 
method for the synthesis of the α-alkyl, β-hydroxy fragment (Figure 34). The method needs 
to be less expensive and involve fewer reaction steps. This fragment is a common unit in all 
mycolic acids and as such the development of an improved method for its synthesis would 
simplify the overall synthesis of all mycolic acids, as well as cord factors. 
 
Figure (34): The α-alkyl-β-hydroxy fragment of mycolic acids (mycolic motif). 
The second aim was to synthesise the specific cis-alkene-α-methyl-trans-alkene mycolic 
acid (155), which contains a double bond at the distal and proximal positions. This type of 
mycolic acid has been isolated from M. brumae. Having prepared the MA (155), the third 
part was the preparation of a number of mycolate esters, by esterification of the mycolic 
acid with different sugars. These include the GroMM (156), GMM (157), the arabino-MA 
fragment from AG (158), TDM (159), and TMM (160) (Figure 35). 
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Figure (35): Target mycolic acid and its sugar and glycerol esters. 
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2.2 Preparation of the mycolic motif unit 
The first target of this project was concerned with the development of a new method for the 
synthesis of the α-alkyl-β-hydroxy fragment of mycolic acids, which is also known as the 
mycolic motif unit. The preparation of this unit is almost certainly the most tedious part of 
mycolic acid synthesis and as such necessitates some improvement. Improving this 
synthetic method is also of major importance as the α-alkyl-β-hydroxy moiety is similar in 
all mycolic acids and their derivatives, such as cord factors. 
2.2.1 Previous work 
Several methods for the preparation of the mycolic motif unit with R,R stereochemistry at 
the chiral α- and β- carbon atoms have been published.202,251 The first includes a direct 
alkylation of a long chain at the α-position relative to the carboxylic group. In this method 
Al Dulayymi et al.251 used (S)-(2-benzeneoxyethyl) oxirane (161) as a chiral intermediate 
prepared from commercially available D-aspartic acid based on a method developed by 
Frick et al.252 In the second method, a short chain allylation was initially carried out, 
followed by further elongation of the chain using a modified Julia-Kocienski reaction in 
order to obtain the desired carbon chain length (Scheme 20). This short allyl chain was 
used because the insertion of the full alkyl group in one step has given variable results and 
low yield (10%). 
 
Scheme (20): The two basic methods for the synthesis of the α-alkyl-β-hydroxy unit. 
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Another method described by Koza et al.203 prepared the mycolic motif unit (102) starting from 
commercially available L-aspartic acid (89) for the synthesis of the (R)-(2-
benzeneoxyethyl)oxirane intermediate (92) in four steps Scheme (21). A short chain Fräter 
allylation followed by a further Julia-Kocienski chain extension was then carried out at the α-
position. They obtained the α-alkyl-β-hydroxy unit in 14 steps with an overall yield of 11%. 
 
Scheme (21): Alternative starting materials for the synthesis of the α-alkyl-β-hydroxy unit. 
Another method for the synthesis of the α-alkyl-β-hydroxy fragment, starting from a dialkyl malate 
has also been investigated (Scheme 22). A selective reduction of diethyl malate with borane 
dimethyl sulfide complex (BMS) and catalytic NaBH4, was first carried out followed by chain 
elongation via a chiral epoxide intermediate. Alkylation at the α-position, which involved a Fräter 
allylation, was then carried out, followed by protection of the secondary alcohol, ozonoylsis, and 
Julia olefination respectively. The desired compound was then obtained, in the correct 
stereochemistry, after hydrogenation. This route was successfully completed in 10 steps with an 
overall yield of 10%.253 The disadvantage of this approach is that it requires the use of expensive 
material such as silver oxide. 
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Scheme (22): Preparation of the α-alkyl-β-hydroxy unit from diethyl malate. 
2.2.2 A new method for the synthesis of the mycolic motif unit 
The work in this thesis involved developing an alternative, more efficient route starting 
from the commercially available and the cheaper starting material L-malic acid (104), over 
fewer steps (6 steps), as shown in Scheme (23). This sequence had been completed before 
for the series of ethyl esters,254 but the key final step proved very difficult to repeat, and 
was optimised in this work using the methyl esters. 
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Scheme (23): The mycolic motif unit. 
 
2.2.3 Preparation of dialkyl (S)-2-hydroxysuccinate 
L-Malic acid (104) was esterified to the diesters (164, 105) using MeOH or EtOH respectively in the 
presence of thionyl chloride at 0 oC and stirring overnight at room temperature, and the crude products 
were purified by flash distillation in 98 and 99% yields respectively (Scheme 24). The structures were 
confirmed by their NMR spectra which were the same as those reported in the literature.255,256  
 
Scheme (24): Esterification of L-malic acid (104) into diesters (164, 105), reagents and conditions: (i) SOCl2, ROH, 0 ºC. 
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2.2.4 Inserting an α-alkyl chain in the mycolic motif unit 
There are a number of methods for the preparation of the α-alkyl-β-hydroxy unit with the 
correct stereochemistry at both the α- and β-carbon atoms. The widely utilized asymmetric 
alkylation method based on the Fräter alkylation is highly diastereoselective160,200 and was 
believed to be the best route for the stereocontrolled insertion of the allyl chain at the α-
position of the β-hydroxy ester. 
2.2.4.1 Preparation of diesters (2R,3S)-2-allyl-3-hydroxysuccinate 
The Fräter alkylation was used for the stereoselective installation of the required allyl chain 
at the α-position of the β-hydroxy diester (164). The allyl chain was attached from the 
bottom face due to the steric hinderance encountered on the top face from the six-
membered ring chelate, intermediate (III). This gave the anti–alkylated product (2R,3S)-
hydroxy ester (165) in 58% yield Scheme (25).202 
 
Scheme (25): Mechanism of the Fräter alkylation. 
The allylation was carried out using LDA generated in situ from MeLi and di-
isopropylamine in dry THF. After 30 minutes, it was cooled to 61°C and then reacted 
with dimethyl (S)-2-hydroxysuccinate (164). In order to ensure the formation of the 
intermediates (I) and (II) the mixture was stirred at 45 to 0 °C for 2 hours, then cooled 
to 62 °C followed by the addition of allyl bromide. A further quantity of allyl bromide 
was added to the mixture which was then stirred at the same temperature for 60 minutes. 
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The reaction was slowly allowed to reach 0 °C and then worked up with sat. NH4Cl 
solution. The product was obtained as a mixture of distereoisomers (165) and (186) 
respectively which were separated by column chromatography to give the required product 
Scheme (26). 
 
Scheme (26): The insertion of the α-allyl chain, reagents and conditions: (i) LDA, 78 °C, allylbromide, dry THF. 
The allylation was confirmed by the 1H NMR spectrum which showed a double double 
doublet at δ 2.99 (J 3.2, 6.6, 8.7 Hz) for the proton at the α-position Table (2). The two 
protons adjacent to the alkene group were also revealed as multiplets at δ 2.50 – 2.40 and a 
doublet of triplets at δ 2.62 (J 6.3, 14.1 Hz) and two singlets corresponding to the methyl 
groups appeared at δ 3.80 and δ 3.69. For the alkene signals, a multiplet corresponding to 
one C=C proton adjacent to the -CH2- group appeared at δ 5.88 – 5.73 and the two other 
terminal C=C protons were revealed as double doublet and doublet at δ 5.17 and 5.12 
respectively. In addition, there was a peak at δ 3.17 for the hydroxyl proton and another one 
at δ 4.31 for the proton at the β-position. The 13C NMR spectrum revealed two carbonyl 
carbon signals at δ 173.8 and 172.4, two olefinic signals at δ 134.6 and 117.8, and the 
signal at δ 70.0 was due to for the carbon adjacent to the hydroxyl group. Then two 
methoxy signals at δ 51.8 and 52.5, and at δ 48.0 for the α-carbon and a CH2 signal at δ 
31.9. In the IR spectrum there were significant peaks for the hydroxyl, alkene and carbonyl 
functional groups at vmax 3468, 1642 and 1741 cm
-1 respectively. The specific rotation was 
recorded as [α] 23
D
 = + 11 (c 1.5, CHCl3). 
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Table (2): Selected 1H and 13C NMR signals for compound (165). 
 
Proton Integration Multiplicity δ/ppm J/ Hz Carbon δ/ppm 
Ha 1 m 5.88 – 5.73 ----- C1 173.8 
Hb 1 dd 5.17 1.4, 17.1 C2 172.4 
Hb’ 1 d 5.12 10.2 C3 134.6 
Hc 1 dd 4.31 3.2, 7.1 
C4 117.8 
Hd 3 s 3.80 ----- C5 70.0 
He 3 s 3.69 ----- C6 52.5 
Hf 1 br.d 3.17 7.1 C7 51.8 
Hg 1 ddd 2.99 3.2, 6.6, 8.7 C8 48.0 
Hh 1 dt 2.62 6.3,14.1 C9 31.9 
Hh/ 1 m 2.5    
 
In order to discover the effect of the HMPA on the yield, the reaction was carried out once 
using HMPA and gave the required product in 59% yield, compared to 58% yield, without 
HMPA. This is therefore advantageous compared to previous methods as it can be carried 
out without the use of HMPA, which is considered to be a carcinogenic compound, without 
having any significant effect on the yield of the required product.  
This allylation reaction was also repeated under the same conditions described above using 
butyl lithium, instead of methyl lithium, and diethyl (S)-2-hydroxysuccinate (105 R = Et) to 
give (166) in 53% yield Scheme (27) with a specific rotation of [α] 23
D
 = + 13.4 (c 1.79, 
CHCl3). (lit.
206 [α] 20
D
 = + 15.1 (c 1.4, CHCl3)). 
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Scheme (27): The insertion of the α-allyl chain: (i) LDA, 78 °C, allylbromide, dry THF. 
 
2.2.5 Protection of the secondary alcohol 
In order to complete the chain extension at the α-position the secondary alcohol of (2R, 3S)-2-
allyl-3-hydroxysuccinate compounds (165) and (166) were protected with a tert-
butyldimethylsilyl group to give products (167) and (168) in 86% yield Scheme (28). The 
protecting group protons for dimethyl (2R,3S)-2-allyl-3-((tert-butyldimethylsilyl) oxy) 
succinate (167) appeared in the 1H NMR spectrum as a singlet at δ 0.88 for the tert-butyl 
group and two singlets at δ 0.07 and 0.05 for the two methyl groups. The two methyl groups 
are not equivalent because of the nearby chiral centre. The specific rotation of product (167) 
was [α] 22
D
 =  (c 1.5, CHCl3) and that of compound (168) was [α] 22D  =  (c 0.81, CHCl3). 
 
Scheme (28): Protection of the secondary alcohol, reagents and conditions: (i) imidazole, TBDMSCl, DMF, 45 ºC, 
86%. 
2.2.6 Oxidation of dialkyl (2R, 3S)-2-allyl-3-((tert-butyldimethylsilyl) oxy)-succinate 
to aldehyde 
The olefins (167) and (168) were oxidised to the aldehydes (169) and (170) with ozone and 
oxygen in dichloromethane at 78 °C for 30 minutes, then the mixture was allowed to reach 
room temperature and triphenylphosphine was added. The aldehydes (169) and (170) were 
obtained in yields of 93% and 84% respectively Scheme (29). Their formation was 
confirmed by their 1H and 13C NMR spectra, which showed signals corresponding to the 
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aldehyde proton, which appeared as a singlet at δ 9.81 and its carbon resonated at δ 199.4 
for compound (169) and at δ 9.81 and δ 199.8 for compound (170).  The specific rotation of 
aldehydes (169) and (170) were [α] 23
D
 = (c 0.72, CHCl3) and (c 2.2, CHCl3) 
respectively.  
 
Scheme (29): Oxidation of the olefin to the aldehyde, reagents and conditions (i): O3/O2, DCM, 78 ºC, 
PPh3. 
 
Figure (36): 1H NMR spectrum of dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2oxoethyl)succinate (169). 
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2.2.7 Preparation of sulfone C18  
2.2.7.1 Preparation of 5-(octadecylsulfonyl)-1-phenyl-1H-tetrazole (171) 
In order to extend the carbon chain at the α-position, the aldehyde prepared in Scheme (30) 
needed to be coupled with sulfone reagents of appropriate carbon chain lengths; For this 
purpose the modified Julia reaction was employed, which will be discussed in more detail in 
section 2.2.8. The first sulfone prepared was the C-18 chain 5-(octadecylsulfonyl)-1-phenyl-
1H-tetrazole (171). 
In order to prepare this, 5-(octadecylthio)-1-phenyl-1H-tetrazole (190) firstly needed to be 
synthesised, and this was achieved by reacting 1-phenyl-1H-tetrazole-5-thiol (189) with 1-
bromooctadecane (188) using K2CO3 and acetone in a yield of 89%. 
 
Scheme (30): Preparation of the sulfone (171), reagents and conditions: (i) K2CO3, 1-phenyl-1H-tetrazole-5-thiol in 
acetone and THF, reflux 3 hours, 89%; (ii) H2O2, (NH4)6Mo7O24.4H2O, THF, IMS, 97%. 
The oxidation of the sulfide with hydrogen peroxide in the presence of ammonium 
molybdate (VI) tetrahydrate in THF and IMS gave the target sulfone (171) Scheme (30).212 
The 1H NMR spectrum of the sulfone (171) included a multiplet at δ 7.77 – 7.57 for the five 
aromatic protons, and a complex triplet at δ 3.79 – 3.69 (J 7.9 Hz) for the two protons 
adjacent to the sulfone Figure (37), which confirmed the success of the reaction. 
 
Figure (37): Signal in the 1H NMR spectrum of the sulfone (171) corresponding to the CH2 next to the sulfonyl 
group. 
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This signal displayed the typical pattern for an AA’BB’ system, where the two substituents 
on the C–C bond mean that A and A’ and B and B’, respectively, are not magnetically 
equivalent Figure (38). 
 
Figure (38): The protons (HA A’ and H BB’) adjacent to a sulfonyl group. 
 
The 13C NMR showed a signal at δ 56.0 for the (-CH2SO2-) group this again confirming 
that the sulfone had been formed. This system was seen throughout this work and was a 
good indication to confirm the success of the reaction. 
2.2.7.2 Preparation of sulfone (C-20 and C-22) for the chain extension 
Two other sulfones with a C-20 (172) and C-22 (173) chain were also prepared. Alcohol (191 
and 192) were brominated using N-bromosuccinimide and triphenylphosphine in 
dichloromethane followed by reaction with 1-phenyl-1H-tetrazole-5-thiol to give the sulfide 
compounds (195) and (196). The subsequent oxidation of these sulfides with meta-
chloroperbenzoic acid was achieved by using dichloromethane and NaHCO3 at 0 
oC, and this 
gave the sulfones (172) and (173) in yields of 96%, Scheme (31). 
 
 
Scheme (31): Preparation of sulfones (C-20 and C-22), reagents and conditions: (i) N-bromosuccinimide, 
Ph3P, DCM, (ii) 1-phenyl-1H-tetrazole-5-thiol, K2CO3, acetone and THF, (iii) m-CPBA, NaHCO3, DCM. 
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The 1H NMR spectrum of compound (195) showed a multiplet at δ 7.65 – 7.48 for the five 
aromatic protons, a triplet at δ 3.40 (J 7.4 Hz) for the (-CH2S-) and a triplet at δ 0.89 (J 6.8 
Hz) for the terminal methyl group. The 13C NMR spectrum showed a signal at δ 154.5 for 
the tetrazole ring carbon, four signals for the aromatic carbons at δ 133.8 – 123.9 and 
signals at δ 33.4 for the long chain carbon bonded to the sulfur atom (-CH2S-) and at δ 14.1 
for the terminal methyl group. The 1H NMR and 13C NMR spectra of compound (196) were 
similar to those of compound (195), mentioned above. 
The 1H NMR spectrum of the sulfone (172) showed a multiplet at δ 7.73 – 7.57 for the five 
aromatic protons and a distorted triplet at δ 3.74 (J 7.9 Hz) for the two protons adjacent to 
the sulfonyl group. Again, the data for sulfone (173) was similar to that of (172).  For the 
oxidation of sulfides (195) and (196) to sulfones (172) and (173) m-CPBA, DCM and 
NaHCO3 were used, rather than using the same conditions as were used for the oxidation of 
(190) to (171) (see Scheme 30). Both sets of reagents can be used for the oxidation, with 
those chosen depending on the solubility of the sulfide compound. 
2.2.8 Extension of the chain 
2.2.8.1 An overview of the Julia-Kocienski olefination reaction 
As mentioned earlier chain extension at the α-position can be carried out using a modified 
Julia reaction to couple the aldehyde prepared in section 2.2.6 with sulfone reagents of 
appropriate carbon chain lengths. This reaction was first described by Marc Julia, and work 
carried out by Kocienski et al.257,258 to modify this method led to it becoming an important 
C _ C bond forming reaction in organic synthesis.259 For this reason it became known as the 
Julia-Kocienski reaction. The reaction was then further modified by Sylvestre Julia,260 who 
replaced the use of phenylsulfones with a new kind of heteroarylsulfones, and since then it 
has been named the modified Julia-Kocienski olefination reaction. This type of chain 
extension is used frequently throughout this study. 
It involves the reaction of metallated sulfone (197) with an aldehyde to form a β-alkoxysulfone 
intermediate (198). Due to the instability of the newly formed intermediate, it undergoes a 
Smiles rearrangement via the intermediate (199) with the transfer of the negative charge from 
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sulfur to oxygen. Finally, elimination of sulfur dioxide and lithium 1-phenyl-1H-tetrazolone 
from (200) gives a mixture of the two alkene isomers (201) (Scheme 32). 
 
Scheme (32): Mechanism of the modified Julia-Kocienski reaction. 
Four heterocyclic activators have been identified for the modified Julia olefination, which 
provide useful levels of stereoselectivity in certain scenarios: benzothiazol-2-yl (BT), pyridin-2-
yl (PYR), 1-phenyl-1H-tetrazol-5-yl (PT) and 1-tert-butyl-1H-tetrazol-5-yl (TBT) (Figure 39). 
 
Figure (39): Four heterocyclic sulfones for the modified Julia olefination. 
1-Phenyl-1H-tetrazol-5-yl sulfonyl (204) was chosen in this work, because it was easy to prepare 
from commercially available materials and it has not shown any problems with self-
condensation.261,262 Julia coupling reactions are also the best method for the preparation of the long 
chain alkenes in the work described here. Furthermore, the by-product of the Julia coupling reaction 
is easily removed compared to the by-products in olefinations such as the Wittig reaction; this 
produces triphenyl phosphonium oxide as a by-product, which is difficult to remove. 
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2.2.8.2 The chain extension of diesters (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-
(2-oxoethyl)succinate compounds (169 and 170) 
Having the sulfone units (171), (172) and (173) in hand, they could now be coupled to the 
previously prepared aldehydes (169 and 170) in a modified Julia olefination reaction. The 
reaction with the C-18 sulfone (171) was firstly carried out and the reaction was started by 
addition of a non-nucleophilic strong base, i.e. lithium bis(trimethylsilyl) amide at – 20 oC. 
Subsequently, the mixture was allowed to reach room temperature and stirred for 3 hours to 
complete the reaction. The reaction appeared to be very straightforward, giving the desired 
alkenes in 76% and 77% yields respectively. The products were a mixture of E- and Z- 
stereoisomers in a 2:1 ratio Scheme (33); The 1H NMR spectrum of the product (206) showed 
the protons of the C–C double bond at δ 5.53 – 5.39 and δ 5.36 – 5.24, while the signal for the 
aldehyde proton had disappeared. The 13C NMR spectrum also confirmed the success of the 
reaction due to the signals at δ 129.9 and 128.6 corresponding to the alkene carbons. 
 
Scheme (33): Chain extension of the aldehydes (169 and 170) by a Julia-Kocienski reaction, reagents and 
conditions: (i) LiN(SiMe3)2, dryTHF,  20 °C, (ii) H2, Pd on carbon, THF and IMS. 
The alkenes were then saturated by hydrogenation using palladium (10%) on carbon as a 
catalyst and hydrogen gas in IMS and THF (1:1) as shown in Scheme (33). The 
hydrogenation sometimes proceeded in a straightforward way, however sometimes it took a 
long time and in some cases, it was even necessary to repeat the hydrogenation. The 
products (174) and (177) gave NMR spectra similar to the olefin compounds but without 
the signals for the alkene protons, which proved that the hydrogenation had been 
completed. The 1H NMR spectrum for compound (174) showed a doublet at δ 4.34 (J 7.2 
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Hz) corresponding to the proton at the β-position, and two singlets at δ 3.73 and δ 3.67 for 
the two (OCH3) groups in the compound. The proton at the α-position appeared as a double 
double doublet at δ 2.83 (J 4.6, 7.2, 10.2 Hz), while the triplet at δ 0.88 (J 6.4 Hz) belonged 
to the terminal methyl group. The 13C NMR spectrum also confirmed the success of the 
reaction due to the disappearance of the signal corresponding to the C=C at δ 129.9 and 
128.6 Figure (40). 
 
 
  
Figure (40): Selected signals in the 1H and 13C NMR spectrum of (174). 
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Similar observations were also made in the NMR spectra of compound (177). The specific 
rotation of compound (174) was [α] 22
D
 =  27 (c 0.69, CHCl3), while that of compound (177) 
was [α] 22
D
 =  (c 0.91, CHCl3).  
This modified Julia-Kocienski olefination was also applied for the coupling of aldehydes 
(169 and 170) with the C-20 and C-22 sulfones, with the NMR spectra of the products 
similar to those described for compound (174), thus again confirming the success of the 
reaction (Scheme 34). 
 
Scheme (34): Julia-Kocienski copling reaction to form (175, 178) and (176, 179), reagents and conditions: (i) 
LiN(SiMe3)2, dryTHF,  20 °C; (ii) H2, Pd on carbon, THFand IMS. 
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2.2.9 Selective reduction of the diesters 
The key step for the preparation of the mycolic motif unit from the diester compounds, is 
the selective reduction of the ester (1) (Figure 41). The selective reduction of such systems 
without the α-chain has been reported in the literature.263,264 Moreover the selective 
reduction of the di-ethyl ester (179) has been investigated by M. Sahb.254 In this earlier 
work a range of conditions were used to reduce (179) and it was observed that at -78 °C no 
reaction occurred, while between -78 °C and -55 °C some of the required aldehyde was 
formed but there was also unreacted starting material. Using various equivalents of the 
reagents diisobutylaluminium hydride (DIBAL-H) and magnesium bromide diethyl etherate 
(MgBr2.Et2O) at a higher temperature of -55°C to 0°C gave different combinations of 
products, with 1.5 equivalents of MgBr2.Et2O and 2.2 equivalents of DIBAL-H giving the 
best result (no starting material and 33 % of the required aldehyde, however 45% of the 
alcohol was also obtained). Because the presence of an ethyl ester caused problems later in 
the synthesis of complete mycolic acids, and to try to improve the yield, similar conditions 
to those described by Sahb were therefore attempted here, a number of times, for the 
selective reduction of diester (176). However, at -55 °C no reaction occurred. This is likely 
to be due to the poor solubility of the reagents at this temperature; the formation of a solid 
was observed when the reagents were added. A range of alternative reaction conditions 
were therefore investigated (see Table 3), with the best yield and selectivity being achieved 
when using DIBAL_H (1.5 equivalents) and MgBr2.Et2O (1.7 equivalents) between -38 and 
-34 °C. This gave an improved yield (78%), compared to previous studies, of the desired 
aldehyde (182), with only 10% of the alcohol (182a) (entry 4), (see Table 3).  
 
Figure (41): Selective reduction of the diester. 
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Table (3): Conditions used for the selective reduction of diester compound (176), with entry 4 giving the best result. 
 
Entry 
 
Temperature MgBr2.Et2O 
eq. 
DIBAL eq. Product Yield % 
1 _ 55 °C 1.5 1.2 176 No reaction 
2 _ 45 to _ 40 °C 1.5 1.3 176 and 182 73, 15 
3 _ 40 to _ 33 °C 1.5 1.5 176, 182, 182a 62, 20, 6 
4 _ 38 to _ 34 °C 1.5 1.7 182, 182a 78, 10 
5 _ 36 to _ 30 °C 1.5 2.5 182a 70 
 
The above conditions were also found to work well with the ethyl ester compounds. 
 
 
2.2.9.1 Selective reduction of diesters (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-
3-tetracosylsuccinate 
Having identified the optimal conditions for the selective reduction, the reduction of compound 
(174) with a shorter α-chain, could be carried out. A solution of magnesium bromide diethyl 
etherate (1.5 eq) and compound (174) in dichloromethene was stirred at room temperature for 
ca.one hour, and then the mixture was cooled to 38 °C. Diisobutylaluminum hydride (1.7 eq) 
was added dropwise over 5 minutes, and the mixture was stirred for 1 hour at 38 to 34 °C 
before being quenched with methanol and saturated aqueous sodium sulfate. The crude product 
was purified by column chromatography to give (180) and (180a) (Scheme 35). 
 
Scheme (35): Selective reduction of diesters (174), reagents and conditions: (i) DIBAL (1.7 eq), MgBr2.Et2O 
(1.5eq), dry DCM, 38 °C. 
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The structure of product (180) was verified by the 1H NMR spectrum, which gave a doublet at δ 
9.63 (J 1.9 Hz) corresponding to the aldehyde proton, a doublet of doublets at δ 4.07 (J 1.9, 5.6 
Hz) for the proton at the β position, a doublet of triplets at δ 2.80 (J 5.7, 8.8) for the proton at the 
α-position and a singlet at δ 3.71 for the one ester group. The 13C NMR spectrum gave a signal at 
δ 203.1 ppm for the aldehyde group (Figure 42). 
 
 
Figure (42): The 1H and 13C NMR spectra for compound (180). 
The second fraction that was obtained with aldehyde (180) was the alcohol (180a). The 1H 
NMR spectrum of (180a) showed a doublet of triplets at δ 3.91 (J 3.6, 7.4 Hz) for the 
proton at the β-position, a br. doublet at δ 3.60 (J 3.6 Hz) for the CH2 adjacent to the 
primary alcohol and a multiplet at δ 2.76 – 2.68 for the α-proton. The 13C NMR spectrum 
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showed signals at δ 173.9 for the carbonyl carbon of the ester, at δ 49.1 for the carbon at the 
α-position, and at δ 73.8 for the carbon at the β-position.  
The alcohols could easily be oxidised to the required aldehydes using PCC in 
dichloromethane, as shown in Scheme (36) below for the oxidation of the longer chain 
alcohol (182a) to the aldehyde (182). 
 
Scheme (36): Oxidation of alcohol (182a) to aldehyde (182), reagents and conditions: (i) PCC, DCM, 87%. 
2.2.10 Summary 
Following the methods described above the mycolic motif was successfully prepared in an 
overall yield of 27% in only 6 steps. This is a significant improvement compared to 
previous methods starting from L-aspartic acid (14 steps, 10% yield)203 and L-malic acid 
(10% yield over 10 steps).253 Moreover, the method described here eliminates the use of 
HMPA. As the mycolic motif is a common unit in all MAs this method can be incorporated 
into the synthesis of all MAs and will reduce the cost and amount of time required in the 
full MA synthesis. 
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2.3 Synthesis of a cis-alkene-α-methyl-trans-alkene 
mycolic acid 
Mycolic acid (155) contains double bonds at both the distal and proximal positions: a cis 
double bond at the distal position and an α-methyl trans alkene at the proximal position. This 
type of mycolic acid has been isolated from the environmental Mycobacterium, M. brumae 
(see page 9). By preparing a single synthetic enantiomer of this type of mycolic acid it can be 
compared to the natural material and also, along with it’s related sugar esters, could be used 
in biological assays for the development of new methods to detect infection by this 
Mycobacterium and to distinguish it from other mycobacterial infections. M. brumae has also 
been shown to have potential to inhibit bladder cancer cell growth,87 therefore synthesis of 
mycolic acids present in this Mycobacterium could also lead to further developments in this 
area. The synthetic route to prepare (155) will be discussed in detail in this section and the 
retrosynthesis is summarised below (Schemes 37_ 40). The protected mycolic acids (207 and 
208) can be broken down into 2 main fragments, that containing the distal position of the 
meromycolate moiety (209), and the intermediate (210) and (211) (Scheme 37). 
 
Scheme (37): The fragment containing the distal position of the meromycolate moiety (209) and the 
intermediates (210 and 211). 
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The intermediates (210 and 211) can then be broken down into the mycolic motif (180) and 
(183), the synthesis of which has already been described, and the proximal position (212) 
and (213) (Scheme 38). 
 
Scheme (38): Retrosynthesis of the fragment that will form the proximal position (210 and 211). 
The proximal position moiety could be synthesised from aldehyde (218) and sulfone (217), 
which could themselves be obtained from and D-mannitol (219) and tetradecanedioic acid 
(222), respectively (Scheme 39). 
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Scheme (39): Retrosynthesis of the fragment (214). 
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The Z- alkene unit at the distal position of the meromycolate chain (209) could be obtained 
from the commercially available cyclic lactone (227) (Scheme 40). 
 
Scheme (40): Retrosynthesis of the Z- alkene at the distal position. 
2.3.1 Preparation of the aldehyde (218) 
D-Mannitol (219) was protected using acetone in the presence of anhydrous zinc chloride to 
give the diol 1,2:5,6-di-O-isopropylidene-D-mannitol (228) in 86% yield.265 Oxidative 
cleavage of diol (228) with sodium metaperiodate in aqueous sodium hydrogen carbonate 
gave the intermediate glyceraldehyde acetonide,266 which was treated in situ with methyl 
diisopropyl-phosphinylacetate, and aqueous potassium carbonate to give the α,β-
unsaturated ester (229), in 70% yield via a Horner-Wadsworth-Emmons reaction,267,268 
(Scheme 41). The 1H NMR spectrum of (229) showed the expected olefin signals as two 
double doublets at δ 6.9 (J 5.7 and 15.8 Hz, vicinal and trans coupling constant) and 6.11 (J 
1.6 and 15.8 Hz, allylic and trans coupling constant), respectively. The methyl ester 
appeared as a singlet at δ 3.75. The 13C NMR showed a signal at δ 110.2 for the acetal 
carbon. 
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Scheme (41): Reagents and conditions: (i) ZnCl2, acetone 86% (ii) NaIO4, NaHCO3, H2O, methyl diisopropyl-
phosphinyl acetate, K2CO3 70%; (iii) MeLi, dry ether, 77%; (iv) LiAlH4, THF, 87%; (v) PCC, CH2Cl2, 87%. 
The diastereoselective conjugate addition of a methyl nucleophile to the α, β-unsaturated 
ester (229) was conducted as reported by Leonard and co-workers.269 Thus, (229) was 
exposed to MeLi in diethyl ether at – 78 oC to give syn-adduct, (230) as a single 
diastereomer in 77% yield. As before, it is important to keep the temperature below – 78 
oC. The added methyl group appeared in the 1H NMR spectrum as a doublet at δ 0.98 (J 6.7 
Hz). This, along with the disappearance of the alkene signals confirmed the formation of 
the product. The 13C NMR spectrum showed signals at δ 173.0 for the carbonyl carbon and 
at δ 108.9 for the cyclic acetal carbon.269 Again, there were no signals corresponding to the 
alkene group. 
The ester (230) was reduced to the corresponding primary alcohol (231) with lithium 
aluminium hydride in dry THF, in good yield 87%. The IR spectrum showed a broad stretch 
at νmax 3427 cm-1 for the O–H group. 
Finally, the alcohol (231) was oxidised to the desired aldehyde (218) with pyridinium 
chlorochromate (PCC) in dichloromethane. The 1H NMR spectrum showed a broad. triplet at δ 
9.77 (J 1.8 Hz) for the aldehyde proton and in the 13C NMR a signal appeared at δ 201.6 for the 
carbonyl carbon.  
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 2.3.2 Preparation of the intermediate C-14 sulfone 
To extend the carbon chain aldehyde (218) could be coupled with a sulfone of required length 
via a Julia reaction. For MA (155) a C-14 sulfone (217) therefore needed to be prepared. The 
Julia reaction was used to extend the chain rather than a Wittig coupling, because preparation of 
a long chain Wittig salt is difficult and also the yield is lower than that in the Julia reaction. 
Tetradecanedioic acid (222) was converted into diester (232), using conc. H2SO4 and 
methanol in a very good yield 98%. Reduction of the diester with LiAlH4 in THF was then 
carried out to give the diol (233). The 1H NMR spectrum confirmed the formation of the 
product due to the disappearance of the signals corresponding to the ester groups and the 
appearance of a triplet at δ 3.65 (J 6.6 Hz) corresponding to the (2×CH2OH) integrating to 
four protons. The next step was monobromination of the diol (233) to 14-bromotetradecan-1-
ol (234) with 48 % HBr in toluene under reflux. Again, the structure was proved by the 1H 
NMR spectrum which showed a triplet at δ 3.64 (J 6.6 Hz) corresponding to the (-CH2OH) 
integrating to two protons and a triplet at δ 3.41 (J 6.9 Hz) corresponding to the (-CH2Br). 
The protection of the hydroxy group was then carried out using trimethyl acetyl chloride; this 
protection is very common and the deprotection is easy with a strong base such as KOH, or 
LiAlH4. Understanding the 
1H and 13C NMR spectra is also easy compared to it the THP 
protecting groups used. Consequently, compound (221) was obtained in 97% yield by 
protecting mono alcohol (234) with trimethyl acetyl chloride in the presence of triethylamine 
and catalytic 4-dimethylaminopyridine (DMAP) (Scheme 42). 
 
Scheme (42): Preparation of compound (221). Reagents and conditions: (i) H2SO4, MeOH, 98%; (ii) LiAlH4, 
THF, 97%; (iii) HBr 48%, toluene, 85%; (iv) trimethyl acetyl chloride, Et3N, DCM, 97%. 
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The 1H NMR spectrum of the protected compound (221) showed a triplet at δ 4.04 (J 6.6 
Hz) for the protons adjacent to the oxygen and a triplet at δ 3.40 (J 6.9 Hz) for the protons 
adjacent to the bromine substituent. The tert-butyl group protons appeared at δ 1.19 as a 
singlet. The 13C NMR spectrum showed a signal at δ 178.6 for the carbonyl carbon, and a 
signal at δ 38.7 for the quaternary carbon of the protecting group, and a signal at δ 27.2 for 
the tert-butyl methyl carbons. The IR showed a peak at 1729 cm-1 for the carbonyl group 
C=O stretch. 
The protected bromo compound (221) was reacted with 1-phenyl-1H-tetrazole-5-thiol in 
acetone to give the sulfide (220) (Scheme 43). The proton NMR spectrum showed a 
multiplet at δ 7.71 – 7.41 for the phenyl group protons and a triplet at δ 3.38 (J 7.4 Hz) for 
the two protons (CH2S). Also, the carbon NMR spectrum showed five signals in the 
aromatic region: one at δ 154.5 for the tetrazole ring carbon, and another four at δ 133.7, 
130.0, 129.7 and 123.8 for the phenyl group carbons. 
 
Scheme (43): Preparation of sulfone C-14 (217), reagents and conditions: (i) 1-phenyl-1H-tetrazole-5-thiol, 
K2CO3, acetone and THF reflux 86%; (ii) H2O2, (NH4)6Mo7O24.4H2O, THF, IMS, 93%. 
Finally, the sulfide (220) was oxidised to the desired sulfone (217), as previously discussed 
and purified by column chromatography. The characteristic signal for the protons adjacent 
to the sulfonyl group appeared as a triplet at δ 3.77 – 3.69 (J 7.9 Hz) as shown in Figure 
(43). The sulfone (217) was thus obtained in five steps in an overall yield of 55%. 
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Figure (43): 1H NMR spectrum of the intermediate sulfone (217). 
2.3.3 Coupling of aldehyde (218) with sulfone (217) 
The aldehyde (218) was used as the source of the α-methyl trans-alkene unit, at the proximal 
position. In order to extend the length of the carbon chain, the aldehyde (218) was coupled to the 
sulfone (217) in a Julia reaction, using lithium bis(trimethylsilyl) amide at 10 oC. Subsequently, 
the reaction mixture was allowed to reach room temperature and stirred for 3 hours to complete 
the reaction. The reaction appeared to be very straightforward, giving the desired alkene in a 69% 
yield, as a mixture of E and Z-isomers. The purified product (235) gave a 1H NMR spectrum 
which revealed peaks for the two alkene protons at δ 5.49 – 5.25 as a multiplet, and a multiplet at 
δ 1.31 – 1.22 for the long chain protons. The 13C NMR spectrum showed two signals at δ 132.6 
and 127.5 for the olefinic carbons. The cyclic acetal carbon appeared at δ 108.6 and two signals 
appeared at δ 79.9 and 67.8 for the carbons adjacent to the oxygen atoms. The alkene mixture was 
then hydrogenated with hydrogen gas in the presence of Pd (10%) on carbon in IMS and THF 
(1:1) to give the saturated compound (236) in a yield of 92% (Scheme 44). 
 
Scheme (44): Preparation of intermediate (236), Reagents and conditions: (i) LiN(SiMe3)2, dry THF, 69%; (ii) 
H2 gas, Pd (10%) on C, IMS and THF, 92%. 
 
CH2a 
 
CH2b 
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2.4 Preparation of the intermediate C-16 sulfone (214) 
In order to couple the above compound (236) with the mycolic motif unit (183) it needed to be 
converted into sulfone (214). Firstly, LiAlH4 in THF was used to remove the protecting pivalate 
ester of (236) to give the corresponding alcohol (216) in an excellent yield, 96%  (Scheme 45). 
The 1H NMR spectrum in CDCl3 showed a triplet at δ 3.50 (J 6.7 Hz) for the two protons 
adjacent to the hydroxyl group. The IR spectrum showed a broad peak at 3400 cm-1 for the O–H 
stretch. The next stage was to perform a Mitsunobu reaction.270 This reaction involves adding 
diethyl azodicarboxylate (DEAD) at 0 ºC under nitrogen gas dropwise to a solution of alcohol 
(216), triphenylphosphine and 1-phenyl-1H-tetrazole-5-thiole in dry THF, and allowing the 
mixture to stir for 3 hours. 
 
Scheme (45): Preparation of the intermediate C-16 sulfone (214). Reagents and conditions: (i) LiAlH4, THF 96%, (ii) diethyl 
azodicarboxylate, 1-phenyl-1H-tetrazole-5-thiol, PPh3, dry THF, 83%, (iii) (NH4)6Mo7O24.4H2O, H2O2, THF, IMS, 96%. 
Finally, the sulfide (215) was oxidised to the corresponding sulfone (214) with hydrogen peroxide 
and ammonium molybdate (VI) tetrahydrate as shown in Scheme (45). The protecting acetal group 
remained during the oxidation, which was confirmed by the NMR spectra. The 1H NMR spectrum 
of the sulfone (214) showed a triplet at δ 3.74 (J 7.9 Hz) for the two protons next to the sulfonyl 
group, a doublet at δ 0.97 (J 6.7 Hz) for the chiral methyl protons and two singlets at δ 1.41 and δ 
1.36 for the two methyls on the acetal protecting group. The acetal carbon signal appeared in the 13C 
NMR spectrum at δ 108.4. 
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2.4.1 Extension of the mycolic motif chain by coupling with sulfone (214) 
This step involved the coupling of the mycolic motif unit (183) with the long chain 
containing the methyl group which would finally be next to the trans-alkene unit. The 
mycolic motif unit and the meromycolate, the aldehyde (183) was coupled with sulfone (214) 
in a modified Julia reaction in the presence of lithium bis(trimethylsilyl) amide in dry THF to 
give the desired alkene (237) as a mixture of E and Z-isomers in 79% yield (Scheme 46). The 
double bond was then hydrogenated using hydrogen gas in the presence of palladium on 
carbon (10%), to give the saturated compound (238) in 78% yield. The specific rotation was 
measured at [α] 24
D
 = + 6.37 (c 1.36 CHCl3), which is close to the value for similar compounds 
that differ only in the chain lengths.203 The structure of compound (238) was confirmed using 
NMR spectroscopy, this showed no signals in the olefinic region, which proved that the 
hydrogenation had been completed, see Table (4). 
 
Scheme (46): The coupling reaction between mycolic motif (183) and intermediate sulfone (214), Reagents and 
conditions: (i) LiN(SiMe3)2, dry THF, 79%; (ii) H2, Pd (10%) on C, IMS and THF, 78%. 
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Table (4): 1H NMR and 13C NMR data analysis of compound (238). 
 
Proton δ/ppm Multiplicity Integration J (Hz) Carbon δ/ppm 
Ha 4.12 m 2 ----- C1 174.6 
Hb 4.01 dd 1 6.2, 7.8 C2 108.5 
Hc 3.95 – 3.78 m 1 ----- C3 80.4 
Hd 3.87 br q 1 6.95 C4 73.2 
He 3.61 br t 1 7.7 C5 67.8 
Hf 2.50 ddd 1 3.8,7.0,10.8 C6 59.9 
Hh 1.59-1.52 m 2 ---- C7 51.6 
Hj 1.49-1.42 m 2 ----- C8 36.5 
Hg 1.40, 1.36 s 2 × 3H ----- C9 33.7 
-CH2 chain 1.33 – 1.18 m 72 ----- C10 32.7-22.7 
Hk 0.97 d 3 6.7 C11 25.8 
Hi 0.89 t 3 4.9 C12 25.5 
Hm 0.87 s 9 ----- C13 18.0 
Hn 0.05,0.03 s 2 × 3H ----- C14 15.6 
     C15 14.1 
    ----- C16 -4.4, -5.0 
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2.5 Synthesis of a model mycolic acid 
Based on a number of literature methods concerning the synthesis and reaction of closely 
allied species,271,272 we can be confident that no significant epimerisation occurs adjacent to 
the aldehyde during the above reaction  (Scheme 46). Two examples from the literature are 
shown below in Schemes 47 and 48.271,272 
 
Scheme (47): Reagents and conditions, (i) n-BuLi, THF, -78 °C – 0 oC 89%. 
 
Scheme (48): Reagents and conditions, (i) n-BuLi, TBSO(CH2)6P+Ph3Br-, THF, -78 °C to rt, 2hrs, 74%. 
Furthermore, to confirm this, the synthesis of a model mycolic acid (244) was also carried 
out to confirm that no epimerisation occurred. Mycolic acid motif (185) was coupled with 
sulfone (173), followed by the reduction of the double bond to give the protected model 
mycolic acid (243). Deprotection of (243) using TBAF in dry THF gave hydroxy ester 
(244), Scheme (49). 
 
Scheme (49): Reagents and conditions: (i) LiN(SiMe3)2, dry THF, 15 oC, 78%; (ii) Pd on 10% C, THF and 
IMS 93%; (iii) TBAF, dry THF, 85%. 
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The molecular rotation ([M]D) confirmed that during the reaction no epimerisation 
occurred; the molecular rotation is defined as one-hundredth of the product of the specific 
rotation and the relative molecular mass of an optically-active compound: 
[𝐌]𝐃 = [𝛂]𝑫
𝒙  (
𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐰𝐞𝐢𝐠𝐡𝐭
𝟏𝟎𝟎
) 
 
the specific rotation of the β-hydroxy ester (244) was [α] 23
D
 = + 5.3 (c 0.91 CHCl3), therefore 
the molecular rotation of (244) was calculated to be + 41.0, which is very close to the 
calculated [M]D value for the corynomycolate reported in the literature (+ 40).
148 Had there 
been any epimerisation, the value for (244) would have been much lower. 
2.6 Preparation of the intermediate aldehyde (211) for final coupling 
In order to have compound (211) ready to be coupled to the meromycolate moiety to form 
the full MA, the acetonide protecting group needed to be removed and the secondary 
alcohol protecting group needed to be changed from the bulky TBDMS group to an acetate. 
The deprotection reagent tetra-n-butyl ammonium fluoride (TBAF) was used to remove the 
sterically hindered tert-butyldimethylsilyl. The product, secondary alcohol (245), was 
obtained in 82% yield, with the IR showing a peak at 3520 cm-1 confirming the formation 
of the O–H bond. The NMR spectra did not show any signals for the tert-butyldimethylsilyl 
group and other signals were as expected. Protection of the alcohol as an acetoxy group 
using acetic anhydride and anhydrous pyridine was then carried out to give product (213) in 
98% yield. The 1H NMR spectrum showed that the proton adjacent to the acetoxy group 
had shifted downfield and appeared as a doublet of triplets at δ 5.10 (J 4.0, 7.5 Hz). The 
methyl protons on the acetyl group also appeared as a singlet at δ 2.03. Following this, 
oxidative cleavage of the cyclic acetal group (213) with periodic acid in dry ether led to the 
corresponding aldehyde (211) in 77% yield (Scheme 50). 
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Scheme (50): The synthesis of α-methyl aldehyde (211), reagent and conditions: (i) TBAF, pyridine, THF, 82%; (ii) 
acetic anhydride, pyridine, dry toluene,98%; (iii) periodic acid, dry ether, 77%. 
The 1H NMR spectrum showed a doublet at δ 9.61 (J 1.9 Hz) for the aldehyde proton, a 
multiplet at δ 2.38 – 2.29 for the proton next to the aldehyde and a doublet at δ 1.09 (J 7.0 
Hz) for the methyl protons at the α-position to the aldehyde. The 13C NMR spectra showed 
a signal at δ 205.3 for the carbonyl carbon of the aldehyde, a signal at δ 46.3 for the carbon 
next to the aldehydes. The disappearance of the signals of the protecting group in the proton 
and carbon NMR spectra confirmed the success of the reaction. The IR spectrum showed a 
peak at 1731cm-1 (C=O) and the specific rotation of (211) was [α] 29
D
 = + 6.0 (c 0.4, CHCl3). 
 2.7 Preparation of methyl (2R,3R,21R)-3-acetoxy-2-eicosyl-21-methyl-22-
oxodocosanoate (212) 
The sulfone (214) and the mycolic motif unit aldehyde (180) were dissolved in THF, 
followed by addition of lithium bis(trimethylsilyl) amide at 15 °C. The reaction mixture 
was allowed to reach room temperature and stirred for 3 hours. The reaction afforded a 
mixture of the E/Z isomers in a ratio 2:1, in an 76% yield Scheme (51). As discussed 
previously (section 2.4.1) we can be confident that no epimerisation has occurred during 
this coupling reaction. Again the 1H NMR spectrum of (246) showed two multiplets at δ 
5.47 – 5.40 and at δ 5.37 – 5.31 respectively for the two alkene protons. The 13C NMR 
spectrum showed two signals at δ 132.7 and 127.5 for the olefinic carbons. This was 
followed by deprotection of the tert-butyldimethylsilyloxy group of compound (246) to 
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give the corresponding secondary alcohol (247) at the β-position. Protection of the alcohol 
as an acetoxy group by using acetic anhydride and anhydrous pyridine in dry toluene gave 
product (248) in 88% yield. Hydrogenation using palladium hydroxide on activated 
charcoal Pd(OH)2, gave the saturated compound (212) in 96% yield. Following this, the 
oxidative cleavage of the cyclic acetal group with periodic acid in dry ether led to 
corresponding aldehyde (210) in 88% yield.  It is important to note that during this 
synthesis the hydrogenation of the alkene (246) was initially attempted, a number of times, 
however it proved to be problematic, with the 1H NMR spectrum indicating that a complex 
mixture had been formed, with loss of the β-hydroxy and methoxy groups. It was therefore 
necessary to deprotect the bulky TBDMS group and re-protect the alcohol with an acetate 
group before hydrogenation of alkene (248) was carried out successfully. 
 
 
Scheme (51): The synthesis of compound (210). Reagents and conditions: (i) LiN(SiMe3)2, dry THF 76%; (ii) TBAF, pyridine, 
THF, 88%; (iii) acetic anhydride, pyridine, dry tolene, 88%; (iv) H2, Pd (OH)2, IMS and THF 96%; (v) periodic acid, dry ether, 88%. 
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The 1H NMR spectrum for compound (210) showed a doublet at δ 9.61 (J 1.7 Hz) for the 
aldehyde proton, a multiplet at δ 2.65 – 2.56 (1H, m) for the α-H next to the ester group, 
another multiplet at δ 2.39 – 2.26 for the proton next to the aldehyde group and a doublet at 
δ 1.09 (J 7.0 Hz) for the methyl protons at the α-position to the aldehyde (Figure 44). The 
13C NMR spectrum showed a signal at δ 202.4 for the carbonyl carbon of the aldehyde and, 
a signal at δ 46.3 for the carbon next to the aldehyde Table (5). 
 
Figure (44): 1H NMR spectrum of compound (210). 
 
Table (5): 1H NMR and 13C NMR data analysis of compound (210). 
 
Proton δppm Multiplicity Integration J (Hz) Carbon δppm 
Ha 9.61 d 1 1.7 C1 205.4 
Hb 5.08 dt 1 4.1,7.6 C2 173.7 
Hc 3.68 s 3 ----- C3 170.4 
Hd 2.65 – 2.56 m 1 ----- C4 74.0 
He 2.39 – 2.26 m 1 ----- C5 51.5 
Hf 2.03 s 3 ----- C6 46.3 
-CH2 chain 1.73 – 1.19 m 92 ----   
Hg 1.09 d 3 7.0 ---- ---- 
Hh 0.88 t 3 6.6 ---- ---- 
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2.8 Preparation of Z-alkene sulfone (209) for final coupling 
2.8.1 Ring opening of lactone for preparation of the 15-carbon chain 
To complete the final coupling reaction for the synthesis of the cis-alkene-α-methyl-trans-
alkene mycolic acid, the moremycolate moiety needed to be prepared. The synthesis started 
with the commercially available and inexpensive ω-pentadecalactone (227). Ring opening 
of the ω-pentadecalactone (227) was achieved by adding it to freshly prepared sodium 
methoxide in methanol and stirring at 80 oC for 3 hours. The solution was acidified with aq. 
HCl (1N) and worked up. The proton NMR spectrum showed the product was a mixture of 
the desired methyl ester and the carboxylic acid. Therefore, the acid was esterified in 
methanol and a catalytic amount of H2SO4 by refluxing for 90 minutes to give 15-
hydroxypentadecanoic acid methyl ester (249) in 86% yield (Scheme 52).273 
 
Scheme (52): Ring opening of the lactone (277). Reagents and conditions: (i) NaOMe, MeOH, H2SO4, 80 °C, 
2 hrs, (ii) MeOH, H2SO4, reflux 1 hr, 86%. 
The 1H NMR spectrum of (249) showed a singlet at δ 3.67 for the methyl ester protons, a 
triplet at δ 3.64 (J 6.5 Hz) for the two protons next to the hydroxy group, and a triplet at δ 
2.31 (J 7.5 Hz) for the two protons next to the carbonyl group. The long chain protons 
appeared as a multiplet at δ 1.41 – 1.15. The 13C NMR spectrum showed a carbonyl signal 
at δ 174.4, a signal at δ 63.0 for the carbon next to the hydroxy group, and a signal at δ 51.4 
for the methyl ester carbon. The IR spectrum showed a broad peak at 3298 cm-1 for the O–
H stretch and another broad peak at 1742 cm-1 for the C=O stretch. 
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2.8.2 Protection with a dihydropyranyl group 
The hydroxyl group of the methyl 15-hydroxypentadecanoate (249) was protected with 
dihydropyran in the presence of pyridinium-p-toluene–sulfonate in dichloromethane to give 
methyl 15-((tetrahydro-2H-pyran-2-yl)oxy)pentadecanoate (250) in 94% yield Scheme (53).274 
 
Scheme (53): Protection the alcohol with a THP group. Reagents and conditions: (i) 3,4-dihydro-
2H-pyran, PPTS, dry DCM, 94%. 
The proton NMR showed the signals of the THP group with a broad multiplet at δ 4.58 ppm 
integrated to one proton corresponding to the acetal proton. There was a triplet at δ 2.30 ppm 
(J 7.5 Hz) integrating to two protons corresponding to the CH2 adjacent to the carbonyl 
group, while the remaining signals of the OCH3 group appeared at δ 3.67. The carbon NMR 
showed signals at δ 174.3 corresponding to the carbonyl group, and at δ 98.8 ppm for the 
carbon of the acetal group of the THP. 
2.8.3 Reduction and oxidation 
The protected methyl ester (250) was reduced with lithium aluminium hydride in THF and 
after quenching with a sat. aq. solution of sodium sulfate alcohol (251) was obtained, which 
was converted to the corresponding aldehyde (226) in 82% yield using PCC in 
dichloromethane Scheme (54). PCC is a mild oxidizing agent and widely used for the 
oxidation of primary alcohols to aldehydes without further oxidation to carboxylic acids, and 
under neutral conditions. 
 
Scheme (54): Preparation of the chain extended α-methyl-trans-cyclopropane aldehyde. Reagents and 
conditions: (i) LiAlH4, THF, 91%; (ii) PCC, DCM, 82%. 
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The proton NMR spectrum of compound (251) confirmed the disappearance of the sharp 
singlet belonging to the methoxy ester (OCH3), and instead showed a broad triplet at δ 3.64 
(J 5.3 Hz) for the two protons next to the alcohol. The carbon NMR spectrum also showed 
a signal at δ 63.0 for the carbon bonded to the hydroxyl group. The IR spectrum showed a 
broad peak at 3392 cm-1 due to the OH group. The 1H NMR spectrum for aldehyde (226) 
showed a triplet at δ 9.75 (J 7.2 Hz), for the aldehyde and a doublet of triplets at δ 2.40 (J 
1.7, 7.4 Hz), integrating to two protons for the adjacent to aldehyde proton. The most 
significant signal of the THP group was a multiplet at δ 4.56 integrating to one proton 
corresponding to the acetal THP. The 13C NMR signal showed an aldehyde signal at δ 
202.9, and the THP acetal carbon appeared at δ 98.8. The IR spectrum also confirmed the 
formation of the aldehyde due to the peak at 1727 cm-1 corresponding to the C=O group, 
while that for the O-H group had disappeared. 
2.9 Synthesis of Z-alkene THP (252) 
2.9.1 Preparation of phosphonium salt 
In order to produce the desired Z alkene THP (252), the Wittig salt (225) needed to be prepared. To 
obtain this esterification of heptadecanoic acid (253) using conc. H2SO4 and methanol was firstly 
carried out to give compound (254), in 99% yield. This was then reduced to alcohol (255) using 
lithium aluminium hydride in THF. The alcohol was characterized by proton NMR, which showed 
a triplet at δ 3.65 ppm (J 6.6 Hz) corresponding to the two protons next to the hydroxyl group, and 
the carbon NMR spectrum also confirmed the disappearance of the carbonyl group. The IR 
spectrum showed a peak at 3389 cm-1 belonging to O-H group in the compound. The alcohol (255) 
was converted into 1-bromoheptadecane (256) using N-bromosuccinimide with triphenylphosphine 
in dichloromethane. The heptadecyltriphenylphosphonium bromide (225) was prepared following 
the literature method.275 It was obtained by refluxing the bromo-compound (256) and 
triphenylphosphine in toluene at 70oC for 4 days (Scheme 55). The pure phosphonium salt (225) 
was obtained in 74% yield after purification by column chromatography, firstly eluting with 
petroleum ether and then dichloromethane/methanol (95:5), and then precipitation in dry ether. 
 91 
 
 
Scheme (55): Synthesis of alkyl phosphonium salt (225), Reagents and conditions: (i) H2SO4, MeOH, 99%;  
(ii) LiAlH4, THF, 95%; (iii) NBS, PPh3, DCM, 92%; (iv) PPh3, toluene, 74%. 
It was found that this method of purifying the phosphonium salt is better than recrystallization 
alone, and can improve the yield of the subsequent Wittig reaction. The proton NMR of (225) 
showed the aromatic protons as a broad multiplet between δ 7.91–7.66 integrating to fifteen 
protons, and the two protons next to the phosphorus appeared as a multiplet at δ 4.03 – 3.49. 
The carbon NMR also showed the aromatic carbons between δ 134.9–118.3. 
2.9.2 Insertion of the first double bond via a Wittig reaction 
The crucially important part of this synthesis was formation of the Z-alkene isomer. There 
is one well known literature method, coupling of an aldehyde with a phosphonium salt in 
the presence of sodium bis(trimethylsilyl)amide that gives the Z-stereoisomer with great 
selectivity. This was attempted using compounds (226) and (225) and gave the required Z-
alkene (252) (Scheme 56). 
 
Scheme (56): Synthesis of Z-alkene (252), reagents and conditions: (i) sodium bis(trimethylsilyl)amide, dry THF, 64%. 
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The proton NMR of (252) confirmed the success of the reaction, which showed the cis double 
bond protons as a broad triplet at δ 5.36 (J 4.7 Hz) integrating to two protons Figure (45). The 
signals of the THP group showed a multiplet at δ 4.59 belonging to the acetal proton. The 
carbon NMR showed the alkene carbons at δ 129.9, and the THP acetal carbon at δ 98.8. 
 
 
Figure (45): The proton NMR signal for the cis alkene protons of (252). 
2.9.3 Deprotection of Z-alkene THP (252) 
The deprotection of the THP group in compound (252) was carried out using pyridinium-p-
toluene sulfonate in a mixture of THF and MeOH stirring at 45 oC for six hours to give alcohol 
(224) in 71% yield, (Scheme 57). The alcohol compound (224) was then treated with 1-phenyl-
1H-tetrazole-5-thiol and triphenylphosphine in the presence of diethyl azodicarboxylate 
(DEAD) to give the Z- alkene sulfide (223) in a very good yield of 96%. Finally, the Z-alkene 
sulfone (209) was prepared via oxidation of sulfide (223) using hydrogen peroxide and 
ammonium molybdate in IMS and THF. 
 
Scheme (57):  Preparation of Z-alkene sulfone (209). Reagents and conditions (i) PPTS, THF, MeOH, at 40 ºC, 71%; (ii) 
1-phenyl-1H-tetrazole-5-thiol, Ph3P, DEAD, dry THF, 96%; (iii) hydrogen peroxide, (NH4)6Mo7O24.4H2O, IMS and 
THF, 83%. 
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The 1H spectrum of compound (224) showed a triplet at δ 3.65 (J 6.6 Hz) for the two protons 
belonging to the carbon next to the OH group and the carbon NMR showed a signal at δ 63.1 
ppm for the same carbon, while the protons belonging to the THP group had disappeared 
from the spectrum. It has been found that there is a broad triplet at δ 3.40 (J 7.4 Hz) 
integrating to two protons belonging to the carbon next to the sulfur atom and the phenyl 
group protons appeared as a multiplet at δ 7.84-7.38 integrating to five protons for the sulfide 
compound (223). The 1H NMR spectrum of the Z-alkene sulfone (209) showed a broad triplet 
at δ 3.74 (J 7.9 Hz) integrating to the two protons next to the sulfonyl group. The sulfonyl 
carbon signal appeared in the carbon NMR spectrum at δ 56.0 (Figure 46). 
 
Figure (46):1H NMR spectrum of sulfone compound (209). 
2.10 Final coupling reaction between the meromycolate moiety and mycolic 
motif unit to form mycolic acid (207) 
Recent studies suggested that the steroselectivity and yield of the Julia olefination is 
sensitive to base with the typical modified Julia-Kocienski olefination using lithium 
bis(trimethylsilyl)amide being likely to give the alkene product as a mixture of cis- and 
trans- stereoisomers. Therefore, as isolation of the trans-alkene would be highly 
problematic, lithium bis(trimethylsilyl)amide was not used as the base. Both Pospíšil et 
al.276 and Kocienski et al. discussed the use of different bases, in particular potassium 
bis(trimethylsilyl)amide, to increase the stereoselectivity in favour of the trans-isomer. 
Koceinski et al. discovered that changing the base used increases stereoselectivity in the 
 
 
Ha Hb 
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order Li<Na<K, and Pospíšil et al. gives evidence that increasing the size of the alkyl chain 
of the aldehyde leads to higher stereoselectivity. The coupling between the α-methyl 
substituted aldehyde (210) and the Z-alkene sulfone (209) to form the protected mycolic 
acid (207) was initially carried out in 1,2-dimethoxyethane with potassium bis 
(trimethylsilyl) amide (1 M in THF or 0.5 M in toluene). This reaction was attempted a 
number of times at various temperatures (between – 20 and 20 °C); however only a very 
small amount of product was formed (max 2% yield), with the 1H NMR spectra indicating 
that a complex mixture was obtained in each case. The problem with this reaction was 
likely to be due to the poor solubility of the compounds in 1,2-dimethoxyethane. An 
alternative method, using dry THF as solvent in the presence of potassium bis 
(trimethylsilyl) amide (1 M in THF or 0.5 M in toluene) at 16 ºC was therefore used, 
which led to the formation of the required product (207) in 39% yield (Scheme 58). 
 
Scheme (58): Reagents and conditions: (i) potassium bis(trimethylsilyl)amide, dry THF, 39%. 
The stereoselective formation of the α-methyl trans alkene was confirmed by NMR 
spectroscopy. The specific rotation of compound (207) was [α] 30
D
 = + 11 (c 0.21 CHCl3).   
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It is again essential that during the synthesis of (207) that no epimerisation occurs adjacent 
to the aldehyde. There are a number of examples of this kind of reaction where the chirality 
is retained,277,278,279 for example Scheme (59) 
 
Scheme (59): Literature example of the retention of chirality adjacent to the aldehyde.280 
The coupling reaction was also carried out between the ethyl ester (211) and sulfone (209) 
to form protected mycolic acid (208) (Scheme 60). 
 
Scheme (60): Reagents and conditions: (i) potassium bis(trimethylsilyl)amide, THF, 47%. 
The structure was confirmed by the 1H NMR spectrum which showed a multiplet at δ 5.41 –  
5.29 and a doublet of doublets at δ 5.24 (J 7.3, 15.4 Hz) corresponding to the alkene protons. 
The coupling constant of 15.4 Hz between the olefinic hydrogen atoms confirmed the 
formation of the trans-alkene. The 13C NMR spectrum showed signals in the olefinic region 
at δ 136.4, 129.9 and 128.4 for the cis and trans-alkene carbons. The specific rotation of the 
product (208) was found to be [α] 23
D
 = + 11 (c 0.17 CHCl3).  
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2.10.1 Deprotection and hydrolysis of (207) to produce free mycolic acid (155) 
Finally, the resulting acetylated mycolic acid methyl ester (207) was hydrolysed using 
lithium hydroxide in a mixture of THF, methanol and water at 45 °C for 16 hours to give 
the free alkene mycolic acid (155), Scheme (61). 
 
Scheme (61): Reagents and conditions: (i) LiOH, MeOH, H2O, THF, 45 °C, 16 h 71%. 
 
After purification by re-crystallization from petrol/ethyl acetate (1:2) the MA (155) was obtained 
in a yield of 71%. The 1H NMR spectrum confirmed the formation of the free MA due to the 
disappearance of the signal at δ 3.68 corresponding to the methyl ester and that at δ 5.09 (J 4.0,7.6 
Hz) corresponding to the acetyl group at the β- position. The IR spectrum further confirmed the 
formation of free mycolic acid (155), which showed a broad peak at 3585 cm-1 for the OH stretch. 
A detailed analysis of the spectroscopic data for (155) is given below. 
 
Figure (47): 1H NMR spectrum of cis-alkene-α-methyl-trans-alkene mycolic acid (155). 
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The 1H NMR spectrum of the cis-alkene-α-methyl-trans-alkene mycolic acid (155) showed 
a multiplet at δ 5.41 – 5.29 (3H) corresponding to two protons of the cis double bond and 
one proton of the trans double bond, and a double doublet at δ 5.24 (J 7.5, 15.3 Hz) 
corresponding to the other proton of the trans double bound. The signals corresponding to 
Hc and Hd appeared as two double triplets at δ 3.73 and δ 2.47 respectively, while the 
proton adjacent to the α-methyl next to the trans double bond appeared as a multiplet at δ 
2.08 – 1.93 with six protons corresponding to CH2 groups next to the double bonds. The 
Figure also shows a multiplet at δ 1.81 – 0.99 corresponding to the long-chain protons. 
Finally, the signals that occur as a doublet at δ 0.94 (J 6.7 Hz) and a triplet at δ 0.89 (J 6.5 
Hz) correspond to the CH3 next to the double bond and the two terminal CH3 groups 
respectively. A summary of the proton and carbon NMR data is given in Table (6). The 
2D-NMR confirmed the structure of (155), where the proton signals of the double bonds 
were correlated to their carbons throughout (Figure 48). 
 
Figure (48): The 2D-NMR for free mycolic acid (155). 
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Table (6): NMR analysis of cis-alkene-α-methyl-trans-alkene mycolic acid. 
 
Proton δ/ppm Multiplicity Integration J/ Hz Carbon δ/ppm 
Ha 
5.41 – 5.29 m 
3 
---- 
C1 
178.5 
Hb 
5.24 dd 
1 
7.5,15.3 
C2 
136.5 
Hc 
3.73 dt 
1 
4.8, 9.4 
C3 
130.4 
Hd 2.47 dt 1 5.2, 9.2 C4 129.9 
He +6CH2 
adjacent to 
double bonds 
 
2.08 – 1.93 m 
 
7 
---- 
 
C5 
 
128.4 
CH3 0.94 d 3 6.7 C6 72.1 
Terminal CH3 
0.89 t 
6 
6.8 
C7 
50.7 
 
The IR data for the cis-alkene-α-methyl-trans-alkene mycolic acid (155) indicated the formation 
of the acid, Table (7). 
 
Table (7): IR analysis of cis- alkene-α- methyl-trans- alkene mycolic acid (155). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stretching Wave number (cm-1) 
 
O-H 3585 
 
C-H 2915 
 
C-H 2848 
 
C=O 1686 
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The structure of (155) was also confirmed by mass spectrometry [TOF-MS-ASAP+–Found 
(M+H)+:1096.1323 C75H147O3 requires: 1096.1350 (Figure 49). 
 
Figure (49): Mass spectrometry data for mycolic acid (155). 
The molecular rotations (see page 85) of individual functional groups in natural mixtures of 
mycolic acids and in model compounds have been identified by Quémard et. al.148 In 
general, the [M]D in such systems where a group of chiral centres are separated by long 
carbon chains are approximately additive; the individual values of the R,R-centres of the   
2-hydroxy acid (ester) fragment in mycolates is estimated as + 40, the RCH=CHCH3- 
fragment as – 25 (for 30% content). Therefore, the [M]D value of the free acid (155) can be 
estimated as +15 (-25+40) based on the sum of hydroxy acid and α-methyl trans alkene 
contributions. The specific rotation of acid (155) was determined to be +2.2 (c 0.92 CHCl3), 
which corresponds to [M]D = +24 which is in agreement with the calculated value using the 
relationship above. 
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By comparison, the specific rotation of the keto mycolic acid (260) was determined to be +7.34 
(c 0.79, CHCl3),
269 which corresponds to [M]D = +92, which is in agreement with the sum of 
the contributions of an S-α-methylketone unit ([M]D = +44) and an R, R-hydroxy acid unit 
([M]D = +40), assuming a very small contribution from the cis-cyclopropane component. 
 
Another example for this occurs in the work of Hanan Ali 281 For the methoxy mycolic acid 
(261) the specific rotation of this acid was determined to be 1.6 (c = 0.99, CHCl3), which 
corresponds to an [M]D = 24. The figure for the (S,S) α-methyl-methoxy fragment may be 
estimated from the present result as  50, the RCH=CHCH3- fragment as – 25 and R,R-
centres of the 2-hydroxy acid (ester) fragment in mycolates is estimated as + 40. Therefore, 
the [M]D value can be estimated as 35 (5025+40) which is in agreement with the 
calculated value. 
 
The amount of ethyl ester (208) obtained was not enough to carry out the same deprotection 
to the free acid (155) (see page 93). 
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2.11 Synthesis of sugar and glycerol esters of MA (155) 
There are many lipids present within the cell wall of M. tuberculosis.67 Mycobacterial cord 
factors are known as very interesting compounds due to their biological activity, which has 
been the subject of many investigations. Studies have shown that these components of 
mycobacteria have immune activity. The outer envelope of all mycobacteria consists of 
TDMs that have unique properties. 2% of the dry weight of M. tuberculosis is made of 
surface lipid making it the most abundant for extraction.125,282 TDM is necessary for the 
survival of the mycobacteria inside macrophages, while GMM has immunological properties. 
GMMs have the capacity to produce T cell proliferative responses in a number of species 
including humans,283 mice, guinea pigs, and cattle. GroMM has been identified in vitro as the 
most immunopotentiating compound among a number of different lipids isolated from the 
mycobacterial cell wall.234 GroMM is a specific immune target in human individuals with 
latent, but not active, tuberculosis, but the in vivo response to GroMM and the relevance of it 
to latent infection remain poorly understood. GroMM is however known to be important in 
vaccines as an adjuvant. The methyl arabino-mycolates (MAM) is a part of the cell wall of 
M. tuberculosis. All these different kinds of sugar and glycerol mycolates could therefore 
play an important role in better understanding the properties of mycobacteria. In addition, 
investigating their biological activity could lead to improvements in the detection and 
diagnosis of mycobacterial diseases. The synthesis of a range of sugar esters of MA (155) 
will be discussed below. 
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2.11.1 Synthesis of GroMM 
The first ester prepared was the GroMM (156), by coupling free MA (155) with the 
protected glycerol (262), followed by deprotection of the sugar moiety (Scheme 62). 
 
Scheme (62): Reagents and conditions: (i) cesium hydrogencarbonate, (S)-2,3-bis(benzyloxy)-propyl-4-
methyl benzene sulfonate, DMF:THF (1:5), 70 oC, 65%; (ii) Na, NH3, 1,4-dioxane, 46%. 
The coupling reaction between the MA (155) and protected glycerol (262), supplied by Dr. J 
Al-Dulayymi, was carried out using cesium hydrogen carbonate to give protected GroMM 
(263) in 65% yield. The structure was confirmed by the 1H NMR spectrum which showed a 
multiplet at δ 7.53 – 7.09 for the ten aromatic protons of the benzyl groups. Protons 
corresponding to the double bond were revealed as a multiplet at δ 5.42 – 5.29 (3H) and a 
double doublet at δ 5.24 (J 7.4, 15.3 Hz). Two doublets occurred at δ 4.68 (J 11.8 Hz) and δ 
4.64 (J 11.8 Hz) for (PhCH2), and one broad singlet at δ 4.55 for the second (PhCH2). Two 
double doublets occurred at δ 4.43 (J 4.0, 11.7 Hz) and δ 4.22 (J 5.5, 11.7 Hz) for the protons 
next to the ester group, and a signal was present at δ 3.60 – 3.57 corresponding to the proton 
at the β-position. The signal corresponding to the proton at the α-position in the mycolate 
component appeared as a triplet of doublets at δ 2.43 (J 5.4, 9.3 Hz). Finally, a doublet at δ 
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0.95 (J 6.7 Hz) and a triplet at δ 0.89 (J 6.8 Hz) belonged to the methyl group and terminal (2 
× CH3) respectively. Formation of the protected compound (263), was also proven by the 
13C 
NMR spectrum, which showed a signal for the carbonyl ester at δ 175.5 and the signals for 
the benzylic carbons at δ 73.5 and δ 72.3. The signals for C7, C9 and C8 in the glycerol unit 
appeared at δ 75.8 δ 69.6 and δ 63.5 respectively. 
The next step was deprotection of the glycerol unit. The most common procedure used for 
the debenzylation is the use of palladium on carbon or palladium hydroxide as a catalyst 
under an atmosphere of hydrogen. This was however, not used for the deprotection of the 
benzyl groups in compound (263) due to the presence of the two double bonds in the 
mycolate compound of the GroMM, which would also be hydrogenated. 
Selective removal of the benzyl groups in (263) was achieved using sodium in liquid 
ammonia, and gave deprotected GroMM (156) in 46% yield. The 1H NMR spectrum 
confirmed that the deprotection of GroMM (156) had been achieved by showing that the 
signal pertaining to the ten aromatic protons at δ 7.53 – 7.09 had disappeared, while the two 
signals presenting as double doublets for the two protons next to the ester group had shifted 
to δ 4.26 (J 4.2, 11.5 Hz) and 4.19 (J 6.4, 11.5 Hz). Two signals seen as multiplets at δ 3.95 
– 3.88 and δ 3.71 – 3.63 corresponded to the three protons next to the hydroxyl groups. 
Also, a broad double doublet at δ 3.56 (J 5.8,11.5 Hz) belonging to the proton at the β-
position, a broad multiplet at δ 2.45 – 2.36 corresponded to the proton in the α- position of 
the mycolate, while the protons of the long chain appeared as a multiplet at δ 1.71 – 1.05. 
The 13C NMR spectrum showed that the signals for the benzylic carbons at δ 7.53 – 7.09 
had disappeared, but all signals expected for the carbons present in GroMM (156) were 
seen, (Table 8). 
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Table (8): The 1H NMR and 13C NMR spectrum analysis of GroMM (156). 
 
Proton Integration Multiplicity δ/ppm J/ Hz Carbon δ/ppm 
Ha 3 m 5.38 – 5.26 ----- C1 175.5 
Hb 1 dd 5.21 7.2, 15.4 C2 136.4 
Hc 1 dd 4.26 4.2, 11.5 C3 130.3 
Hc 1 dd 4.19 6.4, 11.5 
C4 129.8 
Hd 1 m 3.95– 3.88 ----- C5 128.4 
He, He 2 m 3.71 – 3.63 ----- C6 72.7 
Hf 1 dd 3.56 5.8,11.5 C7 69.8 
Hh 1 m 2.45 – 2.36 ----- C8 65.1 
Hi and CH2 next to 
the double bounds 
7 m 2.03 – 1.90 ----- 
C9 63.0 
Alkyl chain 126 m 1.70 – 0.94 ----- C10 52.4 
CH3 α-to the double 
bond 
3 d 0.91 6.7 ----- 
------ 
Terminal CH3 6 t 0.86 6.7 ----- ----- 
 
 
Nano-electrospray ionization (NSI) mass spectrometry was used to reduce fragmentation and 
enhance the abundance of the intact molecular ion of (156), giving (M+H)+: 1170.1713 
(C78H153O5, requires:1170.1712]. 
 
 
 
 
 
 105 
 
2.11.2 Synthesis of GMM 
The coupling between free mycolic acid (155) and protected glucose (264), supplied by Dr. J. Al 
Dulayymi, to form the protected sugar ester, followed by deprotection of the sugar to give free 
GMM (157) was carried out as shown in Scheme (63). 
 
Scheme (63): Reagents and conditions: (i) cesium hydrogen carbonate, DMF:THF (1:5), 70 oC, 67%; (ii) Na, 
NH3, 1,4-dioxane, 25%. 
The protected GMM was obtained in a yield of 67% with the NMR spectra confirming the 
required product had been formed. The1H NMR spectrum showed a multiplet at δ 7.44 – 
7.00 for the twenty aromatic protons and a multiplet at δ 5.42 – 5.30 and a double doublet at 
δ 5.25 (J 7.4, 15.4 Hz), corresponding to the protons of the two double bonds in the 
mycolate moiety. The signals for each of the CH2 groups of the benzyl groups on the sugar 
appeared as doublets in the range δ 4.96 4.61. A doublet occurred at δ 4.55 (J 11.2 Hz), 
corresponding to one proton attached to C-6. A broad doublet appeared at δ 4.53 (J 7.7 Hz), 
which corresponds to the β-anomeric proton attached to C-1 and a double doublet at δ 4.23 
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(J 4.5, 11.7 Hz) corresponds to the second proton attached to C-6. The spectrum also 
showed a broad triplet at δ 3.67 (J 7.6 Hz) associated with the proton attached to the C-2 
and the CH-OH of the mycolate. A multiplet at δ 3.533.49 corresponds to protons attached 
to C-3, C-4 and C-5. The three protons of the α-methyl next to the trans-double bond 
appeared as a doublet at δ 0.95 (J 6.7 Hz). 
The 13C NMR spectrum showed a signal for the carbonyl ester at δ 175.2 and the signals for 
the carbons of the two double bonds at δ 136.5, 130.4, 129.9 and 128.5. Also, the signals 
for the carbons of the benzyl groups appeared at δ 138.4 127.7, while the carbons of the 
sugar appeared at δ 102.3, 84.5, 82.3, 77.8 and 72.9 from C1 to C5, and C6 at δ 62.9. 
Positions C10 and C11 (β-hydroxy position) appeared at δ 84.5 and δ 72.3 respectively. 
Careful removal of the benzyl groups from the protected GMM (265) was achieved by 
using sodium in liquid ammonia to give deprotected GMM (157) as a mixture of α and β 
anomers in a ratio of (0.6:0.4) in 25% yield. The 1H NMR spectrum confirmed that the 
deprotection of compound (265) had been successful; the signal pertaining to the twenty 
aromatic protons at δ 7.447.00 was absent from the spectrum of the free GMM (157), and 
the signals for the CH2 of the benzylic protons were also not present.  
The 1H NMR spectrum showed a multplet at δ 5.37 – 5.23 (3H, m) and a double doublet at δ 
5.19 (J 7.4, 15.4 Hz) corresponding to the protons of the two double bonds in the mycolate 
component. A doublet at δ 5.11 (J 3.3 Hz) corresponds to Hc-α, and another doublet at δ 4.46 (J 
7.7 Hz) to Hc-β. The spectrum also showed a broad doublet at δ 4.41 (J 11.9 Hz) associated 
with Hd-α,β, a broad double doublet at δ 4.24 (J 5.9, 11.8 Hz) corresponding to Hd-α,β, a 
double double doublet at δ 3.95 (J 2.2, 5.8, 9.8 Hz) related to He-α, and another multiplet at δ 
3.67 – 3.58 corresponding to Hk-α and CH-OH of the mycolate component. Another signal 
which appears as a double double doublet at δ 3.483.44 (J 2.2, 5.8, 9.8 Hz) is related to He-β; 
a multiplet at δ 3.433.26 corresponds to Hi,j-α and Hj,k-β. Another broad triplet occurs at δ 
3.17 (J 8.4 Hz) corresponding to Hi-β. All these data confirmed the formation of the free 
GMM, and a detailed analysis of the 1H NMR can be seen in Table (9) below. Formation of the 
deprotected GMM (157) was also demonstrated by the 13C NMR spectrum, which showed that 
the signals for the carbon environments in the aromatic region were not present.  
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The analysis of the 13C NMR spectrum showed all signals expected for the carbons present in 
free GMM (157) 
Table (9): 1H and C13 NMR analysis of GMM (157). 
 
Proton Integration Multiplicity δ/ppm J/ Hz Carbon δ/ppm 
Ha 3 m 5.37 – 5.23 ----- C-1α 92.3 
Hb 1 dd 5.19 7.4, 15.4 C-1β 96.6 
Hc-α 1 d 5.11 3.3 C-2α 72.2 
Hc-β 1 d 4.46 7.7 
C-2β 74.6 
Hd-α,β 1 br. d 4.41 11.9 C-3α 70.5 
Hd-α,β 1 br.dd 4.24 5.9,11.8 C-3β 76.2 
He-α 1 ddd 3.96-3.92 2.2, 5.8, 9.8 C-4α 73.7 
He-β 1 ddd 3.48-3.44 2.2, 5.8, 9.8 C-4 β 70.3 
Hk-α and Hg 2 m 3.43-3.26 ----- C-5α 69.2 
Hi-β 1 br.t 3.17 8.4 C-5β 73.7 
Hm 1 m 2.42 – 2.34 ----- C-6α/β 63.6 
Hn and CH2 next to the 
double bounds 
7 m 2.07 – 1.84 ----- 
C-6α/β 63.5 
CH3 α-to the double bond 3 d 0.89 6.7 C 7 175.2 
Terminal CH3 6 t 0.83 6.7 C8 136.4 
     C9 130.3 
     C10 129.9 
     C11 128.4 
     C12 72.5 
     C-13α/β 52.6 
     C-13α/β 52.4 
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2.11.3 The synthesis of arabino-MA fragment from AG 
The esterification between the free mycolic acid (155) and protected arabinofuranoside (266) which 
was supplied by Dr. J. Al Dulayymi, was carried out using dry cesium hydrogen carbonate in a 
mixture of dry DMF:THF and gave the protected compound (267) in 58% yield, (Scheme 64). The 
1H NMR spectrum of the protected compound (267) showed a multiplet at δ 7.45 – 7.20 for the ten 
aromatic protons, a multiplet at δ 5.41 – 5.29 and a double doublet at δ 5.25 (J 7.4, 15.4 Hz) 
corresponding to 3Ha and 1Hb respectively of the double bonds. A broad singlet at δ 4.92 
corresponded to Hc, and the signals for CH2 of the benzyl group appear as doublet in the range δ 
4.584.48, together with a multiplet at δ 4.24 – 4.20 integrating to one to proton corresponding to 
Hg. Also, a doublet at δ 3.99 (J 2.3 Hz) corresponded to Hd and a double doublet at δ 3.84 (J 2.6, 
6.5 Hz) corresponded to He. A multiplet appeared at δ 4.32-4.28 for Hf, while the singlet at δ 3.38 
corresponded to the methoxy group. The 13C NMR spectrum showed signals for the carbonyl ester 
at δ 175.0, while the two signals for the CH2 of the benzyl group appeared at δ 72.4 and δ 72.1 
together with a signal at δ 72.2 for C12, while C-6, C-7, C-8, C-9 and C-11 were seen at δ 107.2, 
87.9, 83.7, 79.4 and 63.5 respectively. The OCH3 group appeared at δ 54.9. 
 
 
Scheme (64): Reagents and conditions: (i) cesium hydrogen carbonate, DMF:THF (1:5), 70 oC 58%; (ii) Na, NH3, 1,4-
dioxane 39%. 
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The removal of the benzyl groups in (267) was achieved using sodium in liquid ammonia to 
give the deprotected compound (158), in 39% yield. The 1H NMR spectrum of this showed that 
the signals corresponding to Hc had shifted upfield to δ 4.81 from δ 4.92 after losing the 
deshielding effect of the aromatic ring. The 1H NMR spectrum confirmed that the deprotected 
compound (158) had been obtained successfully, Table (10). 
Table (10): NMR 1H and 13C analysis of fragment from AG (158). 
 
Proton Integration Multiplicity δ/ppm J/ Hz Carbon δ/ppm 
Ha 3 m 5.37 – 5.26 ----- C1 175.0 
Hb 1 dd 5.20 7.4, 15.4 C2 136.4 
Hc 1 br.s 4.81 ----- C3 130.3 
Hf 1 dd 4.32 4.7, 9.8 
C4 129.8 
Hf 1 dd 4.28 4.9, 10.1 C5 128.3 
Hg 1 br.q 4.09 4.7 C6 108.6 
Hd 1 dd 4.0 1.9, 3.7 C7 82.0 
He 1 dd 3.87 2.7, 4.7 C8 81.2 
Hi 1 m 3.69 – 3.55 ----- C9 77.9 
OCH3 3 s 3.36 ----- C10 55.0 
Hh 1 m 2.45 – 2.36 ----- C11 63.4 
CH3 α-to the double 
bond 
3 d 0.90 6.7 
C12 72.5 
Terminal CH3 6 t 0.85 6.8 C13 52.5 
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2.12 Synthesis of trehalose esters (TDM and TMM) of the cis-alkene-α-
methyl-trans-alkene mycolic acid 
The synthetic cis-alkene-α-methyl-trans-alkene mycolic acid (155) was esterified with trehalose 
to produce trehalose dimycolate (TDM) and trehalose monomycolate (TMM). In order to 
prepare a TDM from the unsaturated mycolic acid (155), it was necessary to protect the β-
hydroxyl group with a TBDMS protecting group. The mycolic acid (155) was stirred with 
imidazole, tert-butyldimethylsilyl chloride and DMAP in a mixture of DMF/toluene at 70 oC 
for 18 hours.  
The reaction usually leads to the protection of both the β-hydroxy group and the carboxylic acid 
to give (268). The next step was therefore the selective deprotection of the carboxylic acid 
group, by stirring it with K2CO3 in a mixture of THF/H2O/MeOH for 3 hours at 45 
oC, to give 
the target compound (269), (Scheme 65). 
 
Scheme (65): Reagents and conditions: (i) imidazole, DMF, toluene, tert-butyldimethylsilyl chloride, 4-
dimethylaminopyridine 70
 oC, 18 hrs (ii) THF/H2O/MeOH, K2CO3, 80%. 
The proton NMR spectrum of compound (269) showed the silyl protecting group protons as a 
singlet at δ 0.91 integrating to 9H and two singlets at δ 0.12 and δ 0.10, each integrating to 3H, 
for the six protons of the two methyl groups. The 13C NMR spectrum also confirmed the 
protection, which showed that the signals that related to the methyl carbons on the tert-butyl 
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group appeared at δ 25.7, the signal for the quaternary carbon at δ 17.9 and the two signals for 
the methyl groups bonded to silicon at δ  4.3 and δ  5.0. The esterification reaction between 
the protected mycolic acid (269) and protected trehalose (270), which was supplied by Dr. J.  
Al Dulayymi, was achieved successfully after 6 days at room temperature under nitrogen gas 
using coupling reagents 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) 
and DMAP in CH2Cl2. The protected cord factors (TDM and TMM), were then separated by 
column chromatography Scheme (66). 
 
Scheme (66): Reagents and conditions (i) DMAP/EDCI/CH2Cl2, TDM 17%, TMM 70%. 
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The first product to be obtained was the TDM (271) in 17% yield with the structure being 
confirmed by 1H and 13C NMR spectroscopy and MALDI mass spectrometry. The 1H NMR 
spectrum of TDM (271) displayed signals for the tert-butyl protons of the silyl protecting group as a 
singlet at δ 0.88 (18H), with the multiplet at δ 5.41 – 5.30 and the double doublet at δ 5.24 (J 7.4, 
15.4 Hz) corresponding to the eight alkene protons. A doublet at δ 4.85 (J 2.9 Hz) corresponded to 
the two acetal protons of the trehalose. The remaining trehalose protons, including the β-hydroxyl 
protons resonated at δ 4.37, 4.01, 3.93, 3.90, 3.53 and 3.38. The α- proton of the mycolic acid 
appeared as a multiplet at δ 2.61 – 2.51, and a multiplet appeared at δ 2.10 – 1.92, integrating to 
fourteen protons, which corresponded to those next to the double bonds and the proton adjacent to 
the α-methyl next to the trans double bond. The methyl group appeared at δ 0.94 (J 6.7 Hz) as a 
doublet integrating to six protons, while the terminal methyl groups of the alkyl chains appeared as a 
triplet at δ 0.89 (J 6.6 Hz). The protons of the trimethylsilyl protecting groups on the trehalose gave 
three singlets at δ 0.16, 0.15, and 0.14 each integrating to eighteen protons. The methyl groups of 
the TBDMS protecting group showed a singlet at δ 0.06 integrating to twelve protons. 
The 13C NMR spectrum showed a signal at δ 173.8 for the carbonyl carbon. The double bond carbon 
signals appeared at δ 136.5, 130.4, 129.9, and 128.4. Also, the remainder of the sugar carbons gave 
signals between δ 73.4 70.7. The methyl carbon signals of the protecting silyl groups of the sugar 
appeared at δ 1.09, 0.94 and 0.16. Additionally, the carbons of the two methyl groups bonded to 
silicon in the silyl groups of the mycolate component appeared at δ 4.5 and δ 4.7. 
The second fraction was the TMM (272), obtained in a yield of 70%. The hemiacetal protons 
appeared as two doublets at δ 4.92 (J 3.0 Hz) and δ 4.85 (J 2.9 Hz) with an integration of one 
proton for each, here the signals were more complicated due to the loss of symmetry. The 
remaining sugar protons appeared between δ 4.36 – 3.4. It was found that the methyl signals for 
the protecting groups on the sugar were divided into six groups, one for each (Me) situated at 
C2-C3-C4, between δ 0.17 0.13, in each case they integrated to 9H and to 54 hydrogens in 
total. The signals for the protecting groups were similar to those found for the TDM (271), but 
with half the number of the protons relating to mycolic acid sub class. The 13C NMR spectrum 
displayed signals at δ 174.1 for the ester group and at δ 94.5 and 94.4 for the C1 in the sugar 
cores. Signals at δ 4.5 and 4.7 were displayed for the two methyl groups bound to the 
silicon in the TBDMS group. 
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2.12.1 Trehalose deprotection of TDM (271) and TMM (272) 
The trimethylsilyl protecting groups on the trehalose moiety of both TDM (271) and TMM 
(272) were then removed. This deprotection was carried out using tetra-n-butyl ammonium 
fluoride (TBAF) to give the silyl-protected TDM (273) (Scheme 67) and silyl-protected 
TMM (274), (Scheme 68). 
 
Scheme (67): Reagents and conditions: (i) tetrabutylammonium fluoride, THF, TDM, 15%. 
The 1H NMR spectrum of silyl-protected TDM (273) showed a multiplet at δ 5.36 – 5.21 
and a double doublet at δ 5.17 (J 7.7, 14.0 Hz) for the protons of the double bonds while the 
doublet for the hemiacetal protons was shifted to δ 4.98 (J 3.2 Hz). The remaining signals 
for the sugar protons and the β-hydroxyl protons resonated at δ 4.35, 4.20, 3.91, 3.85, 3.73, 
3.46 and 3.34, and were also shifted. The proton at the α-position appeared as a multiplet at 
δ 2.42 – 2.30, while the doublet at δ 0.88 (J 6.7 Hz) corresponded to the α-methyl trans 
group. The terminal methyl groups gave a triplet at δ 0.84 (J 6.3 Hz) and the tert-butyl 
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groups showed as a singlet at δ 0.81 with an integration of eighteen protons. The signals 
corresponding to the trimethylsilyl protecting groups on the sugar were not present in the 
spectrum, which confirmed that the reaction had been successful. 
 
 
Scheme (98): Reagents and conditions: (i) tetrabutylammonium fluoride, THF, TMM 30%. 
The 1H NMR spectrum of the silyl-protected TMM (274) showed a multiplet at δ 5.38 – 
5.26 and a double doublet at δ 5.20 (J 7.4, 15.3 Hz) for the protons of the double bonds, 
while the hemiacetal protons appeared as a broad triplet at δ 5.06 (J 3.5 Hz) and a double 
doublet at δ 4.28 (J 3.7, 10.6 Hz) each with an integration of one proton. The remaining 
sugar protons resonated between δ 4.23 3.46. The signals belonging to the trimethylsilyl 
protecting groups of the sugar at δ 0.17, 0.16 and 0.15 were not present in the 1H NMR 
spectrum, and the signals at δ 1.1, δ 1.0 and δ 0.9, corresponding to the carbons of the 
trimethylsilyl groups,  were also absent from the 13C NMR spectrum, which indicated that 
the removal of the silyl groups from the sugar had been successful. 
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2.12.2 Deprotection of the hydroxy acid part of TDM (273) and TMM (274) 
The final step in the synthesis of TDM (159) and TMM (160) was the removal of the 
TBDMS groups from β-position of compounds (273) and (274). Due to the small amount of 
material for TDM (273) this reaction was not attempted. The deprotection of TMM (274) 
was attempted in dry THF using HF.Pyridine in pyridine, however the compound was lost 
during the purification, Scheme (69). 
 
Scheme (69): Desilylation of the hydroxy acid of TMM (274). 
Neither the free TDM (159) nor TMM (160) were prepared here, however the deprotection 
of the TBDMS group, using HF.Pyridine, has been carried out successfully for similar 
TDM and TMM compounds. It is therefore likely had more material been available this 
deprotection would yield the required products, (159) and (160). 
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Chapter 3 
3. Conclusion and further work 
3.1 Conclusion 
The three main amis of this project wrere: to develop an improved method for the synthesis 
of the α-alkyl β-hydroxy (mycolic motif) unit; to use this for the synthesis of a single 
enantiomer of a cis-alkene-α-methyl-trans-alkene mycolic acid, i.e. found in M. brumae; 
and to prepare various sugar and glycerol esters of this specific M.A. 
Thus, initial work focussed on the development of an improved method for the synthesis of the 
mycolic motif unit. The preparation of this intermediate unit has so far proved to be the most 
difficult part of the mycolic acid synthesis. Many methods have been reported for the 
preparation of α-alkyl-β-hydroxy esters, Al Dulayymi et al.251 used (S)-(2-benzeneoxyethyl) 
oxirane (161) as a chiral intermediate prepared from commercially available D-aspartic acid 
based on a method developed by Frick et al.252 In a different approach, Toschi et al.,202 used a 
short chain allylation at the α- position in the initial step followed by further elongation of this 
by a modified Julia-Kocienski reaction to achieve the intended chain length. 
More recently Koza et al.,203 used L-aspartic acid as the starting material for the synthesis 
of the (R)-(2-benzeneoxyethyl)oxirane intermediate (92) in four steps, followed by a short 
chain Frӓter allylation and a further Julia-Kocienski chain extension at the α-position. Khan 
et al.206 on the other hand prepared the β-hydroxy ester using L-malic acid as starting 
material. This was esterified to give diethyl (S)-malate, which was then alkylated with 
different allylic halides by Frӓter allylation followed by selective reduction with BH3·DMS 
to give diol. 
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In this thesis an alternative method that involved fewer steps was targeted, using the 
cheaper, commercially available L-malic acid as starting material, Scheme (70). 
 
Scheme (70): A new method for the preparation of the mycolic motif unit. Reagents and conditions: (i) 1- SOCl2/ 
ROH;  (ii) LDA/ AllBr/THF; (iii) TBDMSCl / imidazole/ DMF; (iv) O3/O2 ; (v) (1)LiN(SiMe3)2 (2)/ H2/Pd/C; (vi) 
DIBAL/MgBr2.Et2O. 
Following this approach the required mycolic motif unit was successfully obtained in 6 steps in 
an overall yield of 27%. This is a significant improvement compared to previous methods 
starting from L-aspartic acid (14 steps, 10% yield) and L-malic acid (10% yield over 10 steps), 
as the number of reaction steps has been reduced and the overall yield of the product improved.  
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Moreover, there was no need to use HMPA in the preparation of the mycolic motif unit in this 
synthesis (the yield of the allylation step was found to be the same with or without using 
HMPA). Also, as the mycolic motif unit is common to all mycolic acids, having an improved 
route to this will be beneficial in the synthesis of all mycolic acids. 
The next part of this work involved the use of the mycolic motif unit discussed above to prepare 
the cis- alkene-α-methyl- trans-alkene MA (155), which has been isolated from M. brumae. The 
synthesis of this MA (155) was achieved over a multi step sequence from the commercially 
available starting materials D-mannitol (219), tetradecanedioic acid (222) and lactone (227). 
These were used as precursors for various aldehyde and sulfone compounds, which were then 
coupled together to give the target MA. The final coupling step, between the proximal position 
(209) and meromycolate moiety (210) is shown in Scheme (71). 
 
Scheme (71): The coupling to form a mycolic acid. 
The studies carried out to optimise the yield of the α-methyl-trans-alkene proved that the yield of 
the modified Julia olefination and the stereoselectivity in the final coupling reaction were 
sensitive to the base used to deprotonate the sulfone and the solvent polarity. Using 1-phenyl-1H-
tetrazole-5-yl sulfones with potassium bis(trimethylsilyl)amide as base and 1,2-dimethoxyethane 
or tetrahydrofuran as solvent gave high E-stereoselectivity. It was confirmed that if the sulfone or 
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aldehyde was α-substituted (i.e. 210) the reaction was completely sterioselective for the formation 
of the E-isomer. This can be seen in Scheme (71) where the coupling reaction between the 
aldehyde (210) and the sulfone (209) using potassium bis(trimethylsilyl)amide in THF gave the 
desired alkene (207) as only the E-diastereomer in a yield of 35%. This coupling formed the 
whole structure of the cis-alkene-α-methyl-trans-alkene mycolic acid and, following hydrolysis, 
the free mycolic acid (155) was obtained in the correct stereochemistry. 
Having successfully prepared MA (155), the final part of this project involved its use in the 
preparation of a range of sugar and glycerol esters. Esterification of the free mycolic acid 
(155) with protected glycerol (262), glucose tosylate (264) and arabinose tosylate (266) 
gave the protected GroMM (263), GMM (265) and ArM (267). The harder step was the 
debenzylation of the sugar moieties in the presence of the two double bonds, in the MA 
moiety. This was achieved using sodium in liquid ammonia to give free GroMM (156), 
GMM (157) and MAM (158) in yields of 46, 25 and 39% respectively Figure (50). 
 
Figure (50): Sugar and glycerol esters of mycolic acid (155). 
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The synthesis of the TDM and TMM cord factors of MA (155) was also attempted. The 
secondary alcohol of MA (155) was firstly protected as a TDMS group and this was then 
coupled to the protected trehalose (270), which after purification by column 
chromatography gave TDM (271) and TMM (272). Deprotection of the sugar moiety of 
both these compounds gave TDM (273) and TMM (274) in 15% and 30% yields 
respectively Scheme (72).  
   
Scheme (72): Preparation of protected TMM and TDM. 
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Due to the small amount of material obtained for TDM (273), removal of the TBDMS 
group was not attempted. This reaction was attempted for TMM (274) using HF. Pyridine 
in pyridine, however, unfortunately the material was lost during purification. 
In summary a new shorter method for the synthesis of the mycolic motif unit has been 
successfully developed. The synthesis of the free MA (155) and its sugar and glycerol 
esters (156), (157) and (158) has also been achieved. The biololgical activity of these new 
antigens can now be investigated and compared to that of other MA cord factor antigens.  
3.2 Further work 
1. Preparation of a number of different ester mycolates of MA (155) through coupling 
with different sugars, e.g arabino glycerol, di-arabino glycerol, methoxy tri-
arabinose and tri-arabino glycerol, to investigate their biological activity. 
2. Synthesis of an α-mycolic acid of Mycobacterium brumae containing a trans-alkene and 
an α-methyl-cis-alkene (reverse stereochemistry of the synthesised mycolic acid (155)), to 
compare the biological activity for both compounds.  
3. Determine and compare the biological activity of the synthesised compounds. Indeed, the 
choice of new target molecules in each of the sections of this thesis will be determined by 
the results of detailed on-going biological assays. These compounds could then be utilised 
to study the immunological properties of synthetic analogs, which would then allow for 
the determination of those structural features, which are responsible for their biological 
activity. 
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Chapter 4 
4. Experimental 
4.1 General considerations 
All chemicals and reagents were purchased from chemical companies (Sigma-Aldrich, Alfa 
Aesar, and Acros). THF was distilled over sodium and benzophenone under nitrogen, while 
dichloromethane, diisopropylamine and HMPA were distilled over calcium hydride. Petrol 
refers to the fraction b.p. 40–60 °C. Organic solutions were dried over anhydrous 
magnesium sulfate and solvents were removed at 14 mmHg; residual traces of solvent were 
finally removed at 0.1 mmHg. All reactions were performed using glassware dried in an 
oven at (120 ºC). Reactions carried out under inert conditions were carried out under a slow 
stream of nitrogen and for low temperature reactions liquid nitrogen/IMS was used to cool 
the solutions, the temperature being controlled using a digital thermometer. Solid 
compounds were purified by re-crystallisation; column chromatography and distillation 
were used for purification and separation of oily compounds. Column chromatography was 
conducted under medium pressure using silica gel (BDH, particle size 33–70 mm); TLC 
was carried out on pre-coated Kieselgel 60 F254 (Art. 5554; Merck) plates; separated 
components were detected using UV light, I2 or phosphomolybdic acid solution in IMS 
followed by charring. Melting points were measured using a Gallenkamp melting point 
apparatus. Optical rotations were measured as solutions of known concentration in 
chloroform using a Polar 2001 automatic polarimeter. Ozonolysis was carried out by using 
ANSEROS GENERATOR COM, ozone generator series com-AD, ozongenerator COM-
AD-01. All NMR samples were recorded on Bruker Avance (400 MHz) spectrometer and 
were prepared as solutions in deuterated CDCl3 or CD3OD unless otherwise indicated. 
Chemical shifts are quoted in δ relative to the trace resonance of proton chloroform (δH 7.27 
ppm, δC 77.0 ppm), and the resonances of methanol (δH 4.87 and 3.31 ppm, δC 49.00 ppm). 
IR (infrared) spectra were performed on a Perkin-Elmer 1600 FTIR, and using KBr disc for 
the solid compounds. NSI and MALDI mass spectrometry data was obtained from the 
EPSRC UK National Mass Spectrometry Facility at Swansea University and Dr Paul Gates 
(Bristol University). A laboratory book was filled in including chemical safety information 
following COSHH regulations. 
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Experiment 1: Dimethyl (S)-2-hydroxysuccinate (164) 
 
Thionyl chloride SOCl2 (59.5 mL, 0.820 mol) was slowly added to a stirred solution of L-
malic acid 104 (50.0 g, 0.372 mol) in methanol (300 mL) at 0 ºC under N2 and the mixture 
was stirred overnight at room temperature. The reaction mixture was neutralized with 5% 
aqueous NaHCO3 and the excess methanol was evaporated. The aqueous layer was re-
extracted with CH2Cl2 (2 × 200 mL) and then the combined organic layers were dried over 
MgSO4, filtered and concentrated. The crude product was purified by flash distillation at 90 
– 120 ºC to give a colourless oil, dimethyl (S)-2-hydroxysuccinate 164 (59 g, 98%) [α] 23
D
 = 
+5.4 (c 0.56, CHCl3) (lit.
152 [α] 22
D
 = + 8.6 (c 1.2, EtOH)). This showed δH (400 MHz, CDCl3): 
4.50 (1H, dd, J 5.0, 10.3 Hz), 3.80 (3H, s), 3.70 (3H, s), 3.30 (1H, d, J 5.0 Hz), 2.86 (1H, 
dd, J 4.4,16.4 Hz), 2.78 (1H, dd, J 6.2, 16.4 Hz); δC (101 MHz, CDCl3): 173.7, 171.0, 67.2, 
52.8, 52.0, 38.4; νmax:  3489, 3023 ,2956, 2852, 1741, 1439, 1368, 1273, 1219, 1173, 1108, 
1045 cm-1. All data matched those in the literature.152 
Experiment 2: Diethyl (S)-2-hydroxysuccinate (105) 
 
The above experiment was repeated using thionyl chloride SOCl2 (59.5 mL, 0.820 mol) L-
malic acid 104 (50.0 g, 0.372 mol) in ethanol (300 mL) at 0 ºC. The reaction mixture was 
worked up and purified as above to give a colourless oil diethyl (S)-2-hydroxysuccinate 105 (70 
g, 99%) [α] 22
D
 = + 8.2 (c 0.71, CHCl3). (lit.
256 [α]
22
D
 = + 9.1 (c 2.2, EtOH)). This showed δH (400 
MHz, CDCl3): 4.49 (1H, dd, J 5.6, 10.3 Hz), 4.33 – 4.23 (2H, m), 4.18 (2H, q, J 7.1 Hz), 3.22 
(1H, d, J 5.4 Hz), 2.86 (1H, dd, J 4.5, 16.3 Hz), 2.79 (1H, dd, J 6.0, 16.3 Hz), 1.29 (6H, t, J 7.1 
Hz ); δC (101 MHz, CDCl3): 173.6, 170.5, 67.5, 61.9, 60.6, 38.7, 13.2; νmax:  3485, 3020, 2958, 
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2849, 1743, 1436, 1370, 1270, 1220, 1176, 1109, 1049 cm-1. All data matched those in the the 
literature.256 
Experiment 3: Dimethyl (2R,3S)-2-allyl-3-hydroxysuccinate (165) 
 
Methyl lithium (407 mL, 0.610 mol, 1.5 M) was added dropwise to a stirred solution of dry 
diisopropylamine (57.0 mL, 41.1 g, 0.407 mol) in dry THF (150 mL) at 78 ºC which was 
then   allowed to reach room temperature and stirred for 30 min. The solution was cooled 
down again to 61 ºC and dimethyl (S)-2-hydroxysuccinate 164 (30 g, 0.18 mol) in dry 
THF (40 mL) was slowly added. The temperature was allowed to rise gradually up to 45 
ºC and stirring was continued for 1 h whilst maintaining the temperature at 45 ºC, then at 
20 ºC for 40 min, and between 20 ºC and 10 ºC for another 20 min. The mixture was re-
cooled to 62 ºC and allyl bromide (23.9 mL, 33.5 g, 0.277 mol) in dry THF (20 mL) was 
slowly added. Again, the temperature gradually rose to 45 ºC and the reaction was stirred 
for 1 h at this temperature. TLC analysis showed a trace of starting material was left so 
another portion of allyl bromide (22.3 mL, 31.3 g, 0.250 mol) was added and stirring was 
continued at 20 ºC for 1 h and then at 0 ºC for 2 h. The reaction was quenched with a sat. 
aqueous solution of NH4Cl (50 mL) and extracted with ethyl acetate (3 × 150 mL). The 
combined organic layers were dried over MgSO4, filtered and the solvent was evaporated. 
The crude product was purified by column chromatography, eluting with petrol/ethyl 
acetate (1:1) to give a thick yellow oil, dimethyl (2R,3S)-2-allyl-3-hydroxysuccinate 165 (22 g, 
58%), [α] 23
D
 = + 11 (c 1.5, CHCl3), {MALDI-Found [M+H]
+: 203.0914; C9H15O5 requires: 
203.0914}. This showed δH (400 MHz, CDCl3): 5.88 – 5.73 (1H, m), 5.17 (1H, dd, J 1.4, 
17.1 Hz), 5.12 (1H, d, J 10.2 Hz), 4.31 (1H, dd, J 3.2, 7.1 Hz), 3.80 (3H, s), 3.69 (3H, s), 
3.17 (1H, br.d, J 7.1 Hz), 2.99 (1H, ddd, J 3.2, 6.6, 8.7 Hz), 2.62 (1H, dt, J  6.3, 8.1 Hz), 
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2.50 – 2.40 (1H, m); δC (101 MHz, CDCl3): 173.8, 172.4, 134.6, 117.8, 70.0, 52.5, 51.8, 
48.0, 31.9; νmax: 3468, 3020, 2954, 1741, 1642, 1438, 1218, 921 cm-1. 
Experiment 4: Diethyl (2R,3S)-2-allyl-3-hydroxysuccinate (166) 
 
The above experiment was repeated using diethyl (S)-2-hydroxysuccinate 105 (50.0 g, 
0.262 mol), diisopropyl amine (81.0 mL, 58.5 g, 0.578 mol), butyl lithium (542 mL, 0.860 mol, 
1.6 M) and allyl bromide (34.0 mL, 47.7 g, 0.394 mol). The reaction mixture was worked 
up and purified as above to give diethyl (2R,3S)-2-allyl-3-hydroxysuccinate 166 as a thick 
yellow oil (32 g, 53%) [α] 23
D
 = + 13.4 (c 1.79, CHCl3) (lit.
206 [α] 20
D
 = + 11.3 (c 2.23, CHCl3)). 
This showed δH (400 MHz, CDCl3): 5.88 – 5.75 (1H, m), 5.16 (1H, dd, J 1.4, 17.1 Hz), 5.10 
(1H, br.d, J 10.1 Hz), 4.29 (1H, dd, J 5.2, 9.5 Hz), 4.27 – 4.20 (2H, m), 4.13 (2H, q, J 7.1 
Hz), 3.19 (1H, d, J 7.0 Hz), 2.95 (1H, ddd, J 3.1, 6.7, 8.5 Hz), 2.62 (1H, dt, J 6.4, 8.2 Hz), 
2.48 – 2.38 (1H, m), 1.30 (3H, t, J 7.1 Hz), 1.23 (3H, t, J 7.1 Hz); δC (101 MHz, CDCl3): 
173.5, 171.9, 134.9, 118.0, 70.2, 61.8, 60.8, 48.1, 32.1, 14.1, 14.0; νmax: 3494, 3030, 2951, 
2863, 1735, 1643, 1438,1132,1099 cm-1. All data matched those in the literature.206 
Experiment 5: Dimethyl (2R,3S)-2-allyl-3-((tert-butyldimethylsilyl) oxy)succinate (167) 
 
tert-Butyldimethylchlorosilane (24.5 g, 0.162 mol) was added to a stirred solution of 
dimethyl (2R,3S)-2-allyl-3-hydroxysuccinate 165 (25.3 g, 0.125 mol) in dry DMF (150 mL) 
and imidazole (17 g, 0.25 mol) at 0 ºC. The cooling bath was removed, and the reaction 
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mixture was stirred at 45 ºC for 20 h, when TLC showed no starting material. DMF was 
removed by flash distillation and water (100 mL) was added and the product was extracted 
with dichloromethane (3 × 200 mL). The combined organic layers were dried over MgSO4, 
filtered and the solvent was evaporated. The crude product was purified by column 
chromatography, eluting with petrol/ethyl acetate (10:1) to give a thick colorless oil, 
dimethyl (2R,3S)-2-allyl-3-((tert-butyldimethylsilyl)oxy)succinate 167 (34 g, 86%)  [α] 23
D
 = (c 
1.5, CHCl3), {MALDI-Found  [M+H]
+: 317.1775; C15H29O5Si requires: 317.1779}. This 
showed δH (400 MHz, CDCl3): 5.75 (1H, ddt, J 6.9, 10.2, 17.1 Hz), 5.13 (1H, dd, J 1.5, 
17.1 Hz), 5.05 (1H, br.d J 10.2 Hz), 4.37 (1H, d, J 6.0 Hz), 3.75 (3H, s), 3.67 (3H, s), 2.97 
(1H, dt, J 6.1, 8.6 Hz), 2.50 – 2.41 (1H, m), 2.29 – 2.19 (1H, m), 0.88 (9H, s), 0.07 (3H, s), 
0.05 (3H, s); δC (101 MHz, CDCl3): 172.3, 172.2, 134.8, 117.2, 72.9, 51.9, 51.6, 50.0, 31.8, 
25.5, 5.1, 5.5; νmax: 3155, 2954, 2859, 1738, 1640, 1437, 1389, 1255, 1195 cm-1. 
Experiment 6: Diethyl (2R,3S)-2-allyl-3-((tert-butyldimethylsilyl) oxy)succinate (168) 
 
The above experiment was repeated using imidazole (20.6 g, 0.304 mol), tert-
butyldimethylchlorosilane (29.7 g, 0.197 mol) and diethyl (2R,3S)-2-allyl-3-hydroxysuccinate 
166 (35.0 g, 0.152 mol). The mixture was worked up and purified as above to give diethyl 
(2R,3S)-2-allyl-3-((tert-butyldimethylsilyl)oxy)succinate 168 (45 g, 86%) as a thick colorless 
oil [α] 22
D
 =  44 (c 0.81, CHCl3), {Found [M+Na]+: 367.2; C17H32NaO5Si requires: 367.2}. 
This showed δH (400 MHz, CDCl3): 5.77 (1H, ddt, J 6.9, 10.2, 17.1 Hz), 5.11 (1H, dd, J 1.5, 
17.1 Hz), 5.05 (1H, d, J 10.2 Hz), 4.34 (1H, d, J 5.5 Hz), 4.28 – 4.04 (4H, m), 2.96 (1H, dt, J 
6.0, 8.5 Hz), 2.52 – 2.42 (1H, m), 2.29 – 2.18 (1H, m), 1.30 (3H, t, J 7.1 Hz), 1.24 (3H, t, J 7.1 
Hz), 0.89 (9H, s), 0.07 (3H, s), 0.04 (3H, s); δC (101 MHz, CDCl3): 172.0, 171.7, 135.0, 117.1, 
72.9, 61.0, 60.5, 49.9, 31.9, 25.6, 14.1, 4.9, 5.4; νmax: 3155, 2958, 2859, 1730, 1643, 1447, 
1389, 1255, 1192 cm-1. 
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Experiment 7: Dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate (169) 
 
O3 and O2 were bubbled through a stirred solution of dimethyl (2R,3S)-2-allyl-3-((tert-
butyldimethylsilyl)oxy)succinate 167 (30 g, 0.094 mol) in dichloromethane (500 mL) at 
78 ºC for 30 min, until a blue color appeared. After 30 min, the mixture was quenched 
with triphenyl phosphine (37.3 g, 0.142 mol) then the reaction mixture allowed to reach 
room temperature, when TLC showed no starting material. The solvent was evaporated, and 
the crude product was purified by column chromatography eluting with petrol/ethyl acetate 
(5:1) to give a thick colorless oil, dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-
oxoethyl)succinate 169 (28 g, 93%) [α] 23
D
 = (c 0.72, CHCl3), {Found [M+H]+:319.1572 
; C14H27O6Si requires: 319.1571}.This showed δH (400 MHz, CDCl3): 9.81 (1H, br. s), 4.53 
(1H, d, J 4.3 Hz), 3.74 (3H, s), 3.70 (3H, s), 3.50 (1H, dt, J 4.4, 8.9 Hz), 3.02 (1H, dd, J 9.0, 
15.4 Hz), 2.69 (1H, dd, J 4.6, 15.4 Hz), 0.90 (9H, s), 0.10 (3H, s), 0.07 (3H, s); δC (101 
MHz, CDCl3): 199.4, 171.5, 170.9, 72.0, 52.0, 51.9, 43.8, 40.9, 25.4, 25.3, 5.1, 5.63; 
νmax: 3020, 2954, 2845, 1741, 1474, 1437, 1318, 1215, 1182, 1095, 1045, 1006 cm-1. 
 
 
 
 
 
 
 
Experiment 8: Diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate (170) 
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The above (experiment 7) was repeated using diethyl (2R,3S)-2-allyl-3-((tert-
butyldimethylsilyl)oxy)succinate 168 (47.6 g,  0.138 mol) and triphenyl phosphine (54.2 g, 0.207 
mol). The mixture was worked up and purified as above to give diethyl (2S,3R)-2-((tert-
butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate 170 (40 g, 84%) as a thick colorless oil [α] 23
D
 = 41 
(c 2.2, CHCl3), { Found [M+Na]
+: 369.2; C16H30O6SiNa requires: 369.2}. This showed δH (400 
MHz, CDCl3): 9.81 (1H, br. s), 4.48 (1H, d, J 4.0 Hz), 4.25 – 4.09 (4H, m), 3.49 (1H, dt, J 4.3, 8.8 
Hz), 3.03 (1H, dd, J 9.1, 15.3 Hz), 2.65 (1H, dd, J 4.6, 15.2 Hz), 1.28 (3H, t, J 7.1 Hz), 1.24 (3H, t, J 
7.1 Hz), 0.90 (9H, s), 0.10 (3H, s), 0.06 (3H, s); δC (101 MHz, CDCl3): 199.8, 171.2, 170.5, 72.2, 
61.2, 61.1, 44.0, 41.1, 25.6, 14.0, 14.01, 4.9, 5.5; νmax: 3088, 2980, 2845, 2732, 1738, 1459, 1381, 
1318, 1249, 1182, 1095, 1045, 1006 cm-1. 
Experiment 9: 5-(Octadecylthio)-1-phenyl-1H-tetrazole (190) 
 
1-Phenyl-1H-tetrazole-5-thiol (29.4 g, 0.165 mol) was added to a stirred solution of 1-
bromooctadecane 188 (50.0 g, 0.150 mol) and anhydrous potassium carbonate (83 g, 0.60 mol) 
in acetone (400 mL) and THF (100 mL) at room temperature. The reaction mixture refluxed for 
3 h, then worked up and purified as before to give a white solid 5-(octadecylthio)-1-phenyl-1H-
tetrazole 190 (57 g, 89%), m.p. 68-69 ºC, {Found [M+H]+:431.3199; C25H43N4S requires: 
431.3203}. This showed δH (400 MHz, CDCl3): 7.68 – 7.47 (5H, m), 3.40 (2H, t, J 7.4 Hz), 
1.82 (2H, m), 1.49 – 1.18 (30H, m), 0.89 (3H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 154.5 , 133.8, 
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130.0, 129.7, 123.8, 33.4, 31.9, 29.63, 29.61, 29.57, 29.5, 29.4, 29.3, 29.0, 28.99, 28.6, 22.7, 
14.1; νmax: 2914, 2847, 1595, 1499, 1471, 1341, 1273, 1129 cm-1. 
Experiment 10: 5-(Eicosylthio)-1-phenyl-1H-tetrazole (195) 
 
(1): Triphenyl phosphine (52 g, 0.20 mol) was added to a stirred solution of eicosan-1-ol 
191(50.0 g, 0.167 mol) in CH2Cl2 (400 mL). The mixture was cooled to 0 ºC and N-
bromosuccinamide (38.6 g, 0.217 mol) was added in portions and the resulting mixture was 
stirred at room temperature for 3 h. Saturated aqueous sodium bisulphate (150 mL) was 
then added and the product was extracted with CH2Cl2 (2 × 200 mL). The combined 
organic layers were dried over MgSO4, filtered and the solvent was evaporated to give a 
residue, which was refluxed in petrol (150 mL) for 30 min. The triphenyl phosphonium 
oxide was filtered on a pad of celite and washed with petrol (100 mL). The solvent was 
evaporated and the crude product was purified by recrystallization with petrol to give a 
white solid, 1-bromoeicosane 193 (54 g, 90%) which showed δH (400 MHz, CDCl3): 3.43 
(2H, t, J 6.9 Hz), 1.92 – 1.80 (2H, m), 1.48 – 1.16 (34H, m), 0.89 (3H, t, J 6.7 Hz); δC (126 
MHz, CDCl3): 34.1, 33.0, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 28.9, 28.3, 22.8, 14.2; νmax: 
2928, 2854, 1464, 1256, 1057cm-1. 
(2): To a stirred solution of 1-bromoicosane 193 (50.0 g, 0.138 mol) and anhydrous 
potassium carbonate (76.3 g, 0.550 mol) in acetone (400 mL) and THF (100 mL). 1-Phenyl-
1H-tetrazole-5-thiol (25.8 g, 0.140 mol) was added, the reaction mixture was refluxed for 3 
h. After this time TLC showed no staring material was left and solvent was evaporated. The 
crude product was purified by recrystallization from MeOH/acetone (1:1) to give a white 
solid 5-(eicosylthio)-1-phenyl-1H-tetrazole 195 (55 g, 88%),205 m.p. 63-65 ºC. This showed 
δH (400 MHz, CDCl3): 7.65 – 7.48 (5H, m), 3.40 (2H, t, J 7.4 Hz), 1.89 – 1.78 (2H, m), 
1.58 – 1.08 (34H, m), 0.89 (3H, t, J 6.8); δC (101 MHz; CDCl3): 154.5, 133.8, 130.0, 127.7, 
123.9, 33.4, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.1, 29.0, 28.6, 22.7, 14.1; νmax: 2916, 2850, 
1597, 1502, 1473, 1420, 1390, 1247, 1091cm-1. All data matched those in the literature.205 
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Experiment 11: 5-(docosylthio)-1-phenyl-1H-tetrazole (196) 
 
(1): Triphenyl phosphine (48.2 g, 0.183 mol) was added to a stirred solution of docosanol-
1-ol 192 (50.0 g, 0.153 mol) in CH2Cl2 (400 mL). The mixture was cooled to 0 ºC and N-
bromosuccinamide (35.4 g, 0.199 mol) was added in portions and the resulting mixture was 
stirred at room temperature for 3 h. The reaction mixture was worked up and purified as 
before to give 1-bromodocosane 194 as a white solid (55 g, 93%) which showed δH (400 
MHz, CDCl3): 3.42 (2H, t, J 6.9 Hz), 1.93 – 1.80 (2H, m), 1.49 – 1.12 (38H, m), 0.89 (3H, 
t, J 6.7 Hz); δC (101 MHz, CDCl3): 34.0, 32.9, 31.9, 29.7, 29.6, 29.5, 29.4, 28.8, 28.2, 22.7, 
14.1; νmax: 2920, 2850, 1463, 1255cm-1. 
(2): To a stirred solution of 1-bromodocosane 194 (50.0 g, 0.128 mol), anhydrous 
potassium carbonate (70.7 g, 0.514 mol) and1-phenyl-1H-tetrazole-5-thiol (25.2 g, 0.141 
mol) in acetone (400 ml) and THF (100 mL). The reaction mixture was refluxed for 3 h 
then worked up and purified as before to give a white solid 5-(docosylthio)-1-phenyl-1H-
tetrazole 196 (58 g, 93%).202 This showed δH (400 MHz, CDCl3): 7.66 – 7.46 (5H, m), 3.40 
(2H, t, J 7.4 Hz), 1.90 – 1.76 (2H, m), 1.49 – 1.18 (38H, m), 0.89 (3H, t, J 6.7 Hz); δC (101 
MHz; CDCl3): 154.5, 133.8, 130.0, 129.7, 123.9, 33.9, 31.9, 29.7, 29.65, 29.60, 29.53, 
29.43, 29.35, 29.1, 29.0, 28.6, 22.8, 14.10; νmax: 3017, 2925, 2853, 1598, 1500 cm-1. All 
data matched those in the literature.202 
Experiment 12: 5-(Octadecylsulfonyl)-1-phenyl-1H-tetrazole (171) 
 
A solution of ammonium molybdate (VI) tetrahydrate (64.5 g, 0.052 mol) was dissolved in 
cold hydrogen peroxide (35%, 120 mL) and was gradually added to a stirred solution of 5-
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(octadecylthio)-1-phenyl-1H-tetrazole 190 (50 g, 0.11 mol) in IMS (400 mL) and THF (200 
mL) at 5 ºC. The reaction mixture was allowed to reach room temperature and stirred for 2 
h, and then another portion of ammonium molybdate (VI) tetrahydrate (24.3 g, 0.010 mol) 
in cold hydrogen peroxide was added (35 %, 70 mL). The reaction mixture was stirred for 
18 h. The mixture was poured into water (2.5 litres) and extracted with dichloromethane (3 
× 400 mL). The compound organic layers were washed with more water (2 × 400 mL) and 
dried. The solvent was evaporated and the crude product was purified by column 
chromatography, eluting with with petrol/ethyl acetate (5:1), to give a semi solid, 5-
(octadecylsulfonyl)-1-phenyl-1H-tetrazole 171 (52 g, 97%), m.p. 77-78 ºC {Found 
[M+H]+:463.3095; C25H43O2N4S requires: 463.3101}, which showed δH (400 MHz, 
CDCl3): 7.77 – 7.67 (2H, m), 7.66 – 7.57 (3H, m), 3.79 – 3.69 (2H, distorted t, J 7.9 Hz), 
1.96 (2H, m), 1.56 – 1.19 (30H, m), 0.89 (3H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 153.3, 
133.0, 131.4, 129.9, 129.7, 125.0, 56.0, 52.9, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 28.9, 
28.1, 22.7, 21.9, 14.1; νmax: 2960, 2847, 1593, 1498, 1470, 1341, 1152 cm-1. 
Experiment 13: 5-(Eicosylsulfonyl)-1-phenyl-1H-tetrazole (172) 
 
m-Chloroperoxybenzoic acid (62.7 g, 0.270 mol) in dichloromethane (50 mL) was added to 
a stirred solution of 5-(eicosylthio)-1-phenyl-1H-tetrazole 195 (50 g, 0.10 mol) in 
dichloromethane (300 mL) and NaHCO3 (36.6 g, 0.430 mol) at 0 ºC. The reaction mixture 
was stirred at room temperature for 18 h then quenched with NaOH solution (200 mL 10%) 
and stirred for 2 h. The organic was separated and the aqueous layer was re-extracted with 
dichloromethane (2 × 200 mL). The combined organic layers were dried over MgSO4, 
filtered and evaporated to give a white solid, which was recrystallized from MeOH/Acetone 
(1:1) to give a white solid of 5-(eicosylsulfonyl)-1-phenyl-1H-tetrazole 172 (51 g, 96%).205 
This showed δH (400 MHz, CDCl3): 7.73 – 7.69 (2H, m), 7.66 – 7.57 (3H, m), 3.74 (2H, 
distorted t, J 7.9 Hz), 2.01 – 1.91 (2H, m,), 1.53 – 1.19 (34H, m), 0.89 (3H, t, J 6.8 Hz); δC 
(101 MHz; CDCl3): 153.5, 133.1, 131.4, 129.7, 125.1, 56.0, 31.9, 29.7, 29.65, 29.6, 29.5, 
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29.4, 29.3, 29.2, 28.9, 28.1, 22.7, 21.9, 14.1; νmax: 2920, 2849, 1595, 1499, 1470, 1338, 
1153 cm-1. All data were identical to the literature.205 
Experiment 14: 5-(docosylsulfonyl)-1-phenyl-1H-tetrazole (173) 
 
The above experiment was repeated using 5-(docosylthio)-1-phenyl-1H-tetrazole 196 (50.0 
g, 0.102 mol), m-chloroperoxybenzoic acid (80.7 g, 0.257 mol) and NaHCO3 (34.5 g, 0.411 
mol). The reaction mixture was worked up and purified as above to give a white solid, 5-
(docosylsulfonyl)-1-phenyl-1H-tetrazole 173 (51 g, 96%).202 This showed δH (400 MHz, 
CDCl3) 7.73 – 7.68 (2H, m), 7.65 – 7.59 (3H, m), 3.73 (2H, distorted t, J 8.1 Hz), 2.02 – 
1.90 (2H, m), 1.53 – 1.20 (38H, m), 0.89 (3H, t, J 6.7 Hz); δc (101 MHz; CDCl3): 153.5, 
133.1, 131.4, 129.7, 125.1, 56.0, 31.9, 29.7, 29.65, 29.62, 29.55, 29.44, 29.35, 29.2, 28.9, 
28.14, 22.7, 21.9, 14.1; νmax: 3018, 2926, 2854, 1498, 1342, 1152 cm-1. All data data 
matched those in the literature.202 
Experiment 15: Dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-icosylsuccinate (174) 
 
Lithium bis-(trimethylsilyl) amide (90.2 mL, 0.090 mol) was added to a stirred solution of 
dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate 169 (15.3 g, 0.048 
mol) and 5-(octadecylsulfonyl)-1-phenyl-1H-tetrazole 171 (27.8 g, 0.060 mol) in dry THF (250 
mL) at 20 °C under nitrogen atmosphere. The mixture was allowed to reach room temperature 
and stirred for 3 h. TLC showed that the reaction was complete. It was quenched with sat. 
aqueous NH4Cl (250 mL). The product was extracted with petrol/ethyl acetate (10:1, 3 × 150 
mL). The combined organic layers were dried over MgSO4, filtered and the solvent was 
evaporated to give a crude product, which was purified by column chromatography eluting with 
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petrol/ethyl acetate (20:1) to give a thick yellow oil, dimethyl (2S,3R)-2-((tert-
butyldimethylsilyl)oxy)-3-((E/Z)-docos-2-en-1-yl)succinate 206 (20 g,76%)  as a mixture of 
E/Z isomers which showed δH (400 MHz, CDCl3): 5.53 – 5.39 (1H, m), 5.36 – 5.24 (1H, m), 
4.37 (1H, dd, J 6.4, 15.6 Hz), 3.74 (3H, s), 3.66 (3 H, s), 2.90 (1H, m), 2.39 (1H, m), 2.17 (1H, 
m), 1.99 (1H, m), 1.37 – 1.23 (31 H, m), 0.87 (12H, s including t, corresponding to CH3), 0.06 
(3H, s), 0.04 (3H, s); δC (125 MHz, CDCl3): 172.5, 172.4, 133.8, 132.8, 129.9, 128.6, 73.0, 
51.9, 50.7, 41.4, 32.5 – 11.4, -5.0, -5.4. 
Palladium on carbon (10%, 2.0 g) was added to a stirred solution of the above alkene in 
THF/IMS (500 mL, 1:1) and the suspension was stirred overnight under hydrogen 
atmosphere. The suspension was then quenched with a few drops of water and filtered over 
a bed of celite and washed with ethyl acetate (150 mL). The filtrate was concentrated and 
purified by column chromatography eluting with petrol/ethyl acetate (20:1) to give a thick 
oil, dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-eicosylsuccinate 174 (19.8 g, 99%) 
[α] 22
D
 =  (c 0.69, CHCl3) {Found [M+Na]+: 579.4400; C32H64O5SiNa requires: 
579.4415}. This showed δH (400 MHz, CDCl3): 4.34 (1H, d, J 7.2 Hz), 3.73 (3H, s), 3.67 
(3H, s), 2.83 (1H, ddd, J 4.6, 7.2, 10.2 Hz), 1.78 – 1.17 (38H, m), 0.88 (3H, t, J 6.4 Hz), 0.87 
(9H, s) 0.05 (3H, s), 0.04 (3H, s); δC (101 MHz, CDCl3): 173.2, 172.4, 73.8, 51.8, 51.5, 50.6, 
31.9, 29.7, 29.6, 29.5, 29.3, 27.6, 27.3, 25.5, 14.0, 5.2, 5.6; νmax: 2935, 2856, 1760, 1740, 
1473, 1439, 1352 cm-1. 
Experiment 16: Diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-eicosylsuccinate (177) 
 
Lithium bis-(trimethylsilyl) amide (95.2 mL, 0.092 mol) was added to a stirred solution of diethyl 
(2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate 170 (20.0 g, 0.057 mol) and 5-
(octadecylsulfonyl)-1-phenyl-1H-tetrazole 171 (29.3 g, 0.063 mol) ) in dry THF (250 mL) at 10 ºC 
under nitrogen atmosphere. The mixture was worked up, purified and hydrogenation as above to 
give a thick oil of diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-icosylsuccinate 177 (26, 77%) 
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[α] 22
D
 =  (c 0.91, CHCl3), {Found [M+Na]+: 607.5; C34H68O5SiNa requires: 607.5}. This showed 
δH (400 MHz, CDCl3): 4.32 (1H, d, J 6.8 Hz), 4.27 – 4.05 (4H, m), 2.81 (1H, ddd, J 4.7, 6.7,11.4 
Hz), 1.78 – 1.08 (44H, m, including 6H for 2 × CH3), 0.89 (3H, t, J 7.3 Hz ), 0.87(9H, s), 0.06 (3H, 
s), 0.04 (3H, s); δC (101 MHz, CDCl3): 172.7, 172.0, 73.8, 60.9, 60.4, 50.5, 31.9, 29.68, 29.7, 29.6, 
29.5, 29.4, 29.3, 27.7, 27.3, 25.5, 14.2, 14.1, 14.0, 5.0, 5.5; νmax: 2950, 2925, 2855, 1719, 1468, 
1459, 1377, 1180 cm-1. 
Experiment 17: Dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-docosylsuccinate (175) 
 
Lithium bis-(trimethylsilyl) amide (82.9 mL, 0.082 mol) was added a stirred solution of 
dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate 169 (16.0 g, 0.050 
mol) and 5-(icosylsulfonyl)-1-phenyl-1H-tetrazole 172 (27.1 g, 0.055 mol) in dry THF (250 
mL) at 10 ºC under nitrogen atmosphere. The mixture was allowed to reach room temperature 
and stirred for 3 h. then worked up, purified and hydrogenated as before to give a thick yellow 
oil, dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-docosylsuccinate 175 (22 g, 76%) [α] 22
D
 
=  22 (c 0.91, CHCl3) {Found [M+H]+: 585.4905; C34H69O5Si requires: 585.4909}. This 
showed δH (400 MHz, CDCl3): δH (400 MHz, CDCl3): 4.34 (1H, d, J 7.3 Hz), 3.74 (3H, s), 3.68 
(3H, s), 2.83 (1H, ddd, J 4.8, 7.4, 10.4 Hz), 1.71 – 1.05 (42H, m), 0.89 (3H, t, J 6.6 Hz), 0.87 
(9H, s), 0.05 (3H, s), 0.04 (3H, s); δC (101 MHz; CDCl3): 172.9, 172.2, 74.0, 61.0, 60.6, 50.6, 
32.1, 29.9, 29.8, 29.7, 29.6, 3.7, 29.5, 29.4, 27.8, 27.4, 25.7, 22.8, 14.4, 14.3, 14.2, 4.9, 5.4; 
νmax: 2931, 2850, 1767, 1746, 1472, 1434, 1350 cm-1. 
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Experiment 18: Diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-docosylsuccinate (178) 
 
Lithium bis-(trimethylsilyl) amide (71.4 mL, 0.070 mol) was added to a stirred solution of 
diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate 170  (15 g, 0.04 
mol) and sulfone 172 (23.3 g, 0.040 mol) in dry THF (250 mL) at 10 ºC under nitrogen 
atmosphere. The mixture was allowed to reach room temperature and stirred for 3 h. The 
reaction was worked up, purified and hydrogenated as before to give a thick yellow oil, 
diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-docosylsuccinate 178 (20 g, 76%) [α] 22
D
 = 
(c 0.99, CHCl3) {Found [M-tBu]+: 555.4434; C32H63O5Si requires: 555.4443}. Which 
showed δH (400 MHz, CDCl3): 4.33 (1H, d, J 6.8 Hz), 4.26 – 4.10 (4H, m), 2.83 (1H, dt, J 
6.8, 10.1 Hz), 1.79 – 1.18 (48H, m, including 6H for 2 × CH3), 0.91 (3H, t, J 5.2 Hz), 0.89 
(9H, s), 0.08 (3H, s), 0.06 (3H, s); δC (101 MHz, CDCl3): 172.9, 172.2, 74.0, 61.0, 60.6, 
50.6, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 27.8, 27.4, 25.7, 22.8, 14.4, 14.3, 14.2, 4.9, 
5.4; νmax: 2931, 2850, 1767, 1746, 1472, 1434, 1350 cm-1. 
Experiment 19: Dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-tetracosylsuccinate (176) 
 
Lithium bis-(trimethylsilyl) amide (17.2 mL, 0.017 mol) was added to a stirred solution of 
dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate 169 (3.34 g, 
0.014 mol) and 5-(docosylsulfonyl)-1-phenyl-1H-tetrazole 173 (5.98 g, 0.011 mol) in dry 
THF (50 mL) at 10 ºC under nitrogen atmosphere and stirred for 3 h. The mixture was 
worked up, purified and hydrogenated as before to give a thick colorless oil, dimethyl 
(2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-tetracosylsuccinate 176 (4.0 g, 77%), [α] 23
D
 =  22 
(c 1.3, CHCl3) {Found [M+Na]
+: 635.5013; C36H72O5SiNa requires: 635.5047}. This 
showed δH (400 MHz, CDCl3): 4.35 (1H, d, J 7.2 Hz), 3.74 (3H, s), 3.68 (3H, s), 2.84 (1H, 
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ddd, J 4.6, 7.2, 10.0 Hz), 1.40 – 1.21 (46H, m), 0.90 (3H, t, J 7.2 Hz), 0.87 (9H, s), 0.06 
(3H, s), 0.04 (3H, s); δC (101 MHz, CDCl3): 173.2, 172.4, 73.8, 51.9, 51.6, 50.6, 31.9, 29.7, 
29.6, 29.5, 29.4, 27.7, 27.3, 25.5, 22.7, 18.0, 14.1, 5.2, 5.6; νmax: 2927, 2855, 1735, 1467, 
1378, 1252, 1166, 908, 736 cm-1. 
Experiment 20: Diethyl(2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-tetracosylsuccinate (179) 
 
Lithium bis-(trimethylsilyl) amide (32.5 mL, 0.032 mol ) was added to a stirred solution of 
diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-(2-oxoethyl)succinate 170 (6.83 g, 0.019 
mol) and  sulfone 173 (11.2 g, 0.021 mol) worked up and purified as before to give after the 
hydrogenation diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-tetracosylsuccinate 179 
(9.0 g, 75%), [α] 23
D
 =  (c 1.61, CHCl3), {Found [M-tBu]+: 583.4758; C34H68O5Si requires: 
584.4836}. This showed δH (400 MHz, CDCl3): 4.32 (1H, d, J 6.8 Hz), 4.25 – 4.08 (4H, m), 
2.82 (1H, dt, J 4.7, 6.8 Hz), 1.78 – 1.13 (52H, m, including 6H for 2 × CH3), 0.89 (3H, t, J 
6.2 Hz), 0.88 (9H, s), 0.06 (3H, s), 0.04 (3H, s); δC (101 MHz, CDCl3): 172.9, 172.2, 74.0, 
61.0, 60.6, 50.6, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 27.8, 27.4, 25.7, 22.8, 14.3, 14.2, 
14.1, 4.9, 5.4; νmax: 2925, 2855, 1719, 1468, 1377, 1180 cm-1. 
Experiment 21: Methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)docosanoate 
(180) and methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)docosanoate 
(180a) 
 
A solution of dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-icosylsuccinate 174 (5.0 g, 
0.0090 mol) and magnesium bromide dietherate (3.9 g, 0.01 mol) in dichloromethane (150 mL) 
was stirred vigorously at room temperature for 1 h and then cooled to 38 ºC. 
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Diisobutylaluminum hydride (15.6 mL, 0.010 mol 1 M solution in toluene) was added dropwise 
at 38 ºC ensuring that vigorous stirring was maintained throughout the addition and that the 
internal temperature remained constant (colour change noted: orange to grey/orange). The 
reaction mixture was then stirred for a period of 1 h, with the internal temperature being 
maintained in the range 38 to 34 ºC. The mixture was then quenched at 34 ºC by the addition 
of methanol (10 mL) (colour change noted: initial orange colour restored) and after having 
warmed to room temperature the reaction mixture was quenched with a freshly prepared saturated 
aqueous solution of sodium sulfate (10 mL). The resulting mixture was stirred at room 
temperature for a period of 1 1.5 h until the coagulation of the aluminium salts was apparent. 
Magnesium sulfate (10 g) was then added and the mixture was stirred for a further of 10 min prior 
to being filtered, under vacuum, through a small plug of celite. The filter-cake was washed 
thoroughly with dichloromethane (75 mL) and the filtrate was concentrated to afford a pale 
yellow oil. The product was purified by column chromatography, eluting with petrol/ethyl acetate 
(20:1) to give the first fraction a semi-solid methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-
oxoethyl)docosanoate 180 (3.8 g, 78%)  [α] 20
D
 =  18 (c 0.56, CHCl3), {Found [M+Na]+: 549.4; 
C31H62O4SiNa requires: 549.4}. This showed δH (400 MHz, CDCl3): 9.63 (1H, d, J 1.9 Hz), 4.07 
(1H, dd, J 1.9, 5.6 Hz), 3.71 (3H, s), 2.80 (1H, dt, J 5.7, 8.8 Hz), 1.87 – 1.17 (38H, m), 0.92 (3H, 
t,  J 9.3 Hz), 0.91 (9H, s), 0.09 (3H, s), 0.08 (3H, s); δC (101 MHz, CDCl3): 202.1, 173.1, 78.0, 
60.7, 49.1, 32.1, 29.9, 29.8, 29.7, 29.6, 29.4, 29.5, 27.3, 27.2, 25.7, 22.8, 14.4, 14.3, 4.4, 5.0; 
νmax: 2925, 2854, 1739, 1464 cm-1. 
The second fraction was methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-
hydroxyethyl)-docosanoate 180a (0.5 g, 10%) [α] 20
D
 =  (c 0.56, CHCl3), {Found 
[M+Na]+: 551.4; C31H64O4SiNa requires: 551.4}. This showed δH (400 MHz, CDCl3): 3.91 
(1H, dt, J 3.6, 7.4 Hz), 3.66 (3H, s), 3.60 (2H, br. d, J 3.6 Hz), 2.76 – 2.68 (1H, m), 1.66 – 
1.08 (39H, m), 0.87 (12H, s including t, J 6.6 Hz for terminal CH3 ), 0.08 (3H, s), 0.05 (3H, 
s); δC (101 MHz, CDCl3): 173.9, 73.8, 63.6, 51.4, 49.1, 31.9, 29.6, 28.3, 27.5, 25.7, 22.7, 
14.1, 4.5, 5.1; νmax: 3365, 2929, 2858, 1740, 1465, 1254, 1052 cm-1. 
 
 138 
 
Experiment 22: Ethyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)docosanoate (183) 
and ethyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)docosanoate (183a) 
 
The above experiment was repeated using diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-
3-icosylsuccinate 177 (5.0 g, 0.008 mol), magnesium bromide dietherate (3.7 g, 0.013 mol) 
in dichloromethane (120 mL) and diisobutylaluminum hydride (14.8 mL, 0.014 mol 1 M 
solution in toluene). The mixture was worked up and purified as above to give ethyl (R)-2-
((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)docosanoate 183 (3.5 g, 74%) [α]19
D
 =  15.7 
(c 2.65, CHCl3), {Found [M+Na]
+: 563.4; C32H64O4SiNa requires: 563.4}. This showed δH 
(400 MHz, CDCl3): 9.61 (1H, d, J 1.7 Hz), 4.21 – 4.05 (2H, m), 4.03 (1H, dd, J 1.7, 5.2 
Hz), 2.75 (1H, dt, J 5.7, 8.6 Hz), 1.84 – 1.15 (41H, m, including 3H for CH3), 0.89 (9H, s), 
0.87 (3H, t, J 7.0), 0.05 (3H, s), 0.05 (3H, s); δC (101 MHz, CDCl3): 202.8, 171.9, 77.9, 
60.7, 49.0, 31.9, 29.7, 27.4, 27.3, 25.6, 22.7, 14.2, 14.0, 4.6, 5.2; νmax: 2925, 2858, 1742, 
1467 cm-1. 
The second fraction was 183a (0.45 g, 9 %) [α] 22
D
 =  (c 0.8, CHCl3), {Found 
[M+Na]+:565.5; C32H66O4SiNa requires: 565.5}. This showed δH (400 MHz, CDCl3): 4.19 
– 4.06 (2H, m), 3.93 (1H, dt, J 3.7, 7.5 Hz), 3.62 (2H, d, J 3.6 Hz), 2.74 – 2.65 (1H, m), 
1.53 – 1.13 (42H, m, including 3H, for CH3), 0.88 (12H, s, including t, J 7.1 Hz for 
terminal CH3), 0.09 (3H, s), 0.06 (3H, s); δC (101 MHz, CDCl3): 177.8, 74.3, 69.7, 58.4, 
45.9, 31.9, 29.7, 29.6, 29.3, 27.6, 25.5, 23.5, 18.4, 14.0, 4.5, 5.2 ; νmax: 3463, 2926, 2854, 
1730, 1463, 1252, 1059 cm-1. 
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Experiment 23:  Methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)tetracosan- 
oate (181) and methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)tetracosa- 
noate (181a) 
 
A solution of dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-docosylsuccinate 175 
(4.0 g, 0.06 mol) and magnesium bromide dietherate (2.6 g, 0.01 mol) in  dry 
dichloromethane (120 mL) was stirred vigorously at room temperature for 1 h and then 
cooled to 38 ºC. Diisobutylaluminum hydride (11.6 mL, 0.01 mol 1 M solution in toluene) 
was added dropwise at 38 ºC ensuring that vigorous stirring was maintained throughout 
the period of addition and that the internal temperature remained constant (colour change 
noted: orange to grey/orange). The mixture was then stirred for 1 h, with the internal 
temperature being maintained in the range 38 to 34ºC. The reaction was worked up and 
purified as before to give the first fraction, a semi-solid methyl (R)-2-((S)-1-((tert-
butyldimethylsilyl)oxy)-2-oxoethyl)hexacosanoate 181 (2.8 g, 75%) [α]19
D
 =  (c 1.93, 
CHCl3), {Found [M+Na]
+: 577.4612; C33H66O4SiNa requires: 577.4623}. This showed δH 
(400 MHz, CDCl3): 9.61 (1H, d, J 1.9 Hz), 4.05 (1H, dd, J 1.9, 5.6 Hz), 3.69 (3H, s), 2.78 
(1H, dt, J 5.7, 8.9 Hz), 1.86 – 1.18 (42H, m), 0.90 (9H, s), 0.88 (3H, t, J 6.9 Hz), 0.07 (3H, 
s), 0.06 (3H, s); δC (101 MHz, CDCl3): 202.7, 172.1, 78.3,  60.4, 49.2, 31.9, 29.7, 29.6, 
29.5, 29.4, 27.4, 25.6, 22.7, 14.1, 4.5, 5.2; νmax: 2924, 2854, 1739, 1464 cm-1 
The second fraction was methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl) 
hexacosanoate 181a (0.45 g, 12%) [α] 20
D
 =  (c1.9, CHCl3), {Found [M+Na]+: 579.5; 
C33H68O4SiNa requires: 579.5}. This showed δH (400 MHz, CDCl3): 3.95 – 3.89 (1H, 
m), 3.68 (3H, s), 3.62 (2H, d, J 3.4 Hz), 2.77 – 2.68(1H, m), 1.80 – 1.10 (43H, m), 
0.88 (12H, s, including t, J 6.4 Hz for terminal CH3), 0.09 (3H, s), 0.06 (3H, s); δC (101 
MHz CDCl3): 174.9, 74.1, 64.2, 51.2, 47.9, 31.9, 29.7, 29.6, 29.4, 25.6, 23.5, 22.7, 14.1, 4.5, 
5.2; νmax: 3453, 2924, 2854, 1732, 1464, 1255, 1056 cm-1. 
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Experiment 24: Ethyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)tetracosanoate 
(184) and ethyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)tetracosanoate 
(184a) 
 
The above experiment was repeated using diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-
3-docosylsuccinate 178 (3.0 g, 4.9 mmol), magnesium bromide dietherate (1.80 g, 7.34 
mmol) in dichloromethane (90 mL) and diisobutylaluminum hydride (8.3 mL, 8.3 mmol 1 
M solution in toluene). The reaction mixture was worked up and purified as before to give 
ethyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)tetracosanoate 184 (2.0 g, 
72%) [α]19
D
 = (c 1.86, CHCl3) {Found [M+Na]+: 591.5; C34H68O4SiNa requires: 
591.5}. This showed δH (400 MHz, CDCl3): 9.63 (1H, d, J 1.8 Hz), 4.26 – 4.06 (2H, m), 
4.05 (1H, dd, J 1.7, 5.2 Hz), 2.77 (1H, dt, J 5.7, 8.5 Hz), 1.86 – 1.10 (45H, m, including  t, J 
6.7 Hz  for CH3), 0.91 (9H, s), 0.88 (3H, t, J 7.0 Hz), 0.08 (3H, s), 0.07 (3H, s); δC (101 MHz, 
CDCl3): 202.9, 172.3, 78.2, 60.8, 49.5, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 27.5, 27.4, 25.7, 22.8, 
14.4, 14.3, 4.4, 5.0; νmax: 2924, 2855, 1740, 1460 cm-1. 
The second fraction was 184a (0.70 g, 15%) [α] 24
D
 = (c 1.46, CHCl3), {Found [M+Na]+: 
593.5; C34H70O4SiNa requires: 593.5}. This showed δH (400 MHz, CDCl3): 4.20 – 4.08 
(2H, m), 3.92 (1H, dt, J 3.6,7.4 Hz), 3.62 (2H, d, J 3.6 Hz), 2.74 – 2.65 (1H, m), 1.53 – 1.13 
(46H, m, including triplet with coupling constant 6.5 Hz, for CH3), 0.89 (12H, s, including 
t, J 7.2 Hz for terminal CH3), 0.09 (3H, s), 0.06 (3H, s); δC (101 MHz, CDCl3): 175.9, 73.2, 
65.7, 52.4, 45.9, 31.9, 29.7, 29.6, 29.3, 27.6, 25.5, 23.5, 18.4, 14.0, 4.5, 5.2 ; νmax: 3454, 
2924, 2854, 1731, 1464, 1254, 1056 cm-1. 
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Experiment 25: Methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)hexacosa- 
noate(182)  and  methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)hexacosa- 
noate and (182a) 
 
A solution of dimethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-tetracosylsuccinate 176  
(5.0 g, 8.2 mmol) and magnesium bromide dietherate (3.1 g, 12 mmol) in dichloromethane 
(150 mL) was stirred vigorously at room temperature for 1 h and then cooled to 38 ºC. 
Diisobutylaluminum hydride (13.8 mL, 13.9 mmol 1 M solution in toluene) was added 
dropwise at 38 ºC ensuring that vigorous stirring was maintained throughout the period of 
addition and that the internal temperature remained constant (colour change noted: orange to 
grey/orange). The reaction mixture was then stirred for 1 h, with the internal temperature 
being maintained in the range 38 to 34 ºC. The reaction was worked up and purified as 
before to give the first fraction as a semi-solid methyl (R)-2-((S)-1-((tert-
butyldimethylsilyl)oxy)-2-oxoethyl)hexacosanoate 182 (3.0 g, 71%) [α] 24
D
 = (c 2.51, 
CHCl3), {Found [M+H]
+: 583.5112; C35H71O4Si requires: 583.5116}. This showed δH (400 
MHz, CDCl3): 9.61 (1H, d, J 1.9 Hz), 4.05 (1H, dd, J 1.9, 5.6 Hz), 3.69 (3H, s), 2.79 (1H, dt, 
J 5.7,8.9 Hz), 1.61 – 1.19 (46H, m), 0.90 (9H, s), 0.88 (3H, t,  J 5.2 Hz), 0.07 (3H, s), 0.07 
(3H, s); δC (101 MHz, CDCl3): 201.3, 174.1, 68.8, 52.6, 49.0, 31.9, 29.7, 29.6, 29.5, 29.4, 
29.3, 27.4, 27.3, 25.6, 22.7, 14.1,4.5, 5.3; νmax: 2924, 2855, 1740, 1460 cm-1. 
The second fraction was methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl) 
hexacosanoate 182a (0.70 g, 15%) [α] 22
D
 =  (c 0.99, CHCl3), {Found [M+Na]+: 
607.5081; C35H72O4SiNa requires: 607.5092}, which showed δH (400 MHz, CDCl3): 3.95 – 
3.90 (1H, m), 3.69 (3H, s), 3.62 (2H, br. d, J 3.3 Hz), 2.77 – 2.70 (1H, m), 1.89 (1H, dd, J 
5.3, 7.6 Hz), 1.26 (46H, m), 0.89 (12H, s, including t, J 6.7 Hz for terminal CH3), 0.10 (3H, 
s), 0.06 (3H, s); δC (101 MHz, CDCl3): 174.9, 73.9, 63.7, 51.4, 49.0, 31.9, 29.7, 28.3, 27.6, 
25.7, 22.7, 14.1, 4.5, 5.1; νmax: 3363, 2925, 2854, 1738, 1465, 1254, 1056 cm-1. 
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Experiment 26: Ethyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)hexacosanoate 
(185) and  ethyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)hexacosanoate 
(185a) 
 
The above experiment was repeated using diethyl (2S,3R)-2-((tert-butyldimethylsilyl)oxy)-3-
tetracosylsuccinate 179 (0.5 g, 0.7 mmol) magnesium bromide dietherate (0.30 g, 1.1 mmol) 
in dichloromethane (5 mL) and diisobutylaluminum hydride (1.3 mL, 0.001 mol 1 M solution 
in toluene). The reaction mixture was worked up and purified as before to give ethyl (R)-2-
((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)hexacosanoate 185 (0.30 g, 61%) [α] 19
D
=  
(c 2.65, CHCl3), {Found [M+Na]+: 619.5; C36H72O4SiNa requires: 619.5}. This 
showed δH (400 MHz, CDCl3): 9.63 (1H, d, J 1.7 Hz), 4.23 – 4.07 (2H, m), 4.05 (1H, dd, J 
1.7, 5.2 Hz), 2.77 (1H, dt, J 5.7, 8.6 Hz), 1.53 – 1.13 (49H, m including 3H for CH3), 0.90 
(9H, s), 0.89 (3H, t, J 7.5 Hz), 0.07 (3H, s), 0.06 (3H, s); δC (101 MHz, CDCl3): 203.0, 172.1, 
78.0, 60.8, 49.2, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 27.5, 27.4, 25.7, 22.8, 14.4, 14.3, 4.4, 
5.0; νmax: 2924, 2855, 1740, 1460 cm-1. 
The second fraction was 185a (0.11 g, 24%) [α]19
D
 =  (c 1.55, CHCl3), {Found 
[M+Na]+: 621.5; C36H74O4SiNa requires: 621.5}. This showed δH (400 MHz, CDCl3): 
4.15 – 4.10 (2H, m), 3.93 (1H, dt, J 3.5, 7.3 Hz), 3.63 (2H, d, J 3.7 Hz), 2.70 (1H, ddd, J 
4.2, 7.6,11.4 Hz), 1.34 – 1.22 (50H, m including triplet J 6.5 Hz for CH3), 0.89 (12H, s 
including t, J 7.4 Hz for terminal CH3), 0.09 (3H, s), 0.06 (3H, s); δC (101 MHz, CDCl3): 
177.9, 74.3, 69.8, 63.8, 60.3, 58.5, 45.9, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.2, 27.6, 
27.5, 25.7, 25.6, 23.5, 22.7, 14.1, 4.5, 5.2; νmax: 3454, 2924, 2854, 1732, 1464, 1255, 
1053 cm-1. 
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Experiment 27: Methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)hexacosa- 
noate(185) 
 
Methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-hydroxyethyl)hexacosanoate 185a (0.5 g, 
0.83 mmol) in dichloromethane (4 mL) was added to a stirred suspension of pyridinium 
chlorochromate (0.3 g, 1.66 mmol) in dichloromethane (20 mL) in portions at room 
temperature. The mixture was stirred for 2 h. TLC showed no starting material was left. The 
mixture was diluted with petrol/ether (5:1, 200 mL) and filtered through a bed of celite on 
silica. The filtrate was evaporated and concentrated to obtain the crude product. The crude 
product was purified by column chromatography eluting with petrol/ethyl acetate (20:1) gave a 
semi-solid 185 methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)hexacosanoate 
(0.4 g, 82%), which showed 1H, 13C and IR spectra matched those in experiment 25. 
Experiment 28: Dimethyl tetradecanedioate (232) 
 
Conc. H2SO4 (5 mL) was added to a stirred solution of tetradecanoic acid 222 (25.0 g, 
0.096 mol) in methanol (150 mL) and the reaction mixture was refluxed for 3 h when TLC 
showed there was no staring material was left. The excess methanol was evaporated and 
then sat. aq. NaHCO3 (100 mL) was added to neutralize the acid. The product was extracted 
with CH2Cl2 (3 × 200 mL) then the combined organic layers were dried over MgSO4 and 
concentrated. The crude product was purified by column chromatography, eluting with 
petrol/ethyl acetate (5:1) to give a white solid of dimethyl tetradecanedioate 232 (27 g, 
98%) {Found [M+Na]+: 309.2; C16H30O4Na requires: 309.2}.This showed δH (400 MHz, 
CDCl3): 3.55 (6H, s), 2.19 (4H, t, J 7.5 Hz), 1.57 – 1.09 (20H, m); δC (101 MHz, CDCl3): 
173.9, 51.0, 33.8, 29.3, 29.2, 29.0, 28.9, 24.7; νmax: 2929, 2856, 1731, 1438 cm-1. 
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Experiment 29: Tetradecane-1,14-diol (233) 
 
A solution of the dimethyl ester 232 (27.0 g, 0.094 mol) in dry THF (40 mL) was added to a 
stirred suspension solution of LiAlH4 (8.8 g, 0.23 mol) in dry THF (250 mL) at 10 oC and 
the mixture was refluxed for 3 h. When TLC showed no starting material was left, the 
reaction mixture was quenched with sat. aq. sodium sulfate (20 mL) at 10 oC until a white 
precipitate was formed and then MgSO4 (20 g) was added. The mixture was filtered 
through a pad of celite, and washed with THF and the solvent evaporated. The product was 
purified by column chromatography, eluting with petrol/ethyl acetate (5:1) to give a white 
solid, tetradecane-1,14-diol 233 (21 g, 97%).284 This showed δH (400 MHz, CDCl3): 3.65 
(4H, t, J 6.6 Hz), 1.42 – 1.21 (26H, m); δC (101 MHz, CDCl3): 62.6, 32.5, 29.5, 29.3, 25.6; 
νmax: 3410, 2927, 2852, 1424 cm-1. 
Experiment 30: 14-Bromotetradecan-1-ol (234) 
 
Tetradecane-1,14-diol 233 (19 g, 0.082 mol) was dissolved in toluene (150 mL) and 
aqueous HBr (30 mL, 48%) was added then the mixture was refluxed for 18 h. The reaction 
mixture was cooled to room temperature and the organic layer was separated. The aqueous 
layer was extracted with toluene (2 × 100 mL) and the combined organic layers were 
evaporated. The brown oil residue was dissolved in CH2Cl2 (300 mL) and washed with sat. 
aq. sodium bicarbonate (200 mL). The aqueous layer was re-extracted with CH2Cl2 (2 × 
100 mL). The combined organic layers were dried, evaporated. The crude product was 
purified by column chromatography, eluting petrol/ethyl acetate (10:1, then 5:1) to give 14-
bromotetradecan-1-ol 234 (21 g, 85%). {Found [M+Na]+: 315.1309; C14H29BrNaO 
requires: 315.1299}. This showed δH (400 MHz, CDCl3): 3.64 (2H, t, J 6.6 Hz), 3.41 (2H, t, 
J 6.9 Hz), 1.91 – 1.80 (2H, m), 1.65 – 1.20 (23H, m); δC (101 MHz, CDCl3): 63.0, 34.0, 
32.8, 29.6, 29.5, 29.4, 28.8, 28.2, 25.8; νmax: 3583, 3020, 2929, 1523, 1027 cm-1. 
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Experiment 31: 14-Bromotetradecyl pivalate (221) 
 
A solution of trimethylacetyl chloride (11.1 mL ,10.8 g, 0.090 mol, 1.2 mol eq.) in CH2Cl2 
(25 mL) was added to a stirred solution of 14-bromotetradecan-1-ol 234 (17.6 g, 0.060 
mol), triethylammine (12.1 g, 0.120 mol, 2 mol eq.) and 4-dimethylaminopyridine (1g) in 
CH2Cl2 (150 mL), over a period of 15 min. at 5 ºC. The mixture was allowed to reach room 
temperature and stirred for 18 h, then quenched with dilute HCl (150 mL). The organic 
layer was separated, and the aqueous layer was re-extracted with CH2Cl2 (2 × 100 mL). The 
combined organic layers were washed with brine (2 × 200 mL). The organic phase was 
dried, and the solvent was evaporated. The product was purified by column 
chromatography, eluting with petrol/ethyl acetate (5:1) to give a colourless oil 14-
bromotetradecyl pivalate 221 (22 g, 97%).202 This showed δH (400 MHz, CDCl3): 4.04 (2H, 
t, J 6.6 Hz), 3.40 (2H, t, J 6.9 Hz), 1.91 – 1.79 (2H, m), 1.67 – 1.56 (2H, m), 1.47 – 1.23 
(20H, m), 1.19 (9H, s); δC (101 MHz, CDCl3): 178.6, 64.4, 45.1, 38.7, 34.0, 32.9, 29.6, 
29.5, 29.4, 29.2, 28.7, 28.6, 28.2, 27.2, 25.9; νmax: 2927, 2854, 1729, 1479, 1462, 1285, 
1158 cm-1. All data data matched those in the literature.202 
Experiment 32: ((1-Phenyl-1H-tetrazol-5-yl)thio)tetradecyl pivalate (220) 
 
14-Bromotetradecyl pivalate 221 (14.1 g, 0.037 mol) was added to a stirred solution of 
anhydrous potassium carbonate (20.7 g, 0.150 mol) and 1-phenyl-1H-tetrazole-5-thiol (7.37 
g, 0.041 mol)  in acetone (100 mL) and THF (50 mL) at room temperature then the mixture 
was refluxed for 3 h. The reaction mixture was worked up and purified as before to give a 
white solid of ((1-phenyl-1H-tetrazol-5-yl)thio)tetradecyl pivalate 220 (15 g, 86%).{Found 
[M+Na]+: 497.3; C26H42O2N4SNa requires: 497.3}.  This showed δH (400 MHz, CDCl3): 
7.71 – 7.41 (5H, m), 4.03 (2H, t, J 6.6 Hz), 3.38 (2H, t, J 7.4 Hz), 1.88 – 1.71 (2H, m), 1.66 
– 1.52 (2H, m), 1.48 – 1.21 (20H, m), 1.18 (9H, s); δC (101 MHz, CDCl3): 178.6, 154.5, 
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133.7, 130.0, 129.7, 123.8, 64.4, 38.7, 33.3, 29.5, 29.4, 29.2, 29.1, 29.0, 28.6, 28.5, 27.2, 
25.8; νmax: 2929, 2856, 1717, 1501, 1480, 1462, 1388, 1215, 1159 cm-1. 
Experiment 33: 14-((1-Phenyl-1H-tetrazol-5-yl)sulfonyl)tetradecyl pivalate (217) 
 
Ammonium molybdate (VI) tetrahydrate (16.1 g, 0.013 mol) was dissolved in cold 
hydrogen peroxide (35%, 30 mL) and was gradually added to a stirred solution of ((1-
phenyl-1H-tetrazol-5-yl)thio)tetradecyl pivalate 220 (13.7 g, 0.0280 mol) in IMS (200 mL) 
and THF (100 mL) at 0 ºC. The mixture was allowed to reach room temperature and stirred 
for 2 h, and then another portion of ammonium molybdate (VI) tetrahydrate (6.1 g, 0.0040 
mol) in cold aqueus hydrogen peroxide (35 %, 15 mL) was added and stirred for 18 h. The 
mixture was worked up and purified as before to give 14-((1-phenyl-1H-tetrazol-5-
yl)sulfonyl)- tetradecyl pivalate 217 (13 g, 93%), {Found [M+Na]+: 529.2806; 
C26H42O4N4SNa requires: 529.2819}. This showed δH (400 MHz, CDCl3): 7.70  (2H, m), 
7.61 (3H, m), 4.05 (2H, t, J 6.6 Hz), 3.74 (2H,  distorted t, J 7.9 Hz), 1.96 (2H, m), 1.68 – 
1.57 (2H, m), 1.55 – 1.22 (20H, m), 1.20 (9H, s); δC (101 MHz, CDCl3): 178.6, 153.5, 
133.0, 131.4, 129.7, 125.0, 64.4, 56.0, 38.7, 29.5, 29.4, 29.2, 29.1, 28.9, 28.6, 28.1, 27.2, 
26.0, 21.9 ; νmax: 2929, 2856, 1722, 1455, 1338, 1151 cm-1. 
Experiment 34: Methyl (S,E)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)acrylate (229) 
 
A solution of NaIO4 (19.6 g, 0.091 mol) in water (100 mL) was added drop wise to a 
stirred solution of 1,2:5,6-O-isopropylidene-D-mannitol 219 (20 g, 0.076 mol) in 5% 
NaHCO3 (200 mL) at 0 ºC and stirring was continued for 1 h at room temperature. The 
mixture was cooled to 0 ºC and (diisopropoxyphosphoryl)-acetic acid methyl ester (40.0 g, 
0.168 mol) was added with stirring followed by a 6 M solution of aq. K2CO3 (260 mL) at 0 
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– 4 ºC. The mixture was allowed to reach room temperature and stirring was continued for 
20 h. then extracted with CH2Cl2 (3 × 300 mL), the combined organic extracts were dried 
and the solvent was evaporated. The product was purified by column chromatography 
eluting with petrol/ethyl acetate (5:1) to give a colourless oil, (E)-3-((S)-2,2-dimethyl-
[1,3]dioxolan-4-yl)-acrylic acid methyl ester 229 (19 g, 70%) [α] 24
D
 = + 45.2 (c 1.25, 
CHCl3). (lit. [α] 24D  = + 40.4 (c 1.09, CHCl3)). The NMR and IR data match those in the 
literature.269 
Experiment 35: Methyl (R)-3-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate (230) 
 
Methyl lithium (77 mL, 0.107 mol, 1.4M) was added drop wise to a stirred solution of (E)-
3-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-acrylic acid methyl ester 229 (10.0 g, 0.053 mol) 
in dry ether (300 mL) at 78 ºC under nitrogen atmosphere. The mixture was maintained at 
78 ºC for 2.5 h, and then allowed to gradually warm up to 60 ºC when water (10 mL) 
was added. After 5 min, sat. aq. NH4Cl (60 mL) was added, whereupon the temperature 
rose to 40 ºC. The cooling bath was removed and the temperature of the mixture brought 
to 0 ºC by addition of water (100 mL). The organic layer was separated and the aqueous 
layer was extracted with ether (100 mL). The combined organic phases were washed with 
brine (2 × 100 mL), dried and the solvent was evaporated. The crude product was purified 
by column chromatography eluting with petrol /ether (2:1) to give a colourless oil, (R)-3-
((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butyric acid methyl ester 230 (8.0 g, 77%) [α] 23
D
 = + 
8.6 (c 1.1, CHCl3) (litt. [α] 22D  =  + 8.34  (c 1.12, CHCl3)). All data data matched those in the 
literature.269 
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Experiment 36: (R)-3-((S)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-butan-1-ol (231) 
 
A solution of methyl (R)-3-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate 230 (10.0 g, 
0.049 mol)  in dry THF (40 mL) was added to a stirred suspension solution of LiAlH4 (2.8 
g, 0.074 mol) in dry THF (150 mL) at  10 ºC then  the mixture was allowed to reach room 
temperature and refluxed for 1 h. The reaction mixture was worked up and purified as 
before to give a colourless oil, (R)-3-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butan-1-ol 231 
(7.5 g, 87%) [α] 25
D
 = + 19.2 (c 1.12, CHCl3). (lit. [α] 24D  = + 18.1 (c 1.35, CHCl3)). The NMR 
and IR data matched those in the literature.285 
Experiment 37: (R)-3-((S)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-butyraldehyde (218) 
 
A solution of the primary alcohol 231 (7.0 g, 0.04 mol) in CH2Cl2 (30 mL) was added to a 
stirred solution of PCC (17.3 g, 0.080 mol) in CH2Cl2 (250 mL). Addition was done portion 
and portion, and during the addition a black colour appeared. The reaction was stirred for 3 
h. The reaction diluted first with petrol/ethyl acetate (10:1, 250 mL). The solution was 
filtered through a bed of silica and the solvent was evaporated. The product was purified by 
column chromatography eluting with petrol/ethyl acetate (5:1) to give a colourless oil, (R)-
3-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butyraldehyde 218 (6 g, 87%) [α] 23
D
 = + 8.24 (c1.06, 
CHCl3).
285 This showed δH (400 MHz, CDCl3): 9.77 (1H, br. t, J 1.8 Hz), 4.11 – 4.05 (1H, 
m), 3.99 (1H, dd, J 6.7, 8.2 Hz), 3.64 (1H, dd, J 7.3, 8.2 Hz), 2.56 (1H, ddd, J 1.3, 5.1, 16.4 
Hz), 2.44 – 2.33 (1H, m), 2.28 (1H, ddd, J 2.1, 8.0, 16.4 Hz), 1.41 (3H, s), 1.35 (3H, s), 1.0 
(3H, d, J 6.8 Hz); δC (101 MHz, CDCl3): 201.6, 78.6, 66.3, 46.6, 30.4, 26.2, 25.1, 22.6, 
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15.5; νmax: 2985, 1725, 1371, 1215, 1066, 859 cm-1. All data data matched those in the 
literature.285 
Experiment 38: (R)-17-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)octadecyl pivalate (236) 
 
Lithium bis (trimethylsilyl) amide (49.8 mL, 0.049 mol, 1.0 M) was added to a stirred solution 
of 14-((1-phenyl-1H-tetrazol-5-yl)sulfonyl)tetradecyl pivalate  217 (16.9 g, 0.033 mol) and (R)-
3-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butyraldehyde 218 (5.2 g, 0.03 mmol) in dry THF (100 
mL) at 10 ºC under nitrogen atmosphere.  The solution was allowed to reach room temperature 
and stirred for 3 h, then quenched with sat. aq. NH4Cl (100 mL). The product was extracted with 
ethyl acetate (3 × 150 mL). The combined organic layers were dried, and the solvent was 
evaporated. The product was purified by column chromatography, eluting with petrol/ethyl acetate 
(20:1) to give a colourless oil (R)-17-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)octadec-14-en-1-yl 
pivalate 235 (10 g, 69%) as a mixture of two isomers. This showed δH (400 MHz, CDCl3): 5.49 – 
5.25 (2H, m), 4.04 (2H, t, J 6.6 Hz), 4.01 (1H, m), 3.89 (1H, br.q, J 6.8 Hz), 3.61 (1H, br.t, J 7.6Hz), 
2.02 (2H, m), 1.94 – 1.74 (1H, m), 1.69 – 1.55 (2H, m), 1.39 (3H, s), 1.34 (3H, s), 1.31 – 1.22 (22H, 
m), 1.19 (9H, s), 0.96 (3H, d, J 6.7 Hz); δC (101 MHz, CDCl3): 179.6, 132.6, 127.5, 108.6, 79.9, 
67.8, 64.5, 41.3, 36.9, 36.2, 32.6, 30.9, 30.6, 29.7, 29.6, 29.5, 29.2, 29.1, 28.6, 27.2, 26.6, 25.9, 25.6, 
22.6, 20.4, 19.4, 15.7; νmax: 2922, 2853, 1463, 1065, 860 cm-1. 
Palladium 10% on carbon (1.5 g) was added to a stirred solution of the alkenes 235 (10.0 g, 0.020 
mol) in IMS (150 mL) and THF (150 mL) under hydrogen atmosphere. Hydrogenation was carried 
out for 16 h, the solution was filtered over a bed of celite and the solvent was evaporated. The 
product was purified by column chromatography, eluting with petrol/ethyl acetate (20:1) to give 
(R)-17-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)octadecyl pivalate 236 (9.0 g, 92%) [α] 26
D
 = + 12.4 (c 
0.180 CHCl3), {Found [M+Na]
+: 477.3905; C28H54O4Na requires: 477.3914}, This showed δH (400 
MHz, CDCl3): 4.04 (2H, t, J 6.6 Hz), 3.99 (1H, dd, J 6.3, 7.8 Hz), 3.86 (1H, br. q, J 6.9 Hz), 3.59 
(1H, br.t, J 7.7 Hz), 1.61 (2H, m), 1.40 (3H, s), 1.35 (3H, s), 1.32 – 1.23 (34H, m), 1.19 (9H, s), 1.1 
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– 1.07 (1H, m), 0.96 (3H, d, J 6.7 Hz) ; δC (101 MHz, CDCl3): 178.6, 108.5, 80.4, 67.8, 64.4, 38.7, 
36.5, 32.7, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.2, 28.6, 27.2, 26.6, 25.9, 25.5, 15.6; νmax: 2926, 
2854, 1731, 1463, 1397, 1284, 1157 cm-1. 
Experiment 39: (R)-17-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl) octadecan-1-ol (216) 
 
A solution of dimethyl-1,3-dioxolan-4-yl)octadecyl pivalate 236 (9.2 g, 0.01 mol)  in dry 
THF (40 mL) was added to a stirred suspension solution of LiAlH4 (1.0 g, 0.02 mol) in dry 
THF (150 mL) at 10 ºC and the mixture was refluxed for 3 h. The mixture was worked up 
and purified as before to give a white solid, (R)-17-((S)-2,2-dimethyl-1,3-dioxolan-4-yl) 
octadecan-1-ol 216 (7 g, 96%) [α] 25
D
 = + 19 (c 0.18 CHCl3), {Found [M+Na]
+: 393.3334; 
C23H46O3Na requires: 393.3339}. This showed δH (400 MHz, CDCl3): 4.00 (1H, dd, J 6.2, 7.8 
Hz), 3.87 (1H, br. q, J 6.9 Hz), 3.65 (1H, br. t, J 7.7 Hz), 3.50 (2H, t, J 6.7 Hz), 1.60 (2H, m), 
1.41 (3H, s), 1.36 (3H, s), 1.34 – 1.22 (30H, m), 1.08 (1H,m), 0.97 (3H, d, J 6.7 Hz); δC (101 
MHz, CDCl3): 108.5, 80.4, 67.8, 63.0, 36.5, 32.8, 32.7, 29.9, 29.7, 29.6, 29.4, 27.0, 26.6, 
25.7, 25.5, 15.6; νmax 3400, 2916, 2850, 1469, 1370, 1265, 1207, 1158, 1056 cm-1. 
Experiment 40: 5-(((R)-17-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)octadecyl)thio)-1-phenyl-1H-
tetrazole(215) 
 
Diethyl azodicarboxylate (DEAD) (4.4 g, 0.020 mol) in dry THF (10 mL) was added to a 
stirred solution of (R)-17-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)octadecan-1-ol 216 (7.3 g, 
0.01 mol). Triphenylphosphine (6.7 g, 0.02 mol) and 1-phenyl-1H-tetrazole-5-thiol (4.5 g, 
0.02 mol) in dry THF (70 mL) at 0 ºC under nitrogen atmosphere. The mixture was allowed 
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to reach room temperature and then stirred for 3 h. The solvent was evaporated and the 
residue was stirred with petrol/ethyl acetate (10:1, 150 mL) for 30 min and then filtered 
through a pad of celite. The filtrate was evaporated, and the crude product was purified by 
column chromatography, eluting with petrol/ethyl acetate (5:1) to give compound 215 (8.7 g, 
83%) [α] 26
D
 = + 13 (c 0.17 CHCl3),{ Found [M+Na]
+: 553.3534; C30H50O2SN4Na requires: 
553.3547}. This showed δH (400 MHz, CDCl3): 7.63 – 7.49 (5H, m), 3.99 (1H, dd, J 6.2, 7.8 
Hz), 3.86 (1H, br. q, J 6.9 Hz), 3.59 (1H, br. t, J 7.7 Hz), 3.39 (2H, t, J 7.4 Hz), 1.80 (2H, 
m), 1.56 (1H, m), 1.43 (1H,m), 1.40 (3H, s), 1.35 (3H, s), 1.33 – 1.19 (26H, m), 1.08 (1H, 
m), 0.96 (3H, d, J 6.7 Hz); δC (101 MHz, CDCl3): 154.5, 133.7, 130.0, 129.7, 123.8, 108.4, 
80.4, 67.8, 36.5, 33.3, 32.7, 29.8, 29.6, 29.5, 29.4, 29.0, 28.6, 26.9, 26.6, 25.5, 15.6; νmax: 
2975, 2854, 1644, 1501, 1464, 1380, 1245, 1161, 1065 cm-1. 
 
Experiment 41: 5-(((R)-17-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)octadecyl)sulfonyl)-1-phenyl-1H-
tetrazole (214) 
 
Ammonium molybdate VI tetrahydrate (9.1 g, 0.07 mol) was dissolved in cold aqueous 
hydrogen peroxide in (35 %, w/w, 30 mL) and gradually added to a stirred solution of 5-
(((R)-17-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)octadecyl)thio)-1-phenyl-1H-tetrazole 215 (8.7 
g, 0.01 mol)  in IMS (150 mL) and THF (75 mL). The mixture was stirred for 2 h, and then 
another portion of ammonium molybdate VI tetrahydrate (3.4 g, 0.002 mol) in cold aqueous 
hydrogen peroxide in (35 %, w/w, 12 mL) was added and stirred at room temperature for 18 
h. The reaction mixture was worked up and purified as before to give 5-(((R)-17-((S)-2,2-
dimethyl-1,3-dioxolan-4-yl)octadecyl)sulfonyl)-1-phenyl-1H-tetrazole 214 (8.9 g, 96%) [α] 25
D
 
= + 18 (c 0.19 CHCl3), {Found [M+H]
+: 563.3683; C30H51N4O4S requires: 563.3626}. This 
showed δH (400 MHz, CDCl3): 7.73 – 7.68 (2H, m), 7.65 – 7.57 (3H, m), 4.00 (1H, dd, J 6.2, 
7.8 Hz), 3.87 (1H, br. q, J 6.9 Hz), 3.74 (2H, t, J 7.9 Hz), 3.60 (1H, br. t, J 7.7 Hz), 1.96 (2H, 
m), 1.53 – 1.45 (2H, m), 1.41 (3H, s), 1.36 (3H, s), 1.33 – 1.23 (26H, m), 1.11-1.08 (1H, m), 
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0.97 (3H, d, J 6.7 Hz); δC (101 MHz, CDCl3): 153.5, 131.4, 129.7, 125.0, 108.4, 80.4, 67.8, 
56.0, 36.5, 32.7, 29.8, 29.6, 29.5, 29.4, 29.2, 28.9, 28.1, 27.0, 26.6, 25.5, 21.9, 15.6; νmax: 
2928, 2855, 1597, 1498, 1464, 1343, 1259, 1150, 1071 cm-1. 
Experiment 42: Ethyl (2R,3R,21R)-3-((tert-butyldimethylsilyl)oxy)-21-((S)-2,2-dimethyl-
1,3-dioxolan-4-yl)-2-eicosyldocosanoate (238) 
 
Lithium bis(trimethylsilyl) amide (8.3 mL, 0.008 mol, 1.0 M) was added drop wise to a stirred 
solution of ethyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)docosanoate 183 (2.5 g, 
0.004 mol) and 5-(((R)-17-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)octadecyl)sulfonyl)-1-phenyl-1H-
tetrazole 214 (3.1 g, 0.005 mol) in dry THF (50 mL) under nitrogen at 15 ºC. The mixture was 
allowed to reach room temperature, and stirred for 2 h. The mixture was worked up and purified as 
before to give ethyl E/Z-(2R,21R)-3-((tert-butyldimethylsilyl)oxy)-21-((S)-2,2-dimethyl-1,3-
dioxolan-4-yl)-2-eicosyldocos-4-enoate 237 (3.2 g, 79%) as a mixture in ratio (2.5:1). Palladium 
10% on carbon (0.5 g) was added to a stirred solution of the alkenes 237 (3.2 g, 0.003 mol) in IMS 
(100 mL) and THF (100 mL) under hydrogen atmosphere. Hydrogenation was carried out 6 h. The 
mixture was worked up and purified as before to give ethyl (2R,3R,21R)-3-((tert-
butyldimethylsilyl)oxy)-21-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-eicosyldocosanoate 238 (2.5 g, 
78%) [α] 24
D
 = + 6.4 (c 1.4 CHCl3), {Found [M+Na]
+: 901.7999; C55H110O5NaSi requires: 901.8015}. 
This showed δH (400 MHz, CDCl3): 4.12 (2H, m), 4.01 (1H, dd, J 6.2, 7.8 Hz), 3.95 – 3.78 (1H, m), 
3.87 (1H, br. q, J 7.0 Hz), 3.61 (1H, br. t, J 7.7 Hz), 2.50 (1H, ddd, J 3.8, 7.0, 10.8 Hz), 1.59 – 1.52 
(2H, m), 1.49 – 1.42 (2H m), 1.41 (3H, s), 1.36 (3H, s), 1.33 – 1.18 (72H, m), 0.97 (3H, d, J 6.7 
Hz), 0.89 (3H, t, J 4.9 Hz), 0.87 (9H, s), 0.05 (3H, s), 0.03 (3H, s); δC: (101 MHz, CDCl3): 174.6, 
108.5, 80.4, 73.2, 67.8, 65.1, 60.4, 60.0, 59.9, 51.6, 36.5, 33.7, 32.7, 31.9, 30.9, 29.9, 29.8, 29.7, 
29.6, 29.5, 29.4, 29.3, 27.8, 27.4, 27.1, 27.0, 26.6, 25.8, 25.5, 23.8, 22.7, 18.0, 15.6, 14.3, 14.1, 4.4, 
5.0; νmax: 2928, 2855, 1725, 1466, 1381, 1095 cm-1. 
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Experiment 43: Ethyl (2R,3R)-3-((tert-butyldimethylsilyl)oxy)-2-tetracosylhexacosanoate (243) 
 
Lithium bis(trimethylsilyl) amide (2.8 mL, 0.003 mol, 1.06 M) was added dropwise to a 
stirred solution of the aldehyde 185 (1.0 g, 1.67 mmol) and 5-(docosylsulfonyl)-1-phenyl-
1H-tetrazole 173 (1.0 g, 2.0 mmol) in dry THF (15 mL) under nitrogen at 15 ºC. The 
mixture was allowed to reach room temperature, and stirred for 2 h. The reaction mixture 
was worked up and purified as before to give methyl- E/Z- (2R,3R)-3-((tert-butyl 
dimethylsilyl)oxy)-2-tetracosylheptacos-6-enoate 275 as a mixture of two isomers  (1.1 g,  
74%). Palladium 10% on carbon (0.2 g) was added to a stirred solution of the above alkenes 
275 (1.0 g, 0.0011 mole) in IMS (20 mL) and THF (10 mL) under hydrogen atmosphere for 
16 h. The product was purified by column chromatography, eluting with petrol/ethyl acetate 
(20:1) to give a white solid, 243 (0.8 g, 80%) {Found [M+H]+: 891.8918; C58H119O3Si 
requires: 891.8923}.  This showed δH (400 MHz, CDCl3): 4.20 (2H, q, J 7.1 Hz), 3.90 (1H, 
dt, J, 5.8,7.6 Hz), 2.61 (1H, m), 2.18 (3H, s), 1.84 – 1.15 (92H, m), 0.89 (6H, t, J 6.6 Hz); 
δC (101 MHz, CDCl3): 178.6, 73.4, 60.4, 51.6, 50.2, 31.9, 29.7, 29.6, 29.5, 29.4, 28.8, 22.7, 
14.1; νmax: 2915, 2848, 1740, 1467, 1371, 1234, 1169, 1096, cm-1. 
Experiment 44: Ethyl (2R,3R)-3-hydroxy-2-tetracosylhexacosanoate (244) 
 
Tetrabutylammonium fluoride (1.12 mL, in 1.0 M THF, 1.121 mmol) was added dropwise 
to a stirred solution of 243 (0.5 g, 0.56 mmol) in anhydrous THF (5 mL) at 0 ºC under 
nitrogen atmosphere. The mixture was allowed to reach room temperature and stirred for 18 
h when TLC showed no starting material was left. The solvent was evaporated to give the 
residue which was purified by column chromatography on silica gel eluting with 
petrol/ethyl acetate (5:1) to give a white semi-solid, 244 (0.2 g, 47%) [α] 23
D
 = + 5.27 (c 0.91 
CHCl3), {Found [M+Na]
+: 799.7870; C52H104O3Na requires: 799.7878}. This showed δH 
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(400 MHz, CDCl3): 4.19 (2H, q, J 7.1 Hz), 3.65 (1H, dt, J, 5.8,7.6), 2.45 – 2.38 (1H, m), 
2.18 (3H, s), 1.61 – 1.20 (91H, m), 0.86 (6H, t, J 6.7 Hz); δC (101 MHz, CDCl3): 175.9, 
72.3, 60.4, 50.8, 41.4, 31.8, 29.7, 29.6, 29.5, 29.4, 29.3, 27.3, 25.7, 22.7, 22.5, 20.4, 19.4, 
14.3, 14.1; νmax: 3389, 2928, 2855, 1725, 1466 cm-1. 
Experiment 45: Ethyl (2R,3R,21R)-21-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-hydroxy-
2-eicosyldocosanoate (245) 
 
Tetrabutylammonium fluoride (10.4 mL, in 1.0 M THF, 0.010 mol) was added dropwise to 
a stirred solution of ethyl (2R,3R,21R)-3-((tert-butyldimethylsilyl)oxy)-21-((S)-2,2-
dimethyl-1,3-dioxolan-4-yl)-2-icosyldocosanoate 238 (2.3 g, 0.002 mol) in anhydrous THF 
(15 mL) at 0 ºC under nitrogen atmosphere. The mixture was allowed to reach room 
temperature and stirred for 16 h when TLC showed no starting material. The solvent was 
evaporated  to give the residue which was purified by column chromatography on silica gel 
eluting with hexane/ethyl acetate (5:1) to give ethyl (2R,3R,21R)-21-((S)-2,2-dimethyl-1,3-
dioxolan-4-yl)-3-hydroxy-2-eicosyldo-cosanoate 245 (1.64 g, 82%) [α] 24
D
 = + 17.5 (c 1.83 
CHCl3), {Found [M+Na]
+: 787.7137; C49H96O5Na requires: 787.7150}. This showed δH 
(400 MHz, CDCl3): 4.19 (2H, q, J 7.1 Hz), 4.01 (1H, dd, J 6.5, 7.4 Hz), 3.87 (1H, br. q, J 
6.9 Hz), 3.65 (1H, m ), 3.61 (1H, br. t, J 7.7 Hz), 2.45 – 2.38 (1H, m), 1.79 – 1.65 (2H, m), 
1.65 – 1.52 (2H, m), 1.41 (3H, s), 1.36 (3H, s), 1.34 – 1.17 (73H, m), 1.15 – 1.02 (1H, m), 
0.97 (3H, d, J 6.6 Hz), 0.89 (3H, t, J 6.6 Hz) ; δC (101 MHz, CDCl3): 175.8, 108.5, 80.4, 
72.3, 68.0, 67.8, 60.4, 50.8, 36.5, 35.7, 32.7, 31.9, 29.9, 29.7, 29.6, 29.5, 29.4, 29.3, 27.0, 
26.9, 26.6, 25.7, 25.6, 25.5, 22.7, 15.6, 14.3, 14.0; νmax: 3520, 2924, 2854, 1710, 1461, 
1377, 1264, 1189, 1164 cm-1. 
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Experiment 46: Ethyl (2R,3R,21R)-3-acetoxy-21-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-
2-eicosyldocosanoate (213) 
 
A mixture of acetic anhydride (10 mL) and anhydrous pyridine (10 mL) was added to 
stirred solution of the alcohol 245 (1.64 g, 0.002 mol) at room temperature and the mixture 
was stirred for 18 h, then diluted with toluene (10 mL) and the solvent evaporated. The 
product was purified by column chromatography, eluting with petrol/ethyl acetate (5:1) to give 
a white solid, ethyl (2R,3R,21R)-3-acetoxy-21-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-
eicosyldocosanoate 213 (1.7 g, 98%) [α] 24
D
 = + 16.5 (c 1.75 CHCl3), {MALDI-Found 
[M+Na]+: 829.7246; C51H98O6Na requires: 829.7256}. This showed δH (400 MHz, CDCl3): 
5.10 (1H, td, J 4.0, 7.5 Hz), 4.15 (2H, q, J 7.1 Hz), 4.01 (1H, dd, J 6.3, 7.7 Hz), 3.88 (1H, 
br. q, J 7.0 Hz), 3.61 (1H, br. t, J 7.7 Hz), 2.66 – 2.53 (1H, m), 2.03 (3H, s), 1.59 – 1.52 
(4H, m), 1.41 (3H, s), 1.36 (3H, s), 1.34 – 1.16 (71H, m), 1.10 – 1.08 (1H, m), 0.97 (3H, d, 
J 6.7 Hz), 0.89 (3H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 173.1, 170.3, 108.5, 80.4, 74.1, 
67.8, 60.3, 49.6, 36.5, 32.7, 31.9, 31.7, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 28.1, 27.4, 27.0, 
26.6, 25.5, 24.9, 22.7, 22.6, 21.0, 15.6, 14.3, 14.0; νmax: 2927, 2855, 1732, 1467, 1379, 
1248, 1163, 1097 cm-1. 
Experiment 47: Ethyl (2R,3R,21R)-3-acetoxy-2-eicosyl-21-methyl-22-oxodocosanoate (211) 
 
Periodic acid (1.0 g, 4.6 mmol) was added to a stirred solution of ethyl (2R,3R,21R)-3-acetoxy-
21-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-eicosyldocosanoate 213 (1.5 g, 1.85 mmol) in dry ether 
(75 ml) at room temperature under nitrogen. The mixture was stirred for 16 h, when TLC showed 
no starting material. The precipitate was filtered through a bed of celite and washed with ether. 
The solvent was evaporated and the crude product was purified by column chromatography, 
eluting with petrol/ethyl acetate (10:1) to give a white semi-solid, ethyl (2R,3R,21S)-3-acetoxy-2-
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eicosyl-21-methyl-22-oxodocosanoate 211 (1.1 g, 77%) [α] 24
D
 = + 6 (c 0.4 CHCl3) {Found 
[M+Na]+: 757.6659; C47H90O5Na requires: 757.6680}. This showed δH (400 MHz, CDCl3): 9.61 
(1H, d, J 1.9 Hz), 5.09 (1H, td, J 4.0,7.7 Hz), 4.14 (2H, q, J 7.1 Hz), 2.60 (1H, ddd, J 5.5, 9.1, 
10.8 Hz), 2.38 – 2.29 (1H, m), 2.02 (3H, s), 1.46 – 1.17 (95H, m), 1.09 (3H, d, J 7.0 Hz), 0.88 
(3H, t, J 6.7 Hz); δC (101 MHz, CDCl3): 205.3, 173.1, 170.3, 74.2, 60.3, 49.6, 46.3, 31.9, 31.7, 
30.5, 29.7, 29.6, 29.5, 29.4, 29.3, 28.2, 27.4, 26.9, 24.9, 22.7, 21.0, 14.3, 14.0, 13.3; νmax: 2916, 
2855, 1731, 1465, 1375, 1247, 1183, 1025 cm-1. 
Experiment 48: Methyl (2R,3R,21R)-3-acetoxy-21-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-
2-eicosyldocosanoate (212) 
 
Lithium bis(trimethylsilyl) amide (9.3 mL, 0.009 mol, 1.0 M) was added drop wise to a stirred 
solution of methyl (R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)docosanoate 180 (3.0 g, 
0.005 mol) and 5-(((R)-17-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)octadecyl)sulfonyl)-1-phenyl-1H-
tetrazole 214 (3.5 g, 0.006 mol) in dry THF (50 mL) under nitrogen at 15 ºC. The mixture was 
allowed to reach room temperature, and stirred for 2 h. The mixture was worked up and purified as 
before to give (3.8 g, 76%), as a mixture of methyl E/Z- (2R,21R)-3-((tert-butyldimethylsilyl)oxy)-
21-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-eicosyldocos-4-enoate 246. This showed 5.47 – 5.40 
(1H, m), 5.37 – 5.31(1H, m), 4.00 (1H, dd, J 6.3, 7.9 Hz), 3.98–3.89 (1H, m), 3.89 (1H, br.q, J 6.9 
Hz), 3.66 (3H, s), 3.61 (1H, br.t, J 7.9 Hz), 2.56–2.50 (1H, m), 2.35–2.16 (2H, m), 2.01–1.98 (2H, 
m), 1.59–1.51 (3H, m), 1.41 (3H, s), 1.36 (3H, s), 1.39–1.26 (48H, m, v.br.), 1.12–1.07 (1H, m), 
0.97 (3H, d, J 6.6 Hz), 0.89 (3H, t, J 6.9 Hz), 0.87 (9H, s), 0.06 (3H, s), 0.02 (3H, s); δC: 175.1, 
132.7, 127.5, 108.5, 80.4, 73.2, 67.8, 51.4, 51.16, 36.5, 32.8, 32.7, 31.9, 29.9, 29.7, 29.66, 29.64, 
29.62, 29.60, 29.57, 29.53, 29.49, 29.43, 29.36, 29.25, 27.7, 27.6, 27.0, 26.6, 25.7, 25.5, 22.7, 18.0, 
15.6, 14.1, - 4.3, - 5.0; νmax: 2925, 2854, 1740, 1465, 1368, 1253, 1165, 1071cm-1. 
Tetrabutylammonium fluoride (17.6 mL, in 1.0 M THF, 0.010 mol) was added dropwise to a stirred 
solution of the above alkenes 246 in anhydrous THF (15 mL) at 0 ºC under nitrogen atmosphere. 
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The mixture was allowed to reach room temperature and stirred for 16 h. The reaction mixture was 
worked up and purified as before to give a white semi-solid, methyl E/Z-(2R,21R)-21-((S)-2,2-
dimethyl-1,3-dioxolan-4-yl)-3-hydroxy-2-eicosyldocos-4-enoate 247 (2.8 g, 88%).  A mixture of 
acetic anhydride (12 mL) and anhydrous pyridine (12 mL) was added to stirred solution of the 
above alcohol (2.8 g, 3.0 mmol) at room temperature and stirred for 18 h. The mixture was worked 
up and purified as before to give a white semi-solid methyl E/Z-(2R,21R)-3-acetoxy-21-((S)-2,2-
dimethyl-1,3-dioxolan-4-yl)-2-eicosyl docos-4- enoate 248 (2.6 g, 88%). Palladium hydroxide on 
activated charcoal (10% Pd(OH)2-C 0.5g) was added to a stirred solution of the above alkenes (2.6 
g, 3.340 mmol) in ethyl acetate (50 mL) under hydrogen atmosphere for 2 h. The mixture was 
worked up and purified as before to give a white solid, methyl (2R,3R,21R)-3-acetoxy-21-((S)-2,2-
dimethyl-1,3-dioxolan-4-yl)-2-icosyldocosanoate 212 (2.5 g, 96%) [α] 23
D
 = + 17.5 (c 0.92 CHCl3), 
{MALDI-Found [M+Na]+: 815.7093; C50H96O6Na requires: 815.7099}. This showed δH (400 
MHz, CDCl3): 5.09 (1H, td, J 4.1, 7.6 Hz), 4.01 (1H, dd, J 6.4, 7.7 Hz), 3.87 (1H, br. q, J 6.9 Hz), 
3.68 (3H, s), 3.61 (1H, br. t, J 7.7 Hz), 2.67 – 2.57 (1H, m), 2.35 (1H, m), 2.04 (3H, s), 1.41 (3H, s), 
1.36 (3H, s), 1.35 – 1.20 (72H, m), 0.97 (3H, d, J 6.7 Hz), 0.89 (3H, t, J 6.6 Hz); δC (101 MHz, 
CDCl3): 173.7, 170.4, 108.5, 80.4, 74.1, 67.8, 51.6, 49.6, 36.5, 32.7, 31.9, 31.7, 29.9, 29.6, 29.5, 
29.4, 29.3, 28.1, 27.5, 27.1, 26.6, 25.5, 24.9, 22.7, 21.0, 15.6, 14.6, 14.1; νmax: 2916, 2855, 1731, 
1465, 1375, 1247, 1183, 1025 cm-1. 
Experiment 49: Methyl (2R,3R,21R)-3-acetoxy-2-icosyl-21-methyl-22-oxodocosanoate (210) 
 
Periodic acid (1.7 g, 0.0070 mol) was added to a stirred solution of methyl (2R,3R,21R)-3-
acetoxy-21-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-eicosyldocosanoate 212 (2.5 g, 0.0030 
mol) in dry ether (125 mL) at room temperature under nitrogen. The mixture was stirred for 
16 h. The mixture was worked up and purified as before to give a white semi-solid, methyl  
(2R,3R,21R)-3-acetoxy-2-eicosyl-21-methyl-22-oxodocosanoate 210 (2.0 g, 88%) [α] 23
D
 =  + 
6.7 (c 0.53, CHCl3) {Found [M+Na]
+: 743.6506; C46H88O5Na requires: 743.6524}. This 
showed δH (400 MHz, CDCl3): 9.61 (1H, d, J 1.7 Hz), 5.08 (1H, dt, J 4.1,7.6 Hz), 3.68 (3H, 
s), 2.65 – 2.56 (1H, m), 2.39 – 2.26 (1H, m), 2.03 (3H, s), 1.73 – 1.19 (92H, m), 1.09 (3H, 
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d, J 7.0 Hz), 0.88 (3H, t, J 6.6 Hz); δC (101 MHz, CDCl3): 205.4, 173.7, 170.4, 74.0, 51.5, 
49.6, 46.3, 31.9, 31.7, 30.5, 29.7, 29.6, 29.5, 29.4, 29.3, 28.1, 27.5, 26.9, 25.0, 22.7, 21.0, 
14.0, 13.3; νmax: 2916, 2849, 1731, 1439, 1373, 1235, 1197, 1021 cm-1. 
Experiment 50: Methyl 15-hydroxypentadecanoate (249) 
 
Sodium (11.8 g, 0.513 mol) was added to a stirred solution of methanol (400 mL) at 0 ºC. 
The mixture was allowed to reach room temperature until all of the sodium was consumed. 
ω- Pentadecalactone 227 (50 g, 0.20 mol) was added, and the mixture was heated to 80 ºC 
and stirred for 2 h. The reaction was cooled to room temperature and quenched with aq. 
HCl (250 mL, 1N) and water (200 mL). The product was extracted with ethyl acetate (2 × 
250 mL), and the combined organic layers were dried, evaporated to give a white solid as a 
mixture of the ester and the acid. The white solid was dissolved in MeOH (150 mL) and 
H2SO4 (2 mL) was added. The mixture was refluxed for 1 h until no acid was left, then 
cooled to room temperature and methanol was evaporated. The product was dissolved with 
ethyl acetate (200 mL), washed with sat. aq. NaHCO3 (150 mL), and the product was 
extracted with ethyl acetate. The solvent was evaporated and the product was purified by 
recrystallization using petroleum ether to give methyl 15-hydroxypentadecanoate 249 (49 g, 
86%),273 m.p. 45  47 oC (lit. 47  48 °C). This showed δH (400 MHz, CDCl3): 3.67 (3H, s), 
3.64 (2H, t, J 6.5 Hz), 2.31 (2H, t, J 7.5 Hz), 1.70 – 1.49 (4H, m), 1.41 – 1.15 (21H, m); δC 
(101 MHz, CDCl3): 174.4, 63.0, 51.4, 34.1, 32.8, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 25.7, 
24.9; νmax: 3298, 2919, 2850, 1742, 1464, 1178 cm-1. All data were identical to the 
literature.273 
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Experiment 51: Methyl 15-((tetrahydro-2H-pyran-2-yl)oxy)pentadecanoate (250) 
 
3,4-Dihydro-2H-pyran (18.5 g, 0.224 mol) and pyridinium-p-toluene-sulfonate (8.3 g, 0.033 
mol) were added to a stirred solution of 15-hydroxypentadecanoate 249 (30 g, 0.11 mol) in 
dry CH2Cl2 (250 mL) under nitrogen at room temperature. The mixture was stirred for 3 h 
when TLC showed no starting material was left, then quenched by adding sat. aq. NaHCO3 
(150 mL), and extracted with CH2Cl2. The solvent was evaporated and the product was 
purified by column chromatography, eluting with petrol/ethyl acetate (5:2) to give methyl 
15-((tetrahydro-2H-pyran-2-yl)oxy)pentadecanoate 250 (37g, 94%).202 This showed δH 
(400 MHz, CDCl3): 4.58 (1H, m), 3.87 (1H, m), 3.73 (1H, dt, J 6.9, 9.3 Hz), 3.67 (3H, s), 
3.50 (1H, m), 3.38 (1H, dt, J 6.7, 9.4 Hz), 2.30 (2H, t, J 7.5 Hz), 1.83 (1H, m), 1.72 (1H, 
m), 1.59 (4H, m), 1.56 – 1.19 (24H, m); δC (101 MHz, CDCl3): 174.3, 98.8, 67.7, 62.3, 
51.4, 34.1, 30.8, 29.7, 29.6, 29.5, 29.4, 29.2, 29.1, 26.2, 25.5, 24.9, 19.7; νmax: 2929, 2855, 
1731, 1438 cm-1. All data matched those in the literature.202 
Experiment 52: 15-((Tetrahydro-2H-pyran-2-yl)oxy)pentadecan-1-ol (251) 
 
A solution of the methyl 15-((tetrahydro-2H-pyran-2-yl)oxy)pentadecanoate 250 (30.0g, 
0.084 mol) in THF (50 mL)  was added to a stirred suspension solution of LiAlH4 (4.7g, 
0.12 mol) in THF (250 mL) at 10 oC and the mixture was refluxed for 3 h. The mixture 
was worked up and purified as before to give 15-((tetrahydro-2H-pyran-2-
yl)oxy)pentadecan-1-ol 251 (26 g, 91%) {Found [M+NH4]
+: 346.3318; C20H44O3N 
requires: 346.3316}. This showed δH (400 MHz, CDCl3): 4.58 (1H, m), 3.87 (1H, dt, J 5.8, 
7.5 Hz), 3.73 (1H, dt, J 3.4,7.4 Hz), 3.64 (2H, br.t, J 5.3 Hz), 3.50 (1H, m), 3.39 (1H, dt, J 
4.1,7.2 Hz), 1.84 (1H, m), 1.72 (1H, m), 1.58 (4H, m), 1.40 – 1.20 (27H, m); δC (101 MHz, 
CDCl3): 98.8, 67.7, 63.0, 62.3, 32.8, 30.8, 29.7, 29.6, 29.5, 29.4, 26.2, 25.7, 25.5, 19.7; 
νmax: 3392, 2923, 2852, 1468 cm-1. 
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Experiment 53: 15-((Tetrahydro-2H-pyran-2-yl)oxy)pentadecanal (226) 
 
A solution of the primary alcohol 251 (4.0 g, 0.01 mol) in CH2Cl2 (20 mL) was added to a 
stirred solution of PCC (5.2 g, 0.02 mol) in CH2Cl2 (100 mL), a black colour appearing 
during the addition. The reaction was stirred for 3 h then worked up and purified as before 
to give 15-((tetrahydro-2H-pyran-2-yl)oxy)pentadecanal 226 (3.2 g, 82%) {Found 
[M+Na]+: 349.3; C20H38O3Na requires: 342.3}. This showed δH (400 MHz, CDCl3): 9.75 
(1H, t, J 7.2 Hz), 4.56 (1H, m), 3.86 (1H, m), 3.71 (1H, dt, J 6.9, 9.5 Hz), 3.53 – 3.43 (1H, 
m), 3.36 (1H, dt, J 6.7, 9.5 Hz), 2.40 (2 H, dt, J 1.7, 7.4 Hz), 1.82 (1H, m), 1.69 (1H, m), 
1.53 (4H, m), 1.38 – 1.16 (24H, m); δC (101 MHz, CDCl3): 202.9, 98.8, 67.6, 62.3, 43.9, 
30.7, 30.6, 29.7, 29.6, 29.51, 29.5, 29.4, 29.36, 29.3, 29.1, 26.2, 25.7, 25.5, 22.0, 19.6; νmax: 
2926, 2854, 1727, 146 cm-1. 
Experiment 54:   Methyl heptadecanoate (254) 
 
Conc. H2SO4 (3 mL) was added to a stirred solution of heptadecanoic acid (commercially 
available) 253 (25.0 g, 0.092 mol) in methanol (150 mL) and the mixture was refluxed for 3 
h. The reaction was monitored by TLC until no starting material was left. The excess of 
methanol was evaporated and then sat. aq. NaHCO3 (100 mL) was added to neutralize the 
acid. The product was separated, and aqueous layer was extracted with CH2Cl2 (3 × 200 
mL) then the combined organic layers were dried over MgSO4 and concentrated. The crude 
product was purified by recrystallization from petrol to give a white solid, methyl 
heptadecanoate 254 (26 g, 99%). This showed δH (400 MHz, CDCl3): 3.67 (3H, s), 2.31 
(2H, t, J 7.6 Hz), 1.68 – 1.17 (28H, m), 0.88 (3H, t, J 4.9 Hz); δC (101 MHz, CDCl3): 177.4, 
51.4, 34.1, 31.9, 29.7, 29.6, 29.4, 29.1, 25.0, 22.7, 14.1. νmax: 2921, 2850,1744 cm-1. 
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Experiment 55: Heptadecan-1-ol (255) 
 
A solution of the methyl heptadecanoate 254 (36.0 g, 0.126 mol) in THF (30 mL) was 
added to a stirred suspension solution of LiAlH4 (7.1 g, 0.18 mol) in THF (200 mL) at 10 
oC and the mixture was refluxed for 3 h. The mixture was worked up and purified as before 
to give a colourless oil of heptadecan-1-ol 255 (31 g, 95%).201 This showed δH (400 MHz, 
CDCl3): 3.65 (2H, t, J 6.6 Hz), 1.66 – 1.13 (31H, m), 0.89 (3H, t, J 6.8 Hz); δC: (101 MHz, 
CDCl3) 68.0, 63.0, 32.8, 31.9, 29.7, 29.6, 29.4, 29.3, 25.7, 25.6, 22.7, 14.0. νmax: 3389, 
2925, 2856 cm-1. All data matched those in the literature.201 
Experiment 56: 1-Bromoheptadecane (256) 
 
Triphenyl phosphine (38.0 g, 0.144 mol) was added to a stirred solution of heptadecan-1-ol 
255 (30.9 g, 0.120 mol) in CH2Cl2 (300 mL). The mixture was cooled to 0 ºC and N-
bromosuccinamide (27.9 g, 0.157 mol) was added in portions and the resulting mixture was 
stirred at room temperature for 3 h. The mixture was worked up and purified as before to 
give a white solid, 1-bromoheptadecane 256 (36 g, 92%).201 This showed δH (400 MHz, 
CDCl3): 3.42 (2H, t, J 6.9 Hz), 1.92 – 1.81 (2H, m), 1.48 – 1.19 (26H, m), 0.89 (3H, t, J 6.8 
Hz); δC (101 MHz, CDCl3): 34.0, 32.8, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.8, 28.1, 22.7, 
14.1; νmax: 2916, 2848, 1433, 1110 cm-1. All data matched those in the literature.201 
Experiment 57: Heptadecyltriphenylphosphonium bromide (225) 
 
 
1-Bromoheptadecane 256 (20.0 g, 0.062 mol) was added to a stirred solution of triphenyl- 
phosphine (24.6 g, 0.0940 mol) in toluene (150 mL). The mixture was refluxed for 120 h. 
The solvent was evaporated and petroleum ether (100 mL) was added and again evaporated. 
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The residue was treated with diethyl ether (150 mL) and stirred for 1 h; by this time a slurry 
of fine crystals had formed. These were filtered, washed well with ether and dried the 
product was further purified by column chromatography, firstly eluting with petroleum 
ether and then CH2Cl2/MeOH (95:5) to give a white solid, 
heptadecyltriphenylphosphonium bromide 225 (27 g, 74%),201 which showed δH (400 MHz, 
CDCl3): 7.91 – 7.66 (15H, m), 4.03 – 3.49 (2H, m), 1.79 – 1.05 (30H, m), 0.87 (3H, t, J 6.7 
Hz); δC (101 MHz, CDCl3): 134.9, 133.8, 133.7, 130.5, 130.4, 118.3, 31.9, 30.5, 30.3, 29.7, 
29.6, 29.5, 29.3, 29.2, 23.0, 22.7, 22.5, 14.0; νmax: 2916, 2848, 1433, 1110 cm-1. All data 
matched those in the literature.201 
Experiment 58: (Z)-2-(Dotriacont-15-en-1-yloxy)tetrahydro-2H-pyran (252) 
 
Sodium bis(trimethylsilyl)amide, (25.0 mL, 0.025 mol, 1.0 M in THF) was added to a 
stirred solution of heptadecyltriphenylphosphonium bromide 225 (9.70g, 0.016 mol) in dry 
THF (50 mL) at room temperature under nitrogen atmosphere. The mixture was stirred for 
30 min and then aldehyde 226 (2.7 g, 0.008 mol) in dry THF (10 mL) was added at room 
temperature. The mixture was stirred for 3 h, then quenched with sat. aq. NH4Cl (30 mL). 
The product was extracted with petrol/ethyl acetate (10:1, 3 × 50 mL), and the combined 
organic layers were dried and evaporated to give the crude product, which was purified by 
column chromatography, eluting with petrol/ethyl acetate (20:1) to give (Z)-2-(dotriacont-
15-en-1-yloxy)tetrahydro-2H-pyran 252 (2.9 g, 64%), {Found [M+NH4]
+: 566.5869; 
C37H76O2N requires: 566.5871}. This showed δH (400 MHz, CDCl3): 5.36 (2H, br.t, 4.7 
Hz), 4.59 (1H, m), 3.88 (1H, m), 3.74 (1H, dt, J 6.9, 9.5 Hz), 3.51 (1H, m), 3.39 (1H, dt, J 
6.7, 9.6 Hz), 2.02 (4H, m), 1.84 (1H, m), 1.73 (1H, ddt, J 3.2, 5.9, 11.9 Hz), 1.65 – 1.50 
(4H, m), 1.46 – 1.19 (52H, m, J 70.1), 0.89 (3H, t, J 6.8); δC (101 MHz, CDCl3): 133.8, 
133.6, 129.9, 128.7, 128.5, 128.4, 98.8, 67.7, 62.3, 31.9, 30.8, 29.8, 29.7, 29.6, 29.5, 29.4, 
29.3, 27.2, 26.2, 25.5, 22.7, 19.7, 14.1; νmax: 2925, 2853, 1464, 1352 cm-1. 
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Experiment 59: (Z)-Dotriacont-15-en-1-ol (224) 
 
Pyridinum-p-toluenesulfonate (5.6 g, 0.02 mol) was added to a stirred solution of (Z)-2-
(dotriacont-15-en-1-yloxy)tetrahydro-2H-pyran 252 (2.5 g, 4.0 mmol) in THF (40 mL), 
methanol (16 mL) and stirred at 40 ºC for 6 h. Sat. aqueous NaHCO3 (30 mL) and water (20 
mL) were added and the product was extracted with ethyl acetate (3 × 50 mL). The 
combined organic layers were dried, and the solvent was evaporated. The product was 
purified by column chromatography, eluting with petrol/ethyl acetate (10:1) to give (Z)-
dotriacont-15-en-1-ol 224 (1.5 g, 71%), {Found [M+NH4]
+: 482.5292; C32H68ON requires: 
482.5295}. This showed δH (400 MHz, CDCl3): 5.36 (2H, br.t, 4.7 Hz), 3.65 (2H, t, J 6.6 
Hz), 2.02 (4H, m), 1.62 – 1.20 (53H, m), 0.88 (3H, t, J 6.9 Hz); δC (101 MHz, CDCl3): 
129.9, 63.1, 32.8, 32.6, 31.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 27.2, 25.7, 22.7, 14.1; νmax: 
3394, 2928, 2855, 1520, 1423 cm-1. 
Experiment 60: (Z)-5-(Dotriacont-15-en-1-ylthio)-1-phenyl-1H-tetrazole (223) 
 
Diethyl azodicarboxy (0.64 g, 0.003 mol), (Z)-dotriacont-15-en-1-ol 224 (1.32 g, 0.002 mol). 
Triphenylphosphine (0.96 g, 0.003 mol) and 1-phenyl-1H-tetrazole-5-thiol (0.65 g, 0.003 
mol) in dry THF (20 mL) at 0 ºC under nitrogen atmosphere. The mixture was allowed to 
reach room temperature and then stirred for 3 h. The reaction was worked up and purified as 
before to give a thick oil, (Z)-5-(dotriacont-15-en-1-ylthio)-1-phenyl-1H-tetrazole 223 (1.7 g, 
96%), {Found [M+H]+: 625.5230; C39H69N4S requires: 625.5237}. This showed δH (400 
MHz, CDCl3): 7.84 – 7.38 (5H, m), 5.36 (2H, br.t, J 4.7 Hz), 3.40 (2H, t, J 7.4 Hz), 2.02 (4H, 
m), 1.82 (2H, m), 1.51 – 1.17 (50H, m), 0.89 (3H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 154.5, 
130.0, 129.9, 129.8, 129.7, 123.8, 33.4, 31.2, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.0, 27.2, 
22.7, 14.10; νmax: 3020, 2928, 1523, 1476, 1423, 1215, 1019 cm-1. 
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Experiment 61: (Z)-5-(Dotriacont-15-en-1-ylsulfonyl)-1-phenyl-1H-tetrazole (209) 
 
Ammonium molybdate (VI) tetrahydrate (3.1 g, 0.0020 mol) was dissolved in cold 
hydrogen peroxide (35%, 20 mL) and the solution was gradually added to a stirred solution 
of (Z)-5-(dotriacont-15-en-1-ylthio)-1-phenyl-1H-tetrazole 223 (3.5, 0.0050 mol) in IMS 
(100 mL) and THF (50 mL) at 0 °C. The mixture was allowed to reach room temperature 
and stirred for 2 h; then another portion of ammonium molybdate (VI) tetrahydrate (1.1 g, 
0.00090 mol) in cold hydrogen peroxide was added (35 %, 7 mL). The mixture was stirred 
for 18 h. After that it was worked up and purified as before  to give a white solid, (Z)-5-
(dotriacont-15-en-1-ylsulfonyl)-1-phenyl-1H-tetrazole 209 (3.0 g, 83%), {Found [M+H]+: 
657.5140; C39H69N4O2S requires: 657.5136}. Which showed δH (400 MHz, CDCl3): 7.70 
(2H, m), 7.61 (3H, m), 5.36 (2H,br.t, 4.7 Hz), 3.74 (2H, distorted t, J 7.9 Hz), 2.08 – 1.90 
(4H, m), 1.56 – 1.11 (52H, m), 0.89 (3H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 153.5, 133.0, 
131.4, 130.3, 129.9, 129.8, 129.7, 125.0, 123.8, 56.0, 33.4, 32.6, 31.9, 29.8, 29.7, 29.63, 
29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 28.9, 28.1, 27.2, 22.7, 21.9, 14.1; νmax: 3020, 2919, 2850, 
1596, 1469, 1344, 1215, 1019 cm-1. 
Experiment 62: Methyl (2R,3R,21R,22E,37Z)-3-acetoxy-2-eicosyl-21-methyltetrapentaconta-22,37-
dienoate (207) 
 
The aldehyde 210 (0.66 g, 0.91 mmol) was added to a stirred solution of the sulfone 209 
(0.69 g, 1.05 mmol) in dry THF (50 mL) under nitrogen at room temperature. The mixture 
was cooled to 16 ºC and potassium bis (trimethylsilyl) amide (1.5 mL, 1.57 mmol, 1 M in 
THF) was added. The mixture was allowed to reach room temperature and stirred for 3 h. 
Sat. aq. NH4Cl (15 mL) followed by petrol/ethyl acetate (1:1, 50 mL) and the organic layer 
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was separated. The aq. layer was re-extracted with ethyl acetate (2 × 50 mL), the combined 
organic layers were dried and evaporated. The product was purified by column 
chromatography, eluting with petrol/ethyl acetate (20:1) to give a white solid, compound 
207 (0.41 mg, 39%) [α] 30
D
 = + 11.4 (c 0.21 CHCl3) {MALDI-Found [M+Na]
+:1174.1419; 
C78H150O4Na requires: 1174.1410}. This showed δH (400 MHz, CDCl3): 5.41 – 5.28 (3H, 
m), 5.24 (1H, dd, J 7.4, 15.3 Hz), 5.09 (1H, td, J 4.0,7.6 Hz), 3.68 (3H, s), 2.62 (1H, ddd, J 
4.3, 6.8,10.8 Hz), 2.04 (3H, s), 2.02 – 1.93 (7H, m), 1.66 – 1.17 (122H, m), 0.94 (3H, d, J 
6.7 Hz), 0.89 (6H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 173.6, 170.3, 136.5, 130.4, 129.9, 
128.4, 74.1, 51.5, 49.6, 37.2, 36.7, 32.6, 32.5, 31.9, 31.7, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 
29.2, 29.1, 28.1, 27.5, 27.4, 27.2, 25.0, 22.7, 21.0, 14.1; νmax: 2915, 2848, 1737, 1468, 
1375, 1237, 1199, 1021 cm-1. 
Experiment 63:  Ethyl (2R,3R,21R,22E,37Z)-3-acetoxy-2-eicosyl-21-methyltetrapentaconta-
22,37-dienoate (208) 
 
The aldehyde 211 (50.0 mg, 0.068 mmol) in dry THF (1 mL) was added to a stirred solution of 
the sulfone 209 (49.1 mg, 0.074 mmol) in dry THF (4 mL) under nitrogen at room temperature. 
The mixture was cooled to 10 ºC and potassium bis (trimethylsilyl) amide (0.22 mL, 0.111 mmol, 
0.5 M in toluene) was added and the mixture was allowed to reach room temperature and stirred 
for 2 h. Sat. aq. NH4Cl (8 mL) and a mixture of petrol/ethyl acetate (1:1, 50 mL) were added and 
the organic layer was separated. The aqueous layer was re-extracted with petrol/ethyl acetate (1:1, 
2 × 20 mL), the combined organic layers were dried, and the solvent was evaporated. The product 
was purified by column chromatography, eluting with petrol/ethyl acetate (20:1) to give a white 
semi-solid, the title compound 208 (20 mg, 47%) [α] 23
D
 = +10.6 (c 0.170 CHCl3) {MALDI-Found 
[M+Na]+:1188.1580; C79H152O4Na requires: 1188.1583}. This showed δH (400 MHz, CDCl3): 
5.41 – 5.29 (3H, m), 5.24 (1H, dd, J 7.3, 15.4 Hz), 5.10 (1H, td, J 4.1,7.7 Hz), 4.15 (2H, q, J 7.1 
Hz), 2.64 – 2.55 (1H, m), 2.10 – 1.92 (10H, m), 1.69 – 1.12 (122H, m), 0.95 (3H, d, J 6.7 Hz), 
0.88 (9H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 173.1, 170.3, 136.4, 129.9, 128.4, 74.1, 58.3, 49.6, 
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37.2, 36.7, 32.6, 31.9, 31.7, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 27.3, 27.1, 24.9, 22.8, 21.0, 20.9, 
15.2, 14.3, 14.0; νmax: 2924, 2853, 1744, 1464, 1370, 1235, 1177, 1023 cm-1. 
Experiment 64: (2R,3R,21R,22E,37Z)-3-Hydroxy-2-eicosyl-21-methyltetrapentaconta-
22,37-dienoic acid (155) 
 
Lithium hydroxide monohydrate (0.21 g, 5.2 mmol) was added to a stirred solution of 
methyl (2R,3R,21R,22E,37Z)-3-acetoxy-2-icosyl-21-methyltetrapentaconta-22,37-dienoate 
207 (0.4 g, 0.34 mmol) in THF (15 mL), water (2 mL) and MeOH (1.5 mL). The mixture 
was heated at 45 ºC for 16 h. When TLC showed no starting material, the mixture was 
diluted with petrol/ethyl acetate (5:1, 20 mL), and then acidified with sat.aq.solution of 
KHSO4. The product was extracted with warm  petrol/ethyl acetate (5:1, 3 × 50 mL), and 
the combined organic layers were dried over MgSO4, evaporated to give a crude product, 
which was purified by re-crystallization from petrol/ethyl acetate (1:2, 50 mL) to give a 
white solid of (2R,3R,21R,22E,37Z)-3-hydroxy-2-eicosyl-21-methyltetrapentaconta-22,37-
dienoic acid 155 (0.27 g, 71%), m.p. 235-237 ºC, [α] 20
D
 = + 2.2 (c 0.92 CHCl3) {MALDI-
Found [M+Na]+:1096.1323; C75H147O3 requires: 1096.1350}. This showed δH (400 MHz, 
CDCl3): 5.41 – 5.29 (3H, m), 5.24 (1H, dd, J 7.5, 15.3 Hz), 3.73 (1H, dt, J 4.8, 9.4 Hz), 
2.47 (1H, dt, J 5.2, 9.2 Hz), 2.08 – 1.93 (7H, m), 1.81 – 0.99 (124H, m), 0.94 (3H, d, J 6.7 
Hz), 0.89 (6H, t, J 6.8 Hz); δC (101 MHz; CDCl3): 178.5, 136.5, 130.4, 129.9, 128.4, 72.1, 
50.7, 37.2, 36.7, 35.5, 32.6, 31.9, 29.8, 29.7, 29.6, 29.58, 29.5, 29.50, 29.4, 29.4, 29.3, 29.1, 
27.4, 27.3, 27.2, 25.7, 22.7, 21.0, 14.1; νmax: 3585 (broad), 2915, 2848, 1686, 1468, 1376, 
720 cm-1. 
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Experiment 65: (S)-2,3-Bis(benzyloxy)propyl(2R,3R,21R,22E,37Z)-3-hydroxy-2-icosyl-21-
methyltetrapentaconta-22,37-dienoate (263) 
 
Dry cesium hydrogen carbonate (29.0 mg, 0. 150 mmol) was added to a stirred solution of (S)-
2,3-bis(benzyloxy)propyl 4-methylbenzenesulfonate 262 (0.014 mg, 0.033 mmol; supplied by 
Dr. J. Al Dulayymi) and (2R,3R,21R,22E,37Z)-3-hydroxy-2-eicosyl-21-methyltetrapentaconta-
22,37-dienoic acid 155 (33.0 mg, 0.030 mmol) in dry THF and DMF (5:1, 1.5 mL) at room 
temperature. The mixture was brought to 70 °C and stirred at this temperature for two days. 
TLC showed no starting material. Ethyl acetate (20 mL) and water (10 mL) were added. The 
organic layer was separated and the aqueous layer was re-extracted with ethyl acetate (3 × 20 
mL). The combined organic layers were washed with water (10 mL) and brine (10 mL), dried 
over MgSO4, filtered and the solvent was evaporated. The product was purified by column 
chromatography, eluting with petrol/ethyl acetate (5:1) to give a semi-solid (S)-2,3-
bis(benzyloxy)propyl-(2R,3R,21R,22E,37Z)-3-hydroxy-2-eicosyl-21-methyltetrapentaconta-
22,37-dienoate 263 (26 mg, 65%), [α] 20
D
 = + 8.5 (c 0.33, CHCl3), {MALDI-Found [M+Na]
+: 
1372.1; C92H164O5Na requires: 1372.2}. This showed δH (400 MHz, CDCl3): 7.53 – 7.09 (10H, 
m), 5.42 – 5.29 (3H, m), 5.24 (1H, dd, J 7.4, 15.3 Hz), 4.68 (1H, d, J 11.8 Hz), 4.64 (1H, d, J 
11.8 Hz), 4.55 (2H, br. s), 4.43 (1H, dd, J 4.0, 11.7 Hz), 4.22 (1H, dd, J 5.5, 11.7 Hz), 3.87 (1H 
br. pent, J 5.4 Hz), 3.60 – 3.57  (3H, m), 2.43 (1H, dt, J 5.4, 9.3 Hz), 2.09 – 1.91 (7H, m), 
1.86 – 1.00 (123H, m), 0.95 (3H, d, J 6.7 Hz), 0.89 (6H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 
175.5, 138.0, 137.9, 136.5, 130.4, 129.9, 128.4, 128.3, 127.7, 127.6, 75.8, 73.5, 72.3, 72.2, 
69.6, 63.5, 51.4, 37.2, 36.7, 35.5, 34.4, 32.58, 31.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.1, 
27.5, 27.4, 27.2, 26.7, 25.8, 22.7, 20.9, 14.1; νmax: 3519 (broad), 2922, 2853, 1736, 1463, 
1369, 1115, 968, 906 cm-1. 
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Experiment 66: (S)-2,3-Dihydroxypropyl-(2R,3R,21R,22E,37Z)-3-hydroxy-2-icosyl-21-
methyltetrapentaconta-22,37-dienoate (156) 
 
Liquid ammonia (100 mL) was decanted into a (250 mL) two necked flask under a liquid 
nitrogen/methylated spirit condenser protected by a soda lime guard tube. Sodium (~ 50 mg) 
was added until blue colour of solution persisted. The compound 263 (26.0 mg, 0.019 mmol) 
in 1,4-dioxane (2 mL) was added; then the reaction mixture was stirred for 4-5 min until the 
blue colour disappeared. After this the reaction was quenched with NH4Cl (5 mL) and ether 
(30 mL). The ammonia was allowed to evaporate, and the organic layer was separated and the 
aqueous layer was re-extracted with ether (2 × 30 mL). The combined organic layers were 
dried and evaporated. The residue was purified by column chromatography on silica gel 
eluting with CHCl3/MeOH (20:1) to give (S)-2,3-dihydroxypropyl(2R,3R,21R,22E,37Z)-3-
hydroxy-2-eicosyl-21-methyltetrapentaconta-22,37-dienoate 156 (10.4 mg, 46%) [α] 24
D
 = + 
18.3 (c 0.109 CHCl3) {MALDI-Found [M+H]
+: 1170.1713; C78H153O5 requires: 1170.1712}. 
This showed δH (400 MHz, CDCl3+ few drops of CD3OD): 5.38 – 5.26 (3H, m), 5.21 (1H, 
dd, J 7.2, 15.4 Hz), 4.26 (1H, dd, J 4.2, 11.5 Hz), 4.19 (1H, dd, J 6.4, 11.5 Hz), 3.95–3.88 
(1H, m), 3.71–3.63 (2H, m), 3.56 (1H, br.dd, J 5.8,11.5 Hz), 2.45 – 2.36 (1H, m), 2.03 – 1.90 
(7H, m), 1.70 – 0.94 (126H, m), 0.91 (3H, d, J 6.7 Hz), 0.86 (6H, t, J 6.7 Hz); δC (101 MHz, 
CDCl3): 175.5, 136.4, 130.3, 129.8, 128.4, 72.7, 69.8, 65.1, 63.0, 52.4, 37.2, 36.6, 35.0, 32.5, 
31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 27.4, 27.3, 27.1, 25.3, 22.6, 20.9, 14.0; νmax: 
3365 (broad), 2919, 2850, 1719, 1654, 1466,1054 cm-1. The starting material (5 mg) was 
recovered. 
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Experiment 67: Benzyl-2,3,4-tri-O-benzyl-6-O-(2R,3R,21R,22E,37Z) -3-hydroxy-2-
eicosyl-21-methyltetrapentaconta-22,37-dienoate-β-D-glucopyranoside (265) 
 
(2R,3R,21R,22E,37Z)-3-Hydroxy-2-eicosyl-21-methyltetrapentaconta-22,37-dienoic acid 
155 (35 mg, 0.031 mmol) was dissolved in a mixture of THF and DMF (5:1, 1.5 mL) at 
room temperature, and then gently heated until all had dissolved. Dry cesium hydrogen 
carbonate (30.9 mg, 0.159 mmol) and benzyl-2,3,4-tri-O-benzyl-6-O-tosyl-β-D-
glucopyranoside 264 (24.4 mg, 0.035 mmol; supplied by Dr. J. Al Dulayymi) were added. 
The mixture was brought to 70 °C and stirred at this temperature for 18 h. After TLC 
showed no starting material was left, the reaction was quenched with water (5 mL). The 
product was extracted with dichloromethane (3 × 25 mL). The combined organic layers 
were dried over MgSO4 and the solvent was evaporated. The crude product was purified by 
column chromatography, eluting with petrol/ethyl acetate (5:1) to give a semi-solid, the title 
compound 265 (34.5 mg, 67%) [α] 20
D
 = + 12.7 (c 0.730, CHCl3), {MALDI-Found [M+Na]
+: 
1640.1; C109H180O8Na requires: 1640.4}. This showed δH (400 MHz, CDCl3): 7.44 – 7.00 
(20H, m), 5.42 – 5.30 (3H, m), 5.25 (1H, dd, J 7.4, 15.4 Hz), 4.96 (1H, d, J 11.0 Hz), 4.95 
(1H, d, J 11.0 Hz), 4.93 (1H, d, J 12.5 Hz), 4.90 (1H, d, J 11.9 Hz), 4.79 (1H, d, J 10.9 Hz), 
4.72 (1H, d, J 10.9 Hz), 4.71 ( 1H, d, J 11.0 Hz), 4.64 (1H, d, J 12.5 Hz), 4.61 (1H, d, J 
11.9 Hz), 4.55 (1H, d, J 11.0 Hz), 4.53 (1H,br. d, J 7.7 Hz), 4.23 (1H, dd, J 4.5, 11.7 Hz), 
3.67 (2H, br.t, J 7.6 Hz), 3.53 – 3.49  (3H, m), 2.48 (1H, dt, J 5.4, 9.1 Hz), 2.09 – 1.92 (7H, 
m), 1.86 – 1.01 (123H, m), 0.95 (3H, d, J 6.7 Hz), 0.89 (6H, t, J 6.8); δC (101 MHz, 
CDCl3): 175.2, 138.4, 138.3, 137.7, 137.2, 136.5, 130.4, 129.9, 128.5, 128.4, 128.3, 128.1, 
128.0, 127.9, 127.8, 127.7, 102.3, 84.5, 82.3, 77.8, 75.7, 75.1, 74.9, 72.9, 72.3, 71.1, 62.9, 
51.3, 37.2, 36.7, 35.6, 32.6, 31.9, 29.8, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 27.5, 
27.4, 27.2, 25.9, 22.7, 20.9, 14.1; νmax: 3495 (broad), 2916, 2848, 1735, 1465, 1369, 
1111,967, 903 cm-1. 
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Experiment 68: 6-O-(2R,3R,21R,22E,37Z)-3-hydroxy-2-eicosyl-21-methyltetrapentaconta-
22,37-dienoate-α/β-D-glucopyranoside (157) 
 
Liquid ammonia (100 mL) was condensed into a two neck flask (250 mL) under a liquid 
nitrogen/methylated spirit condenser protected by a soda lime guard tube. Sodium (~ 50 
mg) was added until the blue colour of the solution persisted. Compound 265 (33 mg, 0.020 
mmol) in 1,4-dioxane (2 mL) was added and the reaction mixture was stirred for 4-5 min 
until the blue colour disappeared. The reaction was quenched with NH4Cl (5 mL) and ether 
(30 mL) was added. The ammonia was allowed to evaporate, and the organic layer was 
separated and the aqueous layer re-extracted with ether (2 × 30 mL). The combined organic 
layers were dried and evaporated. The residue was purified by column chromatography on 
silica gel, eluting with CHCl3/MeOH (10:1) to give the title compound 157 (6.5 mg, 25%) 
[α] 24
D
 = + 4.9 (c 0.65 CHCl3), {Found [M+NH4]
+: 1275.2135; C81H160O8N requires: 
1275.2138}. This showed δH (α, β isomers) in 6:4 ratio (400 MHz, CDCl3+ few drops of 
CD3OD): 5.37 – 5.23 (3H, m), 5.19 (1H, dd, J 7.4, 15.4 Hz), 5.11 (0.6H, d, J 3.3 Hz, H-
1α), 4.46 (0.4H, d, J 7.7 Hz, H-1β), 4.41 (1H, br. d, J 11.9 Hz, H-6α,β), 4.24 (1H, br. dd, J 
5.9, 11.8 Hz, H-6 α,β), 3.96 –  3.92 (0.6H, ddd, J 2.2, 5.8, 9.8 Hz, H-5α), 3.67 – 3.58 ( 
1.6H, m, H-4α + CH-OH mycolic acid), 3.48 – 3.44 (0.4H, ddd, J 2.2, 5.8, 9.8 Hz, H-5β), 
3.43 – 3.26 (2H, m H-2,3α, H-3,4β), 3.17 (0.4H, br. t, J 8.4 Hz H-2β), 2.42 – 2.34 (1H, m), 
2.07 – 1.84 (7H, m), 1.70 – 0.97 (121H, m), 0.89 (3H, d, J 6.7 Hz), 0.83 (6H, t, J 6.7 Hz); 
δC for α, β isomers (400 MHz, CDCl3 + few drops of CD3OD): 175.2, 136.4, 130.3, 129.9, 
128.4, 96.6 (C-1β), 92.3 (C-1α), 85.5, 76.2, 74.6, 73.7, 72.5, 72.2, 70.5, 70.3, 69.2, 65.7, 
65.6, 63.6, 63.5, 52.6, 52.4, 37.2, 36.6, 35.0, 32.5, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 
27.3, 27.1, 25.4, 22.6, 20.9, 14.0; νmax: 3389 (broad), 2919, 2850, 1735, 1466, 1376, 
1030cm-1. The starting material (4 mg) was recovered. 
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Experiment 69: Methyl 2,3-di-O-benzyl-5-O-[(2R,3R,21R,22E,37Z)-3-hydroxy-2-
eicosyl-21-methyltetrapentaconta-22,37-dienoate]-α-D-arabinofuranosiode (267) 
 
Dry cesium hydrogen carbonate (43 mg, 0.22 mmol) was added to a stirred solution of 
arabinofuranosiode 266 286 (23.8 mg, 0.047 mmol; supplied by Dr. J. Al Dulayymi) and 
(2R,3R,21R,22E,37Z)-3-hydroxy-2-eicosyl-21-methyltetrapentaconta-22,37-dienoic acid 155 
(35 mg, 0.031 mmol) in dry THF and DMF (5:1, 1.5 mL) at room temperature. The mixture 
was brought to 70 °C and stirred at this temperature for 4 days. After TLC showed no starting 
material, the reaction was quenched with water (5 mL). The product was extracted with 
dichloromethane (3 × 25 mL). The combined organic layers were dried over MgSO4 and the 
solvent was evaporated. The product was purified by column chromatography, eluting with 
petrol/ethyl acetate (5:1) to give a semi-solid methyl 2,3-di-O-benzyl-5-O-[(2R,3R,21R, 
22E,37Z)-3-hydroxy-2-eicosyl-2-methyltetrapentaconta-22,37-dienoate]-α-D-arabinofuranoside 
267 (26 mg, 58%) [α] 21
D
 = + 13.9 (c 0.72, CHCl3), {MALDI-Found [M+Na]
+: 1444.2697; 
C95H168O7Na requires: 1444.2682}. This showed δH (400 MHz, CDCl3) 7.45 – 7.20 (10H, m), 
5.41 – 5.29 (3H, m), 5.25 (1H, dd, J 7.4, 15.4 Hz), 4.92 (1H, br. s), 4.58 (1H, d, J 12.0 Hz), 4.56 
(1H, d, J 11.7 Hz), 4.51 (1H, d, J 11.9 Hz), 4.48 (1 H, d, J 11.9 Hz), 4.32 – 4.28 (2H, m), 4.24 – 
4.20 (1H, m), 3.99 (1H, d, J 2.3 Hz), 3.84 (1H, dd, J 2.6, 6.5 Hz), 3.66 – 3.60 (1H, m), 3.38 (3H, 
s), 2.44 (1H, dt, J 5.5, 9.2 Hz), 2.07 – 1.94 (7H, m), 1.73 – 1.01 (123H, m), 0.95 (3H, d, J 6.7 
Hz), 0.89 (6H, t, J 6.7 Hz); δC (101 MHz, CDCl3): 175.0, 137.5, 137.3, 136.5, 130.4, 129.9, 
129.7, 128.5, 128.4, 128.0, 127.9, 107.2, 87.9, 83.7, 79.4, 72.4, 72.2, 72.1, 63.5, 54.9, 51.5, 
37.2, 36.7, 35.5, 32.6, 31.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 27.4, 27.3, 27.2, 25.8, 22.7, 20.9, 
14.1; νmax: 3520 (broad), 2921, 2852, 1734, 1465, 1369, 1110, 965, 908 cm-1. 
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Experiment 70: Methyl-5-O-[(2R,3R,21R,22E,37Z)-3-hydroxy-2-eicosyl-21-methyltetra 
pentaconta-22,37-dienoate]-α-D-arabinofuranosiode (158) 
 
Liquid ammonia (100 mL) was condensed into a two neck flask (250 mL) under a liquid 
nitrogen/methylated spirit condenser protected by a soda lime guard tube. Sodium (~50 mg) 
was added until the blue colour of the solution persisted. Compound 267 (25 mg, 
0.017mmol) in 1,4-dioxane (2 mL) was added and the reaction mixture was stirred for 4-5 
min until the blue colour disappeared. The reaction was quenched with NH4Cl (5 mL) and 
ether (30 mL). The ammonia was allowed to evaporate and the organic layer was separated 
and the aqueous layer re-extracted with ether (2 × 30 mL). The combined organic layers 
were dried and evaporated. The residue was purified by column chromatography on silica 
gel, eluting with CHCl3/MeOH (20:1) to give the title compound 158 (8.6 mg, 39%) [α] 21D  = 
+ 14.85 (c 0.7, CHCl3). {MALDI-Found [M+Na]
+: 1264.1761; C81H156O7Na requires: 
1264.1749}. This showed δH (400 MHz, CDCl3): 5.37 – 5.26 (3H, m), 5.20 (1H, dd, J 7.4, 
15.4 Hz), 4.81 (1H, br. s), 4.32 (1H, dd, J 4.7, 9.8 Hz), 4.28 (1H, dd, J 4.9, 10.1 Hz), 4.09 
(1H, br.q J 4.7 Hz), 4.0 (1H, dd, J ,1.9, 3.7 Hz), 3.87(1H, dd, J 2.7, 4.7 Hz), 3.69 – 3.55 
(1H, m), 3.36 (3H, s), 2.45 – 2.36 (1H, m), 1.96 (7H, m), 1.59 – 1.01 (125H, m), 0.90 (3H, 
d, J 6.7 Hz), 0.85 (6H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 175.0, 136.4, 130.3, 129.8, 
128.3, 108.6, 84.1, 82.0, 81.2, 77.9, 72.5, 63.4, 57.9, 55.0, 52.5, 37.1, 36.6, 35.4, 34.9, 32.6, 
32.48, 31.9, 31.3, 30.2, 29.9, 29.8, 29.6, 29.3, 28.5, 27.3, 27.2, 27.1, 27.0, 26.8, 26.6, 25.6, 
25.3, 24.4, 22.6, 20.8, 14.6, 14.0; νmax: 3402, 2923, 2850, 1726, 1465, 1217, 1096 cm-1. 
Starting material (6 mg) was also recovered. 
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Experiment 71: (2R,3R,21R,22E,37Z)-3-((tert-Butyldimethylsilyl)oxy)-2-icosyl-21-
methyltetrapentaconta-22,37-dienoic acid (269) 
 
Imidazole (0.19 g, 0.0029 mol) was added to a stirred solution of mycolic acid 155 (0.23 g, 
2.0 mmol) in dry DMF (2 mL) and dry toluene (1.5 mL) at room temperature followed by 
the addition of tert-butyldimethylsilylchloride (0.44 g, 0.002 mol) and 4-DMAP (50 mg). 
The reaction mixture was stirred at 70 °C for 24 h. The solvent was removed under high 
vacuum and the residue was diluted with petrol/ethyl acetate (10:2, 50 mL) and water (20 
mL). The organic layer was separated and the aqueous layer was re-extracted with 
petrol/ethyl acetate (10:2, 3 × 20 mL). The combined organic layers were washed with 
water, dried and evaporated to give a colourless oil residue. The residue was dissolved in 
THF (6 mL), water (0.7 mL), and methanol (0.7 mL), and to this was added potassium 
carbonate (150 mg). The mixture was stirred at 45 °C for 3 h, diluted with petrol/ethyl 
acetate (5:2, 30 mL) and water (2 mL) then acidified with potassium hydrogen sulfate to pH 
2. The organic layer was separated and the aqueous layer was re-extracted with petrol/ethyl 
acetate (2 × 20 mL). The combined organic layers were washed with water, dried and 
evaporated to give a residue, which was purified by column chromatography, eluting with 
petrol/ethyl acetate (20:1) to give compound 269 (0.2 g, 80%) [α] 23
D
 = + 3.3 (c 0.84, CHCl3), 
{MALDI-Found [M+Na]+: 1232.2020; C81H160O3SiNa requires: 1232.2029}. This showed 
δH (400 MHz, CDCl3): 5.42 – 5.30 (3H, m), 5.25 (1H, dd, J 7.4, 15.4 Hz), 3.88 (1H, dt, J 
5.2, 10.3 Hz), 2.54 (1H, dt, J 4.7, 9.7 Hz), 2.10 – 1.92 (7H, m), 1.71 – 1.10 (123H, m), 0.95 
(3H, d, J 6.7 Hz), 0.91 (9H, s), 0.89 (6H, t, J 7.0 Hz), 0.12 (3H, s), 0.10 (3H, s); δC (101 
MHz, CDCl3): 177.9, 136.5, 130.3, 129.9, 128.4, 73.5, 50.8, 37.3, 36.7, 34.9, 32.6, 32.0, 
31.6, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 27.5, 27.4, 27.2, 25.7, 24.5, 22.7, 22.6, 
21.0, 17.9 ,14.1, 4.3, 5.0; νmax: 2919, 2850, 1708, 1464, 1361, 1252, 1075 cm-1. 
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Experiment 72: 6,6’-bis-O-(2R,3R,21R,22E,37Z)-3-((tert-Butyldimethylsilyl)oxy)-2-
eicosyl-21-methyltetrapentaconta-22,37-dienoic-2,3,4,2’,3’,4’-hexakis-O-(trimethylsilyl)-
α,α’-trehalose (271)  and 6-O-(2R,3R,21R,22E,37Z)-3-((tert-Butyldimethylsilyl)oxy)-2-
eicosyl-21-methyltetrapentaconta-22,37-dienoic-2,3,4,2’,3’,4’-hexakis-O-(trimethylsilyl)-
α,α’-trehalose (272) 
 
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (0.14g, 0.76 mmol) 
and DMAP (0.09 g, 0.76 mmol) were added to a stirred solution of 269 (0.19 g, 0.16 mmol) 
and protected α,α’-trehalose 270287 (74.0 mg, 0.09 mmol) and powdered 4 Å molecular 
sieves in dry dichloromethane (4 mL) at room temperature under an atmosphere  nitrogen 
atmosphere. The mixture was stirred for 6 days at room temperature, then diluted with 
dichloromethane (5 mL) and silica gel (1 g) was added. The mixture was evaporated under 
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reduced pressure to give a residue, which was purified by column chromatography, eluting 
with petrol/ethyl acetate (20:1) to give the first fraction, TDM 271, as a colourless thick oil 
(50.0 mg, 17%) [α] 23
D
 = + 9.2 (c 0.24, CHCl3), {MALDI-Found [M+Na]
+:3179.9; 
C192H386O15Si8Na requires: 3179.7}. This showed δH (400 MHz, CDCl3): 5.41 – 5.30 (6H, 
m), 5.24 (2H, dd, J 7.4, 15.4 Hz), 4.85 (2H, br. d, J 2.9 Hz), 4.37 (2H, br. d, J 10.3 Hz), 
4.01 (2H, br. dt, J 3.1, 10.7 Hz), 3.93 (2H, br. pent, J 5.2 Hz), 3.90 (2H, br. t, J 8.9 Hz), 
3.53 (2H, br. t, J 9.1 Hz), 3.38 (2H, dd, J 2.8, 9.3 Hz), 2.61 – 2.51 (2H, m), 2.10 – 1.92 
(14H, m), 1.66 – 1.02 (244H, m), 0.94 (6H, d, J 6.7 Hz), 0.89 (12H, t, J 6.6 Hz), 0.88 (18H, 
s), 0.16 (18H, s), 0.15  (18H, s), 0.14 (18H, s), 0.06 (12H, s); δC (101 MHz, CDCl3): 173.8, 
136.5, 130.4, 129.9, 128.4, 94.8, 85.4, 73.4, 72.8, 71.8, 70.7, 66.2, 62.4, 57.7,  51.9, 37.3, 
36.7, 33.4, 32.6, 31.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 28.1, 27.4, 27.2, 25.8, 22.7, 
20.9, 14.1, 1.09, 0.94, 0.16, 4.5, 4.7; νmax: 2927, 2880, 1745,1466, 1379, 1273,1163, 
1100 cm-1. 
The second fraction, TMM 272, was a thick oil (0.13 g, 70%) [α] 23
D
 = + 30.2 (c 0.39, 
CHCl3), {MALDI-Found [M+Na]
+: 1988.5422; C111H228O13Si7Na requires: 1988.5457}. This 
showed δH (400 MHz, CDCl3): 5.47 – 5.29 (3H, m), 5.24 (1H, dd, J 7.4, 15.4 Hz), 4.92 (1H, 
d, J 3.0 Hz), 4.85 (1H, d, J 2.9 Hz), 4.36 (1H, dd, J 1.9, 11.7 Hz), 4.08 (1H, dd, J 4.0, 11.7 
Hz), 4.0 (1H, td, J 2.2, 9.5 Hz), 3.97 –  3.91 (2H, m), 3.88 (1H, dd, J 5.1, 8.9 Hz), 3.84 (1H, 
td, J 3.1, 9.3 Hz), 3.75 – 3.63 (2H, m), 3.5 (1H, dd, J 3.7, 9.0 Hz), 3.49 (1H, dd, J 3.7, 9.0 
Hz), 3.47 (1H, dd, J 3.7, 9.0 Hz), 3.43 (1H, dd, J 3.0, 9.3 Hz), 3.4 (1H, dd, J 3.0, 9.3 Hz), 
2.64 – 2.49 (1H, m), 2.10 – 1.87 (7H, m), 1.78 – 0.98 (123H, m), 0.95 (3H, d, J 6.7 Hz), 0.88 
(6H, t, J 6.6 Hz), 0.87 (9H, s), 0.17 (9H, s), 0.16 (9H, s), 0.155 (9H, s), 0.15 (18H, s), 0.13 
(9H, s), 0.06 (3H, s), 0.055 (3H, s); δC (101 MHz, CDCl3): 174.1, 136.5, 130.4, 129.9, 128.4, 
94.5, 94.4, 73.4, 73.3, 72.9, 72.8, 72.7, 72.0, 71.4, 70.7, 62.5, 61.7, 51.8, 37.3, 36.7, 33.4, 
32.6, 32.6, 31.9, 30.0, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 28.1, 27.5, 27.5, 27.4, 27.2, 
26.4, 25.9, 25.8, 24.8, 22.7, 21.0, 18.0, 14.1, 1.1, 1.0, 0.9, 0.85, 0.17, 0.04, 4.5, 4.7; νmax: 
3607, 2921, 2852, 1741, 1461, 1250,1109, 1077, 836 cm-1. 
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Experiment 73: 6,6’-bis-O-(2R,3R,21R,22E,37Z)-3-((tert-Butyldimethylsilyl)oxy)-2-
icosyl-21-methyltetrapentaconta-22,37-dienoic-α,α’-trehalose (273) 
 
Tetrabutylammonium fluoride (0.12 mL, 0.12 mmol, 1.0 M) was added to a stirred solution 
of TDM 271 (47.9 mg, 0.015 mmol) in dry THF (2 mL) at 5 °C under a nitrogen 
atmosphere. The mixture was allowed to reach room temperature and stirred for 1 h, then 
evaporated to give a residue, which was purified by column chromatography, eluting with 
CHCl3/MeOH (10:1) to give the title compound 273 as a colourless thick oil (6 mg, 15%) 
[α] 23
D
 = + 10.4  (c 0.5, CHCl3). {Found [M+Na]
+: 2747.5; C174H338O15Si2Na requires: 
2747.5}. This showed δH (400 MHz, CDCl3 + few drops of CD3OD): 5.36 – 5.21 (6H, m), 
5.17 (2H, dd, J 7.7, 14.0 Hz), 4.98 (2H, d, J 3.2 Hz), 4.35 (2H, br.dd, J 3.1, 10.7 Hz), 4.20 
(2H, br. d, J 10.5 Hz), 3.91 (2H, br. d, J 9.4 Hz), 3.85 (2H, br. q, J 5.0 Hz), 3.73 (2H, br. t, J 
9.3 Hz), 3.46 (2H, dd, J 3.8, 9.3 Hz), 3.34 (2H,br. m), 2.42 – 2.30 (2H, m), 2.03 – 1.86 
(14H, m), 1.76 – 1.09 (250H, m), 0.88 (6H, d, J 6.7 Hz), 0.84 (12H, t, J 6.3 Hz), 0.81 (18H, 
s), -0.06 (6H, s), -0.07 (6H, s); δC (101 MHz, CDCl3 + few drops of CD3OD): 175.4, 136.3, 
130.2, 129.8, 128.3, 94.4, 85.5, 72.5, 71.3, 70.9, 69.9, 66.0, 63.9, 52.4, 37.1, 36.5, 34.7, 
34.5, 34.4, 32.4, 31.8, 29.5, 29.4, 29.3, 29.2, 29.0, 28.9, 28.8, 27.2, 27.1, 27.0, 26.0, 25.7, 
25.2, 25.0, 22.5, 20.7, 19.9, 13.9, 13.3, 0.3, 6.0.; νmax: 3401, 2925, 2856, 1734, 1459, 
1053 cm-1. 
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Experiment 74: 6-O-(2R,3R,21R,22E,37Z)-3-((tert-Butyldimethylsilyl)oxy)-2-eicosyl-
21-methyltetrapentaconta-22,37-dienoic-α,α’-trehalose (274) 
 
Tetrabutylammonium fluoride (0.5mL, 0.52 mmol, 1.0 M) was added to a stirred solution 
of TMM 272 (0.13 g, 0.06 mmol) in dry THF (3 mL) at 5 °C under a nitrogen atmosphere. 
The mixture was allowed to reach r.t. and stirred for 3 h, then evaporated to give a residue, 
which was purified by column chromatography, eluting with CHCl3/MeOH (5:1) to give 
the title compound 274 (30.0 mg, 30%) [α] 23
D
 = + 18.2 (c 0.45, CHCl3), {MALDI-Found 
[M+Na]+:1556.3071; C93H180O13SiNa requires: 1556.3085}. This showed δH (400 MHz, 
CDCl3 + few drop of CD3OD): 5.38 – 5.26 (3H, m), 5.20 (1H, dd, J 15.3, 7.4 Hz), 5.06 (2H, 
br. t, J 3.5 Hz), 4.28 (1H, dd, J 3.7, 10.6 Hz), 4.21 (1H, dd, J 4.5, 11.8 Hz), 3.9 (1H, br. d, J 
8.3 Hz), 3.87-3.84 (1H, m), 3.81-3.71 (4H, m), 3.65 (1H, dd, J 5.2, 11.6 Hz), 3.47 (1H, dd, 
J 3.9, 5.9 Hz), 3.46 (1H, dd, J 5.9, 9.7 Hz), 2.44 – 2.35 (1H, m), 2.03 – 1.89 (7H, m), 1.83 – 
0.94 (131H, m), 0.90 (3H, d, J 7.8 Hz), 0.83 (6H, t, J 7.0 Hz), 0.81 (9H, s), 0.003  (3H, s), 
0.024 (3H, s); δC (101 MHz, CDCl3+ few drop of CD3OD): 175.5, 136.4, 130.3, 129.8, 
128.3, 94.4, 93.4, 73.2, 72.4, 71.4, 71.2, 70.9, 70.0, 66.1, 65.5, 64.3, 63.2, 62.2, 52.3, 50.1, 
37.2, 36.6, 35.5, 35.3, 34.9, 34.6, 34.4, 32.5, 31.8, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 28.9, 
27.3, 27.2, 27.0, 26.8, 26.6, 26.0, 25.8, 25.5, 25.4, 25.0, 22.6, 20.8, 17.7, 14.0, 5.9; νmax: 
3319, 2973, 2844, 1733, 1467, 1087 cm-1. 
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Chapter 5 
5. Cyclopropene Fatty Acids 
5.1 Introduction 
5.2 Cyclopropene Fatty Acids  
In 1952 Nunn and his group separated the first naturally occurring cyclopropene fatty acid 
from the seed oil of the Sterculia foetida tree.288 The structure was suggested to be 8-(2-
octyl-cycloprop-1-enyl)-octanoic acid, namely sterculic acid (276). 
 
Verma et al. questioned this structure (276) due to inaccurate analysis of the infra-red data 
and rather proposed the structure to be 10-(2-hexylcycloprop-1-enyl) dec-9-enoic acid 
(277).289 
 
The value of this structure was however reduced when it was found that the absorption 
signal in the IR spectrum, which characterises the existence of a di-substituted double bond, 
was found to be due to a polymeric impurity.290 Several other studies also rejected Verma’s 
structure in favour of Nunn’s original structure, which was confirmed by X-ray 
diffraction.291 This was done by hydrogenation the natural sterculic acid (276) to give the 
unnatural cis-9,10-methylene octadecanoic acid and analysing it by X-ray crystallography. 
1H NMR spectroscopy was also used to prove the structure by analysis of the compound. 
Gensler et al., also synthesised and confirmed the structure by preparing the methyl ester of 
sterculic acid (276) successfully in 1969.292 In 1956 the second cyclopropene fatty acid was 
isolated from the seed oil of different plants in the Malvaceae family,293  which  was called 
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malvalic acid (278), and the study of its IR spectrum proposed that it was a homologue of 
sterculic acid.294 Analysis of the crystal structure of dihydromalvalic acid showed that 
malvalic acid (278) was certainly a homologue of sterculic acid (276) and had the structure 
shown below. Conformation of this was obtained in 1970 by the synthesis of its methyl 
ester.295 
 
Other naturally occurring cyclopropene fatty acids that have been isolated, include D-2-
hydroxysterculic acid (279),296 which is believed to be an intermediate in the malvalic acid 
(278) biosynthesis, and sterculynic acid (280)297 which was isolated from Sterculia alata. 
 
5.3 Cyclopropene fatty acids occurrence and conformation 
The first isolation of cyclopropene fatty acids was from a specific number of plant families 
including Malvaceae and Sterculiaceae. However, nowadays they have been isolated from 
different types of plants beside these (Table 11). Sterculia foetida contains the largest 
amount of cyclopropene fatty acids in comparison with other families of plant and, it was 
isolated from this plant first. The amount of cyclopropene fatty acid content in the plant 
also varies with season,298 location within the plant and plant maturity. 
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Table (11): Percentage of malvalic acid (278) and sterculic acid (276) in several plant species. 
 % Fatty acid in seed oil 
Order Family Species 
Malvalic 
Acid (278) 
Sterculic 
Acid (276) 
Malvaceae Sterculiaceae Sterculia foetida299 6.7 54.5 
  Sterculia oblonga300 - 19.0 
 Malvaceae Gossypium hirsutum300 1.1 0.4 
  Triumfetta pilosa301 2.4 6.6 
 Sarcolaenaceae Schizolaena rosea302 0.8 0.4 
Urticales Moraceae Ficus benghalensis303 3.7 1.6 
Fabales Leguminosae Cassia corymbose304 3.2 2.8 
  Telia babul305 2.5 2.1 
Not known Boraginaceae Trichodesma zeylanicum306 8.2 7.8 
 
5.4 Biosynthesis of cyclopropene fatty acids 
There are not many studies concerning the biosynthesis of cyclopropene fatty acids. 
Wilson307 demonstrated the co-occurrence of sterculic acid (276) with its corresponding 
cyclopropane acid (282) suggesting that the cyclopropane is first formed by methylene 
addition to oleic acid (281), followed by dehydrogenation of dihydorsterculic acid (282) to 
sterculic acid, Scheme (73). 
 
Scheme (73): Biosynthesis of sterculic acid. 
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In 1965 Smith et al.308 discovered traces of stearolic acid (283) in sources of sterculic acid 
and suggested that the cyclopropene fatty acid was obtained directly by addition of a 
methylene unit to the internal acetylene, Scheme (74). 
 
Scheme (74): Biosynthesis of sterculic acid. 
Yano309 and his group, however, showed that incubation of the methylene source with 
acetylenic fatty acids gave no cyclopropene fatty acid, but reaction with oleic acid yielded 
the cyclopropane. This therefore proved that oleic acid (281) was the substrate in preference 
to stearolic acid (283). 
 Smith et al.310 proposed that the carbon chains, but not the ring methylene group of 
sterculic and malvalic acids were derived from acetate units. This suggested that malvalic 
acid is biosynthesised from sterculic acid by a one carbon degradation. The subsequent 
isolation of D-2-hydroxysterculic acid (279)311 suggested this was the intermediate in the 
oxidation degradation. The conversion of sterculic acid to malvalic acid was shown to be 
due to an α-oxidative system found in tissues capable of biosynthesising cyclopropene fatty 
acids. Time studies indicated that the α-oxidation occurs after ring formation, but the exact 
mode of action is unknown. 
Scheme (75): Biosynthesis of sterculic acid (276) and malvalic acid (278). 
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5.5 The biological effects of cyclopropene fatty acids 
Cyclopropene fatty acids have significant biological properties that have been known for a 
long time. Feeding pigs on a diet containing cotton seed oils led to them producing a solid 
fat, while the use of milk from cows fed on a similar diet produced butter with a high m.pt. 
The cotton plant Gossypium hirsutus contains cyclopropene fatty acids which explains the 
existence of the cyclopropene fatty acids in the cotton seed oil as a part of the animal’s 
diets. Furthermore, hens fed on a diet containing cotton seed oil produced eggs with pink 
coloured and pasty yolks.312 The pasty yolk is believed to be due to an increase in the 
proportion of saturated to unsaturated fatty acids in the yolk and the pink white disorder is 
believed to be due to an increase in the permeability of the vitellin membrane surrounding 
the yolk.313 These effects were later discovered to be due to the cyclopropene fatty acids in 
the cotton seed oil,314 which led to the realisation that cyclopropene fatty acids could 
potentially be very important as desaturase inhibitors. 
5.6 Cyclopropene fatty acids as desaturase inhibitors 
When rats were given dietary sterculic acid it caused a dramatic difference in the ratios of 
stearic acid to oleic acid, which proved that cyclopropene fatty acids prevented this 
conversion.315 Other studies on hen livers revealed that both malvalic acid (278) and 
sterculic acid (276) prevented the Δ9 desaturation of stearic acid.316 In this case, the amount 
of inhibition was found to depend on the concentration, and a greater inhibition came from 
the methyl esters of the cyclopropene compounds. It has been found that sterculyl-CoA is 
the actual inhibitor of Δ9 desaturase instead of the free acid.315 This proposes that the reason 
for the inability of sterculine (284) and sterculyl alcohol (285) to inhibit Δ9 desaturase to the 
same degree is, because they are not able to form acyl-CoA.  
 
The specific mechanism of cyclopropene fatty acids to inhibit Δ9 desaturase is still unclear. 
It has been found that for the compound to be able to inhibit Δ9 desaturase, the 
cyclopropene ring should be seen at the C9 and / or C10 position. It is proposed that the 
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inhibition effect of sterculic acid (276) is related to the cyclopropene ring as 1,2-dihydroxy 
sterculene presented very little or no effect as an inhibitor.317 The rapid reaction of methyl 
sterculate with thiols, suggests that the inhibiting ability of Δ9 desaturase by sterculic acid 
occurs through reaction with a thiol group within the enzyme. This suggestion is supported 
by the fact that the enzyme is inhibited by compounds such as N-ethylmaleimide which is a 
thiol specific reagent, therefore showing that the thiol groups are important binding sites 
within the active site of Δ9 desaturase.315 Testing of diverse amino acid mimics showed that 
cysteine (286), was the only one that reacted with cyclopropene containing compounds, 
thus suggests that the inhibition is irreversible and that cyclopropene fatty acids can only 
react with cysteine (286) unit at the active site of the enzyme.318 
 
Because of the similarity of sterculic acid (276) and oleic acid (281) in basic shape, it is 
believed that sterculic acid has good inhibition properties towards Δ9 desaturase. 
 
 
 
 
 
 
 
 
5.7 Uses of cyclopropene fatty acids 
As sterculic acid (276) has been shown to be a good inhibitor of Δ9 desaturase many 
industrial uses for the cyclopropene containing fatty acid have been identified. 
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Cyclopropene fatty acids have been used in the food industry, such as cocoa butter which is 
not only significant but also very expensive. Using the fact of inhibition of Δ9 desaturase by 
the sterculic acid a substitute oil could be produced. Using cheaper carbohydrate feedstocks 
for fermenting yeast gives huge quantities of fats counting 5% stearic acid and around 50% 
oleic acid (281). A fat of the same composition to cocoa butter should be produced by 
adding sterculic acid to the yeast culture due to the high levels of stearic acid and low levels 
of oleic acid in cocoa butter, and this was found to be the case. Another major motivation 
for using sterculic acid is in the medical field due to its significant ability to regulate body 
weight. Research conducted on rats by disturbing Δ9 desaturase has shown that increasing 
expenditure of energy, and reducing adiposity in the body are resistant to diet induced 
obesity.319 Therefore, this mutation in the Δ9 desaturase gene has led to global changes in 
the gene expression and altered the metabolic activity which accounts for the loss of body 
fat. The disruption in Δ9 desaturase is therefore a promising therapeutic target in the 
treatment of the metabolic syndrome.320 As sterculic acid (276) is an inhibitor of Δ9 
desaturase, cells were treated with sterculic acid and this was found to reduce their 
adiposity.321 As obesity has now reached epidemic proportions with high levels of obesity 
related diseases this research is very significant. 
Human tumour cells are known to contain higher levels of oleic acid (281) due to the higher 
levels and activity of Δ9 desaturase. This leads to a more permeable membrane which leads 
to an increase in the metabolic rate and cell division which causes the development of 
cancers. However, until recently the relationship between Δ9 desaturase and cancer 
remained unknown. It has now been shown that in lung cancer cells when the Δ9 desaturase 
expression was reduced, the biosynthesis of fatty acids was also significantly impaired 
which shows a causal relationship between Δ9 desaturase and abnormal lipid metabolism in 
cancer cells.322 Numerous different tumour cells exhibit higher levels and higher activity of 
Δ9 desaturase such as in human larynx tumour cells323 and in simian transformed human 
lung fibroblast.324 Research has also shown that males with prostatic malignancy also had 
higher levels of Δ9 desaturase and a threefold increase in some monounsaturated fatty acids. 
Δ9 Desaturase inhibitors could therefore be promising anti-cancer agents.325 Interferon326 is 
a commercially available drug used to treat certain types of cancers and studies have shown 
that it increases the amount of saturated fatty acids in vitro by inhibiting the action of Δ9 
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desaturase. This inhibition decreases membrane fluidity, making the membrane denser.327 
This increase in the membrane rigidity may explain the capacity to inhibit virus release and 
possibly cell division. Interferon’s inhibitory properties may therefore be responsible for its 
anti-cancer properties. Conjugated linoleic acid has also been found to possess some 
inhibitory effects on some forms of mammary carcinogens by decreasing the levels and 
activity of Δ9 desaturase.328 As sterculic acid (276) is a more potent inhibitor of Δ9 
desaturase it is believed that it would have a greater effect on the fluidity of the membrane 
and would therefore be a better anti-cancer agent. Sterculic acid has already displayed some 
anti-tumour effects in vitro and in a tumour model in rats.329 
Sterculic acid may also be effective in the treatment of tuberculosis. The thiourea drug 
isoxyl is used for the treatment of tuberculosis, and has been found to be active against 
multi drug resistant tuberculosis.330 Isoxyl decreases the levels of oleic acid and therefore 
tuberculostearic acid (TBSA) and has some effect on the synthesis of mycolic acids. This 
suggests that isoxyl works by inhibiting Δ9 desaturase. By comparing the effect of isoxyl 
with that of sterculic acid on M. bovis BCG it was shown that both have the same effect on 
the levels of oleic acid. However, sterculic acid had no effect on the synthesis of mycolic 
acids which suggests that isoxyl has different effects on different fatty acids. However, the 
primary effect of isoxyl is to inhibit oleic acid biosynthesis, which is a vital part of the 
mycobacterial membrane. This suggests that alternative Δ9 desaturase inhibitors could also 
be a potential drug target for the treatment of tuberculosis. 
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5.8 Malaria 
The parasite Plasmodium falciparum causes the most severe form of human malaria; which 
results in approximately a million deaths annually from about 250 million cases. Children 
living in Africa represent the majority of the deaths331 caused by the P. falciparum parasite. 
Every 45 seconds malaria causes the death of child in Africa, and this accounts for 20% of 
all childhood deaths. Transmission of malaria is through the bites of infected Anopheles 
mosquitoes. Transmission occurs in the intensive places and it likes to bite people instead 
of animals. In places where high levels of malaria transmit, the immunity of people is a 
significant factor for malaria development. The immunity of individuals is testified 
development from time to time of exposure and this explain why the most deaths in Africa 
happen in young kids who have not yet development this immunity agent’s malaria. 
5.8.1 Treatment 
Quinine (287) was the first efficient medicine for the treatment of P. falciparum malaria 
and it was first isolated from the bark of the Cinchona tree in 1820.332 It was later placed by    
chloroquine (288) and another quinine derivatives.333 The first discovery of chloroquine 
(288) was in 1934 but it was not used for treatment against malaria until 1947. 
 
The subsequent resistance of P. falciparum333,334 to chloroquine has however led to other 
drugs being investigated. Currently an artemisinin (289) based combination therapy is 
recommended for the treatment of P. falciparum malaria. In 1972, artemisinin (289) was 
discovered in the leaves of the common herb plant Artemisia annua. Since then derivatives 
of artemisinin have been synthesised, such as artesunate (290), to improve the efficiency as 
an anti-malarial therapy. Artemisinin and its derivatives have a short half-life therefore they 
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are recommended to be taken in combination with another partner therapy such as 
mefloquine (291), which has a longer half-life.335 
 
5.9 Fatty acids in Plasmodium falciparum 
A red blood cells infected has seen a large rise in the fat content during P. falciparum 
infection336 It has been mentioned that P. falciparum has a restricted capacity to protract 
fatty acids itself during infection. Fatty acids could also get from human serum and 
experiments have shown that the parasite growing is not continuous in a culture without 
them. The oleic acid (281) especially is vital for parasite growth.337 It is believed that these 
fatty acids may be incorporated by passive diffusion through the membranes of P. 
falciparum’s infected red blood cells.338 Research has shown the parasite contains members 
of the type II fatty acid biosynthetic pathway which contradicts earlier reports and suggests 
that P. falciparum can indeed synthesise fatty acids de novo.339 It has been reported that this 
pathway is only active in the liver stages and that it is not vital for the blood stage parasite. 
It can therefore be concluded that blood stage P. falciparum depends on the hosts fatty 
acids, but not much research has been done to see if these fatty acids can be modified by the 
parasite. The Δ9desaturase was subsequently discovered to be present in the parasite, which 
suggests that the fatty acids can be modified. Further investigations were made into the 
importance of Δ9 desaturase to the P. falciparum parasite.340 This study showed that P. 
falciparum can desaturate scavenged stearic acid and that the activity of Δ9 desaturase is 
essential for parasite growth in the blood stages. 
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5.10 Results and discussion 
The initial aim of the project was the development of a flexible route to sterculic acid and 
analogous CPFAs. Studies of the inhibitory effects of these analogues on Δ9 desaturase 
could then be carried out. As it has been discovered that unsaturated fatty acids are essential 
for P. falciparum growth, this strengthens the impetus to investigate Δ9 desaturase 
inhibitors as potential anti-malarial drugs. As sterculic acid (276) is a potent inhibitor of Δ9 
desaturase, analogues of sterculic acid (276) will be synthesised in order to try and 
maximise the inhibition against P. falciparum Δ9 desaturase. This could then guide us 
towards a better inhibitor and may also convey more information about the active site of the 
enzyme and could be an important target in anti malarial treatment. 
5.11 Synthesis of sterculic acid analogues 
For the synthesis of all the analogues discussed below, 1,1,2-tribromo-2-octyl cyclopropane 
(292), which was supplied by Dr. J. Al-Dulayymi, was used as the basic bulding block; this 
forms the alkyl chain as well as allowing for the formation of the cyclopropene ring from 
the cyclopropane via a coupling reaction with an electrophile.   
 
Scheme (76): Formation of a lithiated cyclopropene. 
The 1,1,2-tribromo-2-octyl cyclopropane (292) is firstly treated with two equivalents of n-
butyl lithium to give lithiated cyclopropane, followed by reaction with an electrophile to 
give desired compound. 
5.11.1 Synthesis of 7-(2-octyl-cycloprop-1-enyl)heptanoic acid methyl ester 
(293)  
7-(2-Octyl-cycloprop-1-enyl)heptanoic acid methyl ester (293)341 or to give its common 
name, methyl malvalate, was the first analogue synthesised. This is also one of the few 
naturally occurring cyclopropene fatty acids and contains one less carbon atom in its acid side 
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chain compared to sterculic acid (276) but it still has the second cyclopropene carbon at the 
C-9 position. 
1,6-Diiodo-hexane (295) was synthesised from the commercially available 1,6-hexanediol 
in one step using phosphoric acid, phosphorus pentoxide and potassium iodide. The 
reaction mixture was stirred at 120 °C for 6 hours to give, after work up, (295) in 74% yield, 
Scheme (77). 
 
Scheme (77): Synthesis of 1,6 di-iodo-hexane (295). 
The 1H NMR spectrum of compound (295) confirmed that the reaction had been successful 
due to the triplet at δ 3.20 (J 7.0 Hz) integrating to four protons corresponding to the 
(2×CH2I). This diiodide (295) was then coupled to the lithiocyclopropene derived by 
reaction of 1,1,2-tribromo-2-octyl cyclopropane (292) with methyllithium, in the first step 
of the synthesis of (293), Scheme (78). 
 
Scheme (78): Synthesis of 7-(2-octyl-cycloprop-1-enyl)-heptanoic acid methyl ester. (i) n-BuLi, HMPA, 
I(CH2)6I (295), 23%; (ii) NaCN, DMSO, 83%; (iii) NaOH, EtOH/H2O, TBAH, DCM, 53%; (iv) ether, 
diazomethane 80%. 
The coupling was carried out in the presence of HMPA to form 1-(6-iodo-hexyl)-2-octyl-
cyclopropene (296) in 23% yield. The presence of the cyclopropene ring in this product could 
be easily confirmed by the 1H NMR spectrum which showed a singlet at δ 0.78 integrating to 
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two cyclopropene protons. Thene was also a triplet at δ 3.20 (J 7.0 Hz) for the methylene 
group adjacent to the iodine. The double bond of the cyclopropene ring could also be easily 
identified in the 13C NMR spectrum with two peaks present at δ 109.0 and δ 109.6. 
Iodide (296) was then heated to 60 °C with sodium cyanide in DMSO.342 This converted the 
iodide into the nitrile to form 7-(2-octyl-cycloprop-1-enyl)-heptanenitrile (297). The 
formation of the nitrile could again be easily confirmed due to the characteristic peaks in 
the IR spectrum (2245 cm-1) and 13C NMR spectrum at (δ 119.8), respectively. All 
remaining data were as expected for cyanide (297) with the only other significant peak in 
the 1H NMR spectrum occurring as a triplet at δ 2.35 (J 7.1 Hz) for the methylene group 
adjacent to the cyanide. 
The next stage was to convert the nitrile into the corresponding acid (278) by treating (297) 
with sodium hydroxide and TBAH in DCM to give the required product in 53% yield. This 
conversion was confirmed by the 1H NMR and 13C NMR spectra which showed signals at δ 
2.37 (t, J 7.5 Hz) corresponding to the (CH2COOH) and δ 179.8 corresponding to the 
carbonyl group, respectively. Also, the IR spectrum showed a peak for the OH at 3027 cm-1. 
The final step was the conversion of the free malvalic acid (278) to the corresponding 
methyl ester through the reaction of the acid with diazomethane in presence of ether. The 
esterification was confirmed by the 1H NMR and 13C NMR spectra which showed a singlet 
at δ 3.68 corresponding to the methyl ester and a signal at δ 174.3 corresponding to the 
carbonyl group respectively (Figure 51). 
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Figure (51): 1H NMR spectrum of the compound (278). 
5.11.2 The synthesis of 9-(2-octyl-cycloprop-1-enyl)-nonanoic acid methyl 
ester (298) 
 
9-(2-Octyl-cycloprop-1-enyl)-nonanoic acid methyl ester (298) was the next analogue 
prepared to see if increasing the number of carbon atoms would cause a difference in the 
inhibitory capacity of the analogue. Compound (298) also contains the cyclopropene at the 
C10 position and therefore should exhibit inhibitory qualities. Before this could be prepared, 
1,8-diiodo octane was prepared from the corresponding diol (1,8-octane diol) (299),  
following the same method as was used for the synthesis of 1,6-diiodo-hexane (295) (see 
Scheme 78). Diiodo octane (300) was obtained in an overall yield of 78% (Scheme 79). 
 
Scheme (79): Synthesis of 1,8-diiodo- octane. 
 
 
Ha 
Hc 
Hb 
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The synthesis of (298) then proceeded as shown in Scheme (80), giving the required 
product in an overall yield of 6%, compared to 8% for the previous analogue (292). 
 
Scheme (80): Reagents and conditions: (i) n-BuLi, HMPA, I(CH2)6I, 21%; (ii) NaCN, DMSO, 78%; (iii) 
NaOH, EtOH/H2O, TBAH, DCM, 44%; (iv) ether, diazomethane 83%. 
5.11.3 Esterification of free sterculic acid 
Having prepared methyl esters (293) and (298) natural sterculic acid (276) was also 
converted to its methyl ester. Natural sterculic acid, provided by Dr. J. Al-Dulayymi, was 
esterified using an excess solution of diazomethane in ether to give (304) in 85% yield 
Scheme (81)341,343. The 1H and 13C NMR spectra were as expected, and confirmed the 
formation of the methyl ester. 
 
Scheme (81): Esterification of free sterculic acid. 
 
5.12 The synthesis of 8-methoxy-8-(2-octyl-cycloprop-1-enyl)-octanoic acid 
methyl ester (344)  
5.12.1 Introduction of new functional groups 
The next analogue to be prepared (305) incorporated a functional group into the carboxylic 
acid side chain of the sterculic acid (276). Again, this was prepared to investigate their 
effects on the level of inhibition. 
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The OMe group would be included at the C-8 position, which is adjacent to the 
cyclopropene ring. It is known that the cyclopropene reacts with the enzymes active site, 
therefore, the C-8 position should also be close to or part of the active site. Adding 
functional groups at this position might therefore have a profound effect in one way or 
another on the compounds ability to inhibit Δ9 desaturase. The chain length in this case 
would be identical to that of sterculic acid as changing more than one aspect of the 
molecule would make it difficult to know what effect each individual aspect of the 
molecule would have on the inhibitory qualities of the molecule. 
 
To prepare 8-methoxy-8-(2-octyl-cycloprop-1-enyl)-octanoic acid methyl ester (305), 7-bromo 
heptanal (307) needed to be prepared (Scheme 82). 
 
Scheme (82): Synthesis of 7-bromo heptanal (i) PCC, CH2Cl2, 77%. 
 
This was obtained by oxidising (306) in 77% yield and the structure was confirmed by 
NMR. The 1H NMR spectrum showed a triplet at δ 9.78 (J 1.7 Hz) corresponding to the 
aldehyde proton and another triplet at δ 3.42 (J 6.8 Hz) belonging to the CH2 adjacent to the 
bromine atom. Also, the 13C showed a signal at δ 202.5 for aldehyde carbon. This aldehyde 
was then used immediately as the electrophile in the coupling reaction with the 
lithiocyclopropene derived from 1,1,2-tribromo-2-octylcyclopropane (292), (Scheme 83). 
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Scheme (83): Synthesis of 8-methoxy-8-(2-octyl-cycloprop-1-enyl)-octanoic acid methyl ester (i) n-BuLi; HMPA, 
Br(CH2)6COH; MeI, 46%; (ii) NaCN, DMSO, 43%; (iii) NaOH, EtOH, H2O; TBAH, CH2Cl2, 93%; (iv) ether, 
diazomethane 80%. 
The formation of compound (308) was confirmed by the H1 NMR spectrum, which 
indicated the   presence of a methoxy group due to a three proton singlet at δ 3.31. The 
protons on the carbon atom next to the bromide were seen as a triplet at δ 3.18 (J 7.0 Hz) 
integrating to two protons as expected. Two peaks were observed in the 13C NMR spectrum 
at δ 108.6 and δ 114.1 representing the two carbon atoms of the double bond of the 
cyclopropene ring. However, the characteristic singlet at around δ 0.78 in the 1H NMR 
spectrum was not apparent. In this case a doublet was seen at δ 0.94 (J 8.5 Hz). The 
inclusion of a functional group at the C8 position therefore caused the two cyclopropene 
protons to become non-equivalent. 
1-(7-Bromo-1-methoxy-heptyl)-2-octyl-cyclopropene (308) was then heated at 60 °C with 
sodium cyanide in DMSO as before. This formed nitrile (309) which again showed the 
distinctive peaks at 2246 cm-1 in the IR spectrum and at δ 119.8 ppm in the 13C NMR 
spectrum, whilst all other peaks were as for the starting material with the two cyclopropene 
protons again observed as a doublet and the methoxy group as a singlet integrating to three 
protons. 
8-Methoxy-8-(2-octyl-cycloprop-1-enyl)-octanenitrile (309) was therefore reacted with 
aqueous sodium hydroxide and heated under reflux to give the carboxylate. TBAH and 
dichloromethane were then added, and the mixture was stirred. The disappearance of the 
peaks representing the nitrile was evident in both the IR and 13C NMR spectra. The 1H 
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NMR spectrum showed a triplet at δ 2.45 (J 7.2 Hz) corresponding to the CH2COOH while 
the 13C NMR spectrum showed a signal at δ 174.2 corresponding to the carbonyl group in 
the acid (310). The next step was esterification of the acid using diazomethane in ether to 
give 8-methoxy-8-(2-octyl-cycloprop-1-enyl)-octanoic acid methyl ester (305).  The 1H 
NMR data showed two singlets at δ 3.66 and δ 3.30 representing the two methoxy groups. 
The presence of the cyclopropene could also be confirmed with a characteristic peak in the 
IR spectrum at 1863 cm-1, two signals in the 13C NMR spectrum at δ 114.0 ppm and δ 108.6 
ppm and doublet at δ 0.93 (J 8.5 Hz) ppm in the 1H NMR spectrum confirming that the ring 
did not decompose during this reaction. 
5.13 Effects of the synthesised cyclopropene fatty acids on Toxoplasma gondii 
Toxoplasma gondii is a zoonotic pathogen that is the causative agent of toxoplasmosis, a 
disease which affects both humans and animals. Stearoyl-CoA desaturase (SCD), which is a 
key enzyme for the synthesis of unsaturated fatty acids, is predicted to exist in T. gondii and 
the inhibition of this enzyme by sterculic acid has been shown. Analogues of sterculic acid 
i.e. (293), (298), (304) and (305), were therefore prepared during this project so that their 
anti-parasitic effects against T. gondii could also be investigated. 
Three assays were carried out using these compounds, by Qun Liu and co-workers at China 
Agricultural University: a tachyzoite release assay; a tachyzoite proliferation assay; and an 
MTS assay. The results of these assays have been published344 and will be discussed below. 
(i) Tachyzoite release assay 
This assay investigated the effect of the test compounds on tachyzoite release from host 
cells. The effect on the intracellular T. gondii was tested by adding a 1mM concentration of 
each compound or 0.1% DMSO, as a control, to the cell cultures. Cell rupture and 
tachyzoite release was then observed by microscope at 0, 12, 24 and 36 hours. Due to a 
1mM concentration of sterculic acid leading to cell death within 12 hours, the concentration 
was reduced to 0.1mM; that of the analogues was kept at 1mM. In the culture treated with 
DMSO tachyzoite release started after 24 hours and after 36 hours only a small number of 
intact cells remained. In contrast, most of the cells treated with sterculic acid and the related 
methyl esters were unchanged after 36 hours, with only a small amount of tachyzoite 
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release being observed. Of all the test compounds (305) led to the least amount of 
tachyzoite release. 
(ii) Tachyzoite proliferation assay 
For this assay tachyzoites were fluorescently labelled and were observed under a 
microscope. Freshly released parasites were used to infect cell monolayers and were 
allowed to replicate for 18 hours in the culture medium with sterculic acid and the related 
methyl esters; DMSO was again used as a control. After this time the number of 
parasitophorous vacuoles containing 1 to 8 tachyzoites were counted. The results showed 
that all the methyl ester compounds inhibited the tachyzoite proliferation, with (305) again 
being the most effective, with only a small percentage (3%) of the parasitophorous vacuoles 
containing 8 tachyzoites, compared to DMSO, where there were 40 %. 
(iii) MTS assay 
Cells infected with T. gondii tachyzoites were grown in culture medium with different 
concentrations of sterculic acid and the methyl ester analogues. After 24 hours anti-T. 
gondii and host cell cytotoxicity were measured. Cells grew in the presence of all the 
methyl ester analogues, with (305) promoting cell growth. As was previously observed, 
sterculic acid was cytotoxic to the cells. Increasing the concentration of the test compounds 
increased the anti-T. gondii activity of the cells. The EC50 values (i.e. concentration of test 
compound that inhibits the T. gondii induced cytopathic effect by 50%) for the methyl ester 
analogues ranged from 248µM (305) to 428 µM (298), again suggesting that (305) was the 
most effective compound of those tested. 
The above assays have shown that sterculic acid and all the methyl ester analogues, (293), 
(298), (304) and (305), inhibited T. gondii growth in vitro. In all the assays, (305), with a 
methoxy substituent at the C-8 position, was most effective. It is believed that the 
compounds inhibited growth by targeting the synthesis of unsaturated fatty acid. Future 
work could be to investigate the in vivo effects of the analogues used in this study. In 
addition, other analogues with different substituents at the C-8 position could be prepared to 
see if they exhibit similar effects to (305). 
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5.14 Experimental 
Preparation of 1,6–diiodohexcane (295)345 
 
Hexane 1,6-diol 294 (12 g, 0.10 mol) was added to a stired solution of phosphoric acid (27 
mL, 45g, 0.40 mol), potassium iodide (66 g, 0.40 mol) and phosphorous pentoxide (13 g, 91 
mol) and the reaction mixture was stirred at 120 oC for 6 h. The cooled product mixture was 
poured into water (250 mL) and extracted with petrol (3 × 100 mL). The combined organic 
layers were then washed with water (100 mL), saturated sodium bicarbonate (100 mL), 
saturated sodium thiosulphate (50 mL) and brine (100 mL), dried over MgSO4 and 
evaporated. The crude product was purified by column chromatography, eluting with petrol 
to afford the product 295 (28 g, 74%). This showed δH (400 MHz, CDCl3): 3.20 (4H, t, J 
7.0 Hz), 1.91 – 1.78 (4H, m), 1.48 – 1.37 (4H, m); δC (101 MHz, CDCl3): 6.8, 29.4, 33.2; 
νmax: 2926, 2851, 1736, 14560, 1423, 1175, 720 cm-1. 
Preparation of 1, 8–diiodooctane (300)  
 
1,8- Octane diol 299 (14 g, 0.10 mol) was added to a stired solution of phosphoric acid (27 
mL, 45 g, 0.40 mol), phosphorous pentoxide (13 g, 91 mol) and potassium iodide (66 g, 
0.40 mol) at room temperature. The mixture was worked up and purified as before to give 
1, 8–diiodooctane 300 (26 g, 78%). This showed δH (400 MHz, CDCl3): 3.19 (4H, t, J 7.0 
Hz), 1.87 – 1.77 (4H, m), 1.44 – 1.20 (8H, m); δC (101 MHz, CDCl3): 33.5, 30.4, 28.4, 7.6; 
νmax: 2928, 2853 ,1734,1459,1424,1176, 720 cm-1. All data matched those in the 
literature.345 
1-(6-Iodo-hexyl)-2-octyl-cycloprop-1-ene (296)  
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To a stirred solution of 1,1,2-tribromo-2-octyl-cyclopropane 293 (3.0 g, 0.0076 mol) in dry 
ether (50 mL), n-butyl lithium (1.6 M, 12 mL, 0.019 mol) was added dropwise under N2 (g) 
at 78 °C. The mixture was allowed to reach room temperature, stirred for 30 min and then 
cooled to 0 °C. HMPA (2.64 g, 2.72 mL, 0.0152 mol) was then added dropwise followed by 
1,6-diiodo-hexane 295 (2.6 g, 7.7 mmol). The mixture was stirred overnight at room 
temperature and then cooled to 0 °C. Water (50 mL) was added and the product was 
extracted with ether (2 × 100 mL). The combined organic layers were washed with water (2 
× 20 mL), dried and evaporated. Column chromatography eluting with petrol gave 1-(6-
iodo-hexyl)-2-octyl-cyclopropene 296 (0.64 g, 23%) as a colourless oil. This showed δH 
(400 MHz, CDCl3): 3.20 (2H, t, J 7.0 Hz), 2.43 – 2.36 (4H, m), 1.90 – 1.81 (2H, m), 1.62 – 
1.50 (2H, m), 1.52 – 1.23 (16H, m), 0.89 (3H, t, J 6.9 Hz), 0.78 (2H, s); δC (101 MHz, 
CDCl3): 109.6,109.0, 45.1, 33.9, 33.5, 32.8, 31.9, 29.4, 29.3, 28.5, 28.0, 27.4, 27.2, 26.0, 
22.7, 14.1, 7.4; νmax: 2928, 2857, 1872, 1462 cm-1. All data matched those in the 
literature.346 
1-(8-Iodo-octyl)-2-octyl-cyclopropene (301)  
 
The above experiment was repeated using n-butyl lithium (1.6 M, 12 mL, 0.019 mol) and 
1,1,2-tribromo-2-octyl cyclopropane (3.0 g, 0.0076 mol) in dry ether (50 mL). HMPA (2.64 
mL, 2.72 g, 0.0152 mol) was added dropwise followed by 1,8-diiodo-octane 300 (2.9 g, 
0.0078 mol) and the reaction mixture was worked up and purified as before, to give 1-(8-
iodo-octyl)-2-octyl-cyclopropene 301 (0.64 g, 21%) as a colourless oil. This showed δH 
(400 MHz, CDCl3): 3.42 (2H, t, J 6.9 Hz), 2.38 (4H, t, J 7.1 Hz), 1.85 (2H, p, J 7.1 Hz), 
1.59 – 1.49 (4H, m), 1.48 – 1.36 (2H, m), 1.37 – 1.23 (16H, m), 0.89 (3H, t, J 6.8 Hz), 0.78 
(2H, s); δC (101 MHz, CDCl3):  109.4, 109.2, 45.1, 32.7, 31.9, 29.4, 29.3, 29.3, 29.2, 28.9, 
27.4, 27.3, 26.9, 26.1, 26.0, 22.7, 14.1, 7.4; νmax: 2927, 2856, 1872, 1464 cm-1. All data 
matched those in the literature.346 
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7-(2-Octyl-cycloprop-1-enyl)-heptanenitrile (297)  
 
Sodium cyanide (0.25g, 0.0051 mol) was added to a stirred solution of 1-(6-iodo-hexyl)-2-
octyl-cyclopropene 296 (0.64 g, 0.0017 mol) in DMSO (40 mL). The mixture was heated to 
60 °C for 4 h or until TLC showed no starting material was left. Water (15 mL) was added 
to the cooled solution and the mixture was extracted with ether (2 × 100 mL). The 
combined organic layers were washed with saturated aqueous NH4Cl (30 mL), dried, 
filtered and evaporated. Column chromatography, eluting with petrol/ethyl acetate (5:2) 
gave 7-(2-octyl-cycloprop-1-enyl)-heptanenitrile 297 (0.4 g, 83%) as a yellow oil, which 
showed δH (400 MHz, CDCl3): 2.40 (4H, t, J 7 Hz), 2.35 (2H, t, J 7.1 Hz), 1.68 (2H, p, J 
7.2 Hz), 1.62 – 1.54 (6H, m), 1.53 – 1.44 (2H, m), 1.40 – 1.19 (10H, m), 0.89 (3H, t, J 7.0 
Hz), 0.78 (2H, s); δC (101 MHz, CDCl3): 119.8, 109.8, 108.9, 31.9, 29.4, 29.4, 29.3, 28.5, 
27.4, 27.0, 26.0, 25.8, 25.3, 22.3, 17.1, 14.1, 7.4; νmax: 2925, 2857, 2245, 1872, 1462 cm-1. 
All data matched those in the literature.346 
9-(2-Octyl-cycloprop-1-enyl)-nonanenitrile (302)  
 
The above experiment was repeated using sodium cyanide (0.21 g, 0.0025 mol) and 1-(8-
chloro-octyl)-2-octyl-cyclopropene 301 (0.32 g, 0.00081 mol) in DMSO (40 mL). The 
reaction mixture was worked up and purified as before to give 9-(2-octyl-cycloprop-1-
enyl)-nonanenitrile 302 (0.18 g, 78%) as a yellow oil. This showed δH (400 MHz, CDCl3): 
2.39 (4H, br.t, J 7.1 Hz), 2.34 (2H, t, J 7.1Hz), 1.67 (2H, p J 7.4 Hz), 1.59 – 1.50 (4H, m), 
1.49 – 1.40 (2H, m), 1.37 – 1.23 (16H, m), 0.89 (3H, t, J 6.9 Hz), 0.78 (2H, s); δC (101 
MHz, CDCl3): 119.8, 109.5, 109.2, 31.9, 29.4, 29.3, 29.2, 29.1, 28.8, 28.7, 27.4, 27.3, 26.1, 
26.0, 25.4, 22.7, 17.1, 14.1, 7.4; νmax: 2928, 2854, 2247, 1462 cm-1. All data matched those 
in the literature.346 
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8-(2-Octylcycloprop-1-enyl) heptanoic acid (278)  
 
Sodium hydroxide (0.25 g, 0.0064 mol) was dissolved in a mixture of ethanol (3.5 mL) and 
water (0.5 mL). 7-(2-Octylcycloprop-1-enyl)heptanenitrile 297 (0.31g, 0.0011mol) was 
then added and the mixture was heated under reflux under N2 for 8 h. The ethanol was 
evaporated and to the residue 0.1 M TBAH solution, (20 mL) was added. Dichloromethane 
(20 mL) was then added and the mixture was stirred for 12 h. The solution was acidified to 
~pH 3 with aqueous potassium hydrogen sulfate. The mixture was separated, and the 
organic solution was washed with water (3 × 30 mL), dried, filtered and evaporated. 
Column chromatography eluting with petrol/ethyl acetate (5:2) gave 8-(2-octylcycloprop-1-
enyl)heptanoic acid 278 (0.3 g, 53%) as a colourless oil. This showed δH (400 MHz, 
CDCl3): 2.39 (4H, t, J 7.1 Hz), 2.37 (2H, t J 7.5 Hz), 1.65 (2H, m), 1.58 – 1.50 (4H, m), 
1.38 – 1.24 (15H, m), 0.87 (3H, t, J 3.4 Hz), 0.77 (2H, s); δC (101 MHz, CDCl3): 179.8, 
109.5, 34.0, 31.9, 29.4, 29.3, 29.2, 29.1, 29.0, 27.4, 27.3, 26.0, 25.9, 24.6, 22.7, 14.1, 7.4; 
νmax: br. 3027, 2926, 2850, 1711, 1464 cm-1. All data matched those in the literature.346 
9-(2-Octylcycloprop-1-enyl)nonanoic acid(303)  
 
The above experiment was repeated using sodium hydroxide (0.19 g, 0.0048 mol) and 9-(2-
octyl-cycloprop-1-enyl)-nonanenitrile 302 (0.24g, 0.00082 mol) in a mixture of ethanol (3.5 
mL) and water (0.5 mL). The reaction mixture was worked up and purified as before to give 
9-(2-octylcycloprop-1-enyl)decanoic acid 303 (0.11 g, 44%) as a colourless oil. This 
showed δH (400 MHz, CDCl3): 2.39 (4H, t, J 7.2 Hz), 2.34 (2H, t, J 7.7 Hz), 1.68 – 1.60 
(2H, m), 1.59 – 1.49 (4H, m), 1.37 – 1.23 (19H, m), 0.89 (3H, t, J 7.0 Hz), 0.77 (2H, s); δC 
(101 MHz, CDCl3): 179.8, 109.5, 109.2, 34.0, 31.9, 29.4, 29.3, 29.2, 29.1, 29.0, 27.4, 27.3, 
26.0, 25.9, 24.6, 22.7, 14.1, 7.4; νmax: br. 3030, 2927, 2857, 1711, 1464 cm-1. All data 
matched those in the literature.346 
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7-(2-Octyl-cycloprop-1-enyl)-heptanoic acid methyl ester (293)341 
 
To a stirred solution of 8-(2-octylcycloprop-1-enyl) heptanoic acid 278 (0.3 g, 0.0010 mol) in 
ether (5 mL) an excess of diazomethane solution in ether (5 mL) was added dropwise, and 
reaction mixture was then stirred for 1015 min. When TLC showed no starting material 
was left, the solution was evaporated to give a pure product, 7-(2-octyl-cycloprop-1-enyl)-
heptanoic acid methyl ester 292 (0.25 g, 80%). This showed δH (400 MHz, CDCl3): 3.68 (3H, 
s), 2.38 (4H, t, J 6.8 Hz), 2.32 (2H, t, J 7.6 Hz), 1.69 – 1.57 (2H, m), 1.59 – 1.49 (4H, m), 1.39 
– 1.22 (14H, m), 0.89 (3H, t, J 6.9 Hz), 0.77 (2H, s); δC(101 MHz, CDCl3): 174.3, 109.4, 109.2, 
45.1, 32.7, 31.9, 29.4, 29.3, 29.3, 29.2, 28.9, 27.4, 27.3, 26.9, 26.1, 26.0, 22.7, 14.1, 7.4; νmax: 
2927, 2856, 1872, 1742, 1464 cm-1. All data matched those in the literature.346  
9-(2-Octyl-cycloprop-1-enyl)-nonanoic acid methyl ester (298)  
 
To a stirred solution of 8-(2-octylcycloprop-1-enyl)nonanoic acid 303 (0.11 g, 0.00035 
mol) (5 mL) ether an excess of diazomethane solution in ether (3 mL) was added dropwise, 
and reaction mixture was then stirred for 1015 min. When TLC showed no starting 
material was left, the solution was evaporated to give a pure product, 7-(2-octyl-cycloprop-
1-enyl)-nonanoic acid methyl ester 298 (0.1 g, 83%) This showed δH (400 MHz, CDCl3): 
3.68 (3H, s), 2.38 (4H, t, J 7.1Hz), 2.32 (2H, t, J 7.6 Hz), 1.66 – 1.50 (6H, m), 1.39 – 1.22 
(18H, m), 0.89 (3H, t, J 6.8 Hz), 0.78 (2H, s); δC(101 MHz, CDCl3): 174.3, 109.4, 109.3, 
51.4, 34.1, 31.9, 29.4, 29.3, 29.2, 29.1, 27.4, 27.3, 26.1, 26.0, 25.0, 22.7, 14.1, 7.4; νmax: 
2927, 2855, 1869, 1744, 1464 cm-1. All data matched those in the literature.346 
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8-(2-Octylcycloprop-1-enyl)octanoic acid methyl aster (304)  
 
To a stirred solution of -8-(2-octyl-cycloprop-1-enyl)-octanoicacid 276 (0.4 g, 0.0013mol) 
in (5 mL) ether, an excess of diazomethane solution in ether (6 mL) was added dropwise, 
and the reaction mixture then stirred for 1015 min. When TLC showed no starting material 
was remaining, the solution was evaporated to give an essentially pure product, 7-(2-octyl-
cycloprop-1-enyl)-nonanoic acid methyl ester 304 (0.4 g, 85%). This showed δH(400 MHz, 
CDCl3): 3.67 (3H, s), 2.38 (2H, t, J 7.1 Hz), 2.31 (2H, t, J 7.5 Hz), 1.69 – 1.49 (6H, m), 
1.39 – 1.18 (18H, m), 0.89 (3H, t, J 6.6 Hz), 0.77 (2H, s); δC (101 MHz, CDCl3): 174.3, 
109.4, 109.3, 109.3, 51.4, 34.1, 31.9, 29.4, 29.3, 29.2, 29.1, 27.4, 27.3, 26.0, 26.0, 25.0, 
22.7, 14.1, 7.4; νmax: 2929, 2858, 1865, 1745, 1464cm-1. All data matched those in the 
literature.346 
7-Bromo-heptanal (307)  
 
A solution of 7-bromo-heptan-1-ol 306 (3.25 g, 0.0167 mol) in dichloromethane (20 mL) 
was added dropwise to a stirred suspension of PCC (7.18 g, 0.0334 mol) in 
dichloromethane (100 mL). During the addition a black colour appeared and the reaction 
mixture was then stirred for 2 h after which time TLC showed that no starting material was 
left. Petrol/ethyl acetate (5:1) (70 mL) was added to the reaction mixture, forming a thick 
black precipitate, which was removed by filtration through a bed of silica gel/celite, and the 
solvent was removed by rotary evaporation. Column chromatography, eluting with 
petrol/ethyl acetate (5:1) gave 7-bromo-heptanal 307 (2.5g, 77%) as a colourless oil. This 
showed δH (400 MHz, CDCl3): 9.78 (1H, t, J 1.7 Hz), 3.42 (2H, t, J 6.8 Hz), 2.46 (2H, td, J 
1.7, 7.3 Hz), 1.88 (2H, p, J 7.2 Hz), 1.66 (2H, p, J, 7.3), 1.52 – 1.43 (2H, m), 1.41 – 1.31 
(2H, m); δC (101 MHz, CDCl3): 202.5, 43.7, 33.7, 32.5, 28.3, 27.9, 21.8; νmax: 2935, 2858, 
1725, 1461 cm-1. All data matched those in the literature.346 
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1-(7-Bromo-1-methoxyheptyl)-2-octyl-cyclopropene (308)  
 
n-Butyl lithium (1.6 M, 12 mL, 0.019 mol) was added dropwise to a stirred solution of 
1,1,2-tribromo-2-octyl cyclopropane 293 (3.0 g, 0.0076 mol) in dry ether (50 mL) under N2 
at 78 °C. The mixture was allowed to reach room temperature, stirred for 30 min and then 
cooled to 0 °C, after which HMPA (2.72 g, 2.64 mL, 0.0150 mol) was added dropwise 
followed by 7-bromo-heptanal 307 (1.6 g, 0.0083 mol). The mixture was then stirred for 3 h 
and iodomethane (4.75 g, 10.8 mL, 0.0761 mol) was added. The mixture was stirred 
overnight at room temperature, cooled to 0 °C and water (70 mL) was added. The resulting 
solution was extracted with ether (2 × 100 mL) and the combined organic layers washed 
with water (2 × 20 mL), dried, filtered and evaporated. Column chromatography, eluting 
with petrol/ethyl acetate (5:1) gave (±)-1-(7-bromo-1-methoxy-heptyl)-2-octyl-
cyclopropene 308 (1.3 g, 46%) as a colourless oil. This showed δH(400 MHz, CDCl3): 4.19 
(1H, t, J 6.3 Hz), 3.31 (3H, s), 3.18 (2H, t, J 7.0 Hz), 2.45 (2H, dt, J 0.6, 7.3 Hz), 1.81 (2H, 
m), 1.68 (2H, m), 1.57 (2H, p, J 7.3 Hz), 1.30 (16H, m), 0.94 (2H, d, J 8.5 Hz), 0.88 (3H, t, 
J 6.9 Hz); δC (101 MHz, CDCl3): 114.1, 108.6, 76.3, 33.4, 33.3, 31.9, 30.4, 29.4, 29.3, 29.2, 
28.5, 27.2, 26.6, 26.1, 25.1, 22.7, 14.1, 7.5, 7.0; νmax: 2925, 2854, 1463cm-1. All data 
matched those in the literature.346 
8-Methoxy-8-(2-octyl-cycloprop-1-enyl)-octanenitrile (309)  
 
Sodium cyanide (0.40 g, 0.00810 mol) was added to a stirred solution of (±)-1-(7-bromo-1-
methoxy-heptyl)-2-octyl-cyclopropene 308 (1.2 g, 0.0034 mol) in DMSO (40 mL). The 
mixture was heated to 60 °C for 3 h or until the TLC showed no starting material was left. 
Water (15 mL) was added to the cooled solution and the product was extracted with ether (2 
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× 100 mL). The combined organic layers were washed with a saturated aqueous solution of 
NH4Cl (30 mL), dried, filtered and evaporated. Column chromatography, eluting with 
petrol/ethyl acetate (5:2) gave 8-methoxy-8-(2-octyl-cycloprop-1-enyl)-octanenitrile 309 
(0.46 g, 43%) as a yellow oil This showed δH(400 MHz, CDCl3): 4.20 (1H, t, J 6.6 Hz), 
3.32 (3H, s), 2.45 (2H, t, J 7.3 Hz), 2.33 (2H, t, J 7.1 Hz), 1.68 (4H, m), 1.58 (2H, m), 1.46 
(2H, m), 1.30 (14H, m), 0.95 (2H, d, J 8.5 Hz), 0.89 (3H, t, J 6.8 Hz); δC (101 MHz, 
CDCl3): 119.8, 114.2, 108.6, 76.3, 56.6, 39.4,33.3, 31.8, 29.4, 29.3, 28.7, 28.6, 27.2, 26.1, 
25.3, 25.0, 22.7, 17.1, 14.1, 7.5; νmax: 2925, 2854, 2246, 1865, 1465 cm-1. All data matched 
those in the literature.346 
8-Methoxy-8-(2-octyl-cycloprop-1-enyl)-octanoicacid (310)  
 
Sodium hydroxide (0.35 g, 0.0087 mol) was dissolved in a mixture of ethanol (3.5 mL) and 
water (0.5 mL). 8-Methoxy-8-(2-octyl-cycloprop-1-enyl)-octanenitrile 309 (0.46 g, 0.00150 
mol) was then added and the mixture heated under reflux under N2 for 8 h. The ethanol was 
evaporated and to the residue (0.1 M TBAH solution 40 mL) was added. Dichloromethane 
(20mL) was then added and the mixture was stirred for 12 h. The solution was acidified to ~pH 
3 with aqueous potassium hydrogen sulfate. The mixture was separated, and the organic 
solution was washed with water (3 × 30 mL) and the solution was dried, filtered and 
evaporated. Column chromatography, eluting with petrol/ethyl acetate (5:2) gave 8-methoxy-8-
(2-octyl-cycloprop-1-enyl)-octanoic acid 310 (0.43 g, 93%). This showed δH (400 MHz, 
CDCl3) 4.20 (2H, t, J 6.4 Hz), 3.32 (3H, s), 2.45 (2H, t, J 7.2 Hz), 2.36 (2H, t, J 7.5 Hz), 1.74 – 
1.43 (6H, m), 1.42 – 1.18 (16H, m), 0.94 (2H, d, J 8.5 Hz), 0.89 (3H, t, J 6.9 Hz); δC (101 MHz, 
CDCl3): 174.2, 108.6, 114.0, 55.6, 33.5, 33.3, 31.9, 29.4, 30.0, 29.2, 29.0, 27.2, 26.0, 25.8, 25.1, 
24.6, 20.0, 14.0, 7.5; νmax: 2927, 2855, 1863, 1743, 1464 cm-1. All data matched those in the 
literature.346 
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8-Methoxy-8-(2-octyl-cycloprop-1-enyl)-octanoic acid methyl ester (305)  
 
To a stirred solution of 8-methoxy-8-(2-octyl-cycloprop-1-enyl)-octanoicacid 310 (0.43 g, 
0.00131 mol) and ether (5 mL) an excess of diazomethane solution in ether (5 mL) was added 
dropwise. The mixture was then stirred for 10-15 min, then TLC give a pure product, 7-(2-
octyl-cycloprop-1-enyl)-nonanoic acid methyl ester 305 (0.4 g, 80%). This showed δH (400 
MHz, CDCl3):4.19 (1H, t, J 6.5 Hz), 3.66 (3H, s), 3.30 (3H, s), 2.44 (2H, t, J 7.25 Hz), 2.29 
(2H, t, J 7.6 Hz), 1.61 (6H, m), 1.31 (16H, m), 0.93 (2H, d, J 8.5 Hz), 0.88 (3H, t, J 6.9 Hz); δC 
(101 MHz, CDCl3): 174.2, 114.0, 108.6, 76.4, 56.5, 51.4, 34.0, 33.3, 31.9, 29.4, 29.3, 29.2, 
29.1, 27.2, 26.1, 25.2, 24.9, 22.6, 14.1, 7.5; νmax: 2927, 2855, 1863, 1743, 1464 cm-1. All data 
matched those in the literature.346 
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